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ABSTRACT 
Maximizing the potential of cancer immunotherapy requires model systems that closely 
recapitulate human disease to study T cell responses to tumor antigens and to test immune 
therapeutic strategies.  Current model systems largely relied on chemically-induced and 
spontaneous tumors in immunodeficient mice or on transplanted tumors.  Such systems are 
limited because they fail to reproduce the complex interactions that exist among an emerging 
tumor, its microenvironment and the multiple elements of an intact immune system.  We created 
a new system that is compatible with Cre-loxP-regulatable mouse cancer models in which the 
defined antigen SIY is specifically over-expressed in tumors, mimicking clinically-relevant 
tumor-associated antigens.  To demonstrate the utility of this system, we characterized SIY-
reactive T cells in the context of lung adenocarcinoma, revealing multiple levels of antigen-
specific T cell tolerance that serve to limit an effective anti-tumor response.  Thymic deletion 
reduced the number of SIY-reactive T cells present in the animals.  When potentially self-
reactive T cells in the periphery were activated, they were efficiently eliminated.  Inhibition of 
apoptosis resulted in more persistent self-reactive T cells, but these cells became anergic to 
antigen stimulation.  Finally, in the presence of tumors over-expressing SIY, SIY-specific T cells 
required a higher level of costimulation to achieve functional activation. 
Adoptive cell transfer (ACT) therapy for cancer has demonstrated tremendous efficacy in 
clinical trials, particularly for the treatment of metastatic melanoma.  There is great potential in 
broadening the application of ACT to treat other cancer types, but the threat of severe 
autoimmunity may limit its use.  Studies in other model systems have demonstrated successful 
induction of anti-tumor immunity against self-antigens without detrimental autoimmunity.  This 
is possibly due to the preferential recognition of tumor over normal somatic tissue by activated T 
cells.  In our system, SIY provides a means to achieve this bias because of its over-expression in 
tumors.  Thus, we applied adoptive T cell transfer therapy combined with lymphodepleting pre-
conditioning to treat autochthonous lung tumors over-expressing SIY self-antigen.  With this 
treatment, we overcame peripheral tolerance, successfully inducing large number of functional 
anti-tumor T cells.  These T cells are able to influence lung tumors over-expressing self-antigen.  
Importantly, despite large numbers of potentially self-reactive T cells, we did not observed overt 
autoimmunity. 
Immune tolerance thwarts efforts to utilize immune therapy against cancer.  We have 
discerned many mechanisms by which tolerance to cancer in potential achieved.  Both Foxp3
+
 T 
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regulatory cell and myeloid-derived suppressor cell populations are expanded in the presence of 
cancer in our mouse models.  In addition, we identified LAG-3 as a potential factor that serves to 
limit anti-tumor T cell activity in the context of adoptive cell transfer therapy.  Our new system 
represents a valuable tool in which to explore the mechanisms that contribute to T cell tolerance 
to cancer and to evaluate therapies aimed at overcoming this tolerance.  In addition, our model 
provides a platform, on which more advanced mouse models of human cancer can be generated 
for cancer immunology. 
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CHAPTER 1: 
 
Introduction 
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I. THE CANCER PARTS LIST 
Cancer as a list of parts 
Cancer is a collection of diseases characterized by aberrant cellular proliferation and 
altered tissue homeostasis.  The general paradigm for cancer development and progression 
around the turn of the century was the accumulation of sequential genetic and epigenetic 
alterations that give cells a selective advantage.  This perspective focuses on mutant genes and 
the resulting alterations in cell signaling pathways and epigenetic state.  Indeed, Hanahan and 
Weinberg’s seminal review on the “hallmarks of cancer” highlights genetic changes in cancer 
that lead to the acquisition of six essential traits: (1) self-sufficiency in growth signals, (2) 
insensitivity to anti-growth signals, (3) evasion of programmed cell death, (4) limitless 
replicative capacity, (5) sustained ability to recruit blood vessels, and (6) tissue invasion and 
metastasis (Hanahan and Weinberg, 2000).  Although the latter two capacities involve interaction 
with non-mutant cells in the tumor microenvironment, the cause of these events was attributed to 
genetic alterations in the tumor cells.  The presumption with this mutant cancer cell-centric view 
is that the key to cancer therapy lies in targeting signaling pathways and cellular processes within 
the cancer cells themselves.  We know, however, that cancer is not simply a mass of mutant 
cells, but rather a heterogeneous tissue consisting of mutant tumor cells within a highly 
interactive microenvironment (Bissell and Radisky, 2001). 
Evidence that both cell autonomous and non-cell autonomous elements contribute to 
cancer initiation and progression has been present for over a century (Mantovani et al., 2008).  
Hanahan and Weinberg did, in fact, state that the tumor microenvironment was sure to play a 
major role in tumorigenesis, noting in particular that tumors are composed of heterogeneous cell 
types (Hanahan and Weinberg, 2000).  The study of non-cell autonomous modifiers of cancer, 
  - 14 - 
however, has proven unwieldy compared to the study of cell-autonomous factors.  The former 
requires the use complex model systems, such as three-dimensional cultures and animal models 
(Debnath and Brugge, 2005; Fischbach et al., 2007; Frese and Tuveson, 2007; Jonkers and 
Berns, 2002).  The necessity of these higher order systems and other complications have caused 
the study of the tumor microenvironment to lag behind the study of cancer genetics and its cell 
autonomous consequences.  Despite this, important insights into the tumor microenvironment 
and systemic host environment in cancer have emerged.  These studies have opened interesting 
avenues for more fruitful research and more possibilities for the development of cancer therapies. 
The tumor microenvironment consists of extracellular matrix (ECM), fibroblasts, 
immune cells, and vasculature.  These components interact heavily with one another and 
certainly with the mutant tumor cells themselves.  The tumor microenvironment supports tumor 
progression, but, in principle, each part can be altered to either render tumor cells vulnerable to 
suppression or to directly suppress tumor advancement.  With this in mind, I propose an 
alternative framework with which to view cancer.  Rather than focusing on acquired traits 
derived from genetic events, one can view cancer in terms of its parts list, and how these 
components influence cancer progression (Figure 1). 
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The cancer parts list consists of cell-autonomous parts and non-cell-autonomous parts 
and includes (1) the genetics and (2) the epigenetics of the mutant tumor cells, (3) the ECM, (4) 
fibroblasts, (5) immune cells, and (6) the vasculature (Figure 1).  The genetics component 
includes mutations in oncogenes and tumor suppressor genes that drive cancer development 
(Futreal et al., 2004; Sherr, 2004).  Furthermore, non-mutant genetic variants, or polymorphisms, 
are also important in modifying the phenotype of cancer (de la Chapelle, 2004; Pharoah et al., 
2004).  The epigenetics of cancer is influenced by the cell and tissue type of origin and the 
differentiation status, or potency, of particular cancer cells (Bernstein et al., 2007).  In addition, 
genetic events can lead to alterations in epigenetic state, which can, in turn, affect the dynamics 
of additional genetic change (Jallepalli and Lengauer, 2001; Michor et al., 2004). 
The non-cell autonomous parts of cancer, or the tumor microenvironment, can be 
recruited to the lesion or subverted by genetic and epigenetic changes in the mutant tumor cells, 
as previously mentioned (Hanahan and Weinberg, 2000).  The microenvironment, however, can 
also feed back and influence genes and gene expression in the mutant tumor cells as well as 
affect other components of the tumor microenvironment.  The ECM controls tissue architecture 
and regulates the availability of soluble factors, both of which can influence tumor cell signaling 
(Butcher et al., 2009; Erler and Weaver, 2009).  Fibroblasts can express factors that directly 
promote tumor growth and metastasis.  In addition, they also produce ECM, help to recruit blood 
vessels, secrete factors to employ immune cells to aid in cancer development, and contribute to 
immune suppression (Kalluri and Zeisberg, 2006).  Blood vessels recruited to cancer provide 
tumor cells with oxygen and nutrients to promote growth as well as conduits through which 
tumor cells can metastasize (Bergers and Benjamin, 2003).  Fortunately, the cancer vasculature 
also provides a means by which anti-tumor drugs can be delivered and immune cells can travel to 
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attack mutant tumor cells.  Finally, the immune system consists of many cell types that 
collectively function to accomplish opposing roles in cancer (de Visser et al., 2006; Mantovani et 
al., 2008). 
The immune system in cancer 
The immune system can be divided into the innate and adaptive arms.  The innate 
immune system represents the first line of defense against pathogens and functions 
independently of specific antigens.  Innate immune cells recognize molecules associated with 
pathogens and pathogen infected cells, leading to engulfment and neutralization of pathogens.  
Innate immune responses also activate adaptive immunity.  The innate immune system consists 
of myeloid cell types, such as macrophages, neutrophils, and dendritic cells, and lymphoid cells, 
such as natural killer (NK) cells.  Macrophages and dendritic cells, specifically, can cross-present 
pathogen-associated antigens to the adaptive immune system and activate it.  In contrast to the 
innate immune system, the adaptive immune system is antigen-dependent.  The adaptive arm 
consists of T and B lymphocytes, which bear receptors that possess specificity for particular 
antigens.  T cell receptors (TCRs), in association with co-receptors CD8 and CD4, recognize 
antigens associated with major histocompatibility (MHC) molecules, class I and class II, 
respectively.  B cell receptors (BCRs), on the other hand, can recognize soluble antigens.  BCRs 
can be surface-bound or secreted from B cells as antibodies.  TCRs and BCRs both exhibit 
enormous diversity allowing the immune system the ability to specifically recognize and defend 
its host from generally any pathogen.  Further general discussion of the immune system is 
beyond the scope of this thesis.  More information can be found in the textbook Janeways’ 
Immunobiology (Murphy et al., 2008). 
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The link between chronic inflammation caused by pathogens, independent of the role of 
oncogenic viruses, and cancer has been established (Mantovani et al., 2008).  For example, 
infection of the bacterium Helicobacter pylori predisposes individuals to gastric cancer.  Exactly 
how inflammation promotes tumor initiation and progression is still being explored, but innate 
immune cells have been described in this role.  Macrophages, mast cells, and granulocytes are 
thought to generate free radicals that lead to genetic mutation and secrete cytokines that promote 
tumorigenesis via paracrine signaling in tumor cells (de Visser et al., 2006).  In addition, 
macrophages can promote neo-angiogenesis and produce immunosuppressive cytokines that 
block anti-tumor immune responses (Murdoch et al., 2008).  Furthermore, quite counter-
intuitively, both B cells and T cells of the immune system have been described to promote cancer 
growth (de Visser et al., 2005; Prehn and Prehn, 2008).  I will end the general discussion of how 
the components of cancer influence tumor progression here.  I will dedicate the rest of this thesis 
to describing the immune system’s role, and that of cytotoxic CD8
+
 T cells in particular, in tumor 
suppression. 
 
II. A HISTORICAL PERSPECTIVE ON CANCER IMMUNE SURVEILLANCE 
History 
The notion that a functional interaction exists between the immune system and cancer, be 
it supporting or suppressing, has subsisted for more than a century.  In 1863, upon observing 
tumor-infiltrating lymphocytes, Rudolf Virchow speculated that inflammation was a 
predisposing element in tumorigenesis.  In direct opposition to this idea, in 1909, Paul Ehrlich 
proposed that the immune system could be used therapeutically to treat cancer.  Interestingly, 
despite preceding major conceptual advances in immunology, the suggestion of immune therapy 
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for cancer had already been put into practice by then.  In the 1890s, William Coley used 
preparations of killed bacteria cultures to inoculate patients bearing sarcomas.  This vaccination 
did, in fact, result in some cases of tumor regression (Visser, 2008). 
Several decades later, after the discovery of allograft rejection, several researchers were 
able to establish the existence of tumor antigens.  With the use of inbred mouse and rat strains, 
researchers vaccinated animals against syngeneic transplantation of tumors induced by 
carcinogens or transforming viruses (Foley, 1953; Klein, 1966; Old and Boyse, 1964).  Although 
specific identification of these tumor antigens was not possible at this time, this substantiated the 
hypothesis that the immune system could indeed distinguish tumor from self.  Soon afterwards, 
the conjecture that the immune system suppressed malignancies was formally articulated as the 
“cancer immunosurveillance” hypothesis by Sir Macfarlane Burnet and Lewis Thomas, in the 
1960s (Dunn et al., 2002). 
As the cancer immunosurveillance hypothesis was being formulated, experiments 
concerning the immune system’s role in tumor suppression continued (Dunn et al., 2002).  The 
basic premise of these studies was aimed at testing the prediction that immune deficiency in 
animal models would lead to a higher incidence of spontaneous and carcinogen-induced cancer.  
Initial experiments utilizing experimentally-induced methods of immune suppression, however, 
concluded in the late 1960s with ambiguous and contradictory results.  The only firm conclusion 
that could be made was that the immune system suppressed malignancies associated with 
bacterial and viral infections.  A few years later, following the discovery of the athymic nude 
mouse, additional studies were performed by Osias Stutman and others in these genetically 
immunodeficient animals.  These extensive experiments demonstrated no difference in the 
incidence of chemically-induced or spontaneous cancer between wild-type and nude mice, 
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irrespective of age, dose of carcinogen, or observation time.  Unfortunately, the nature of the 
immunodeficiency and compensatory immune mechanisms in nude mice were not well 
understood at that time, and, thus, caused misinterpretation of the data.  While these studies did 
not completely extinguish the idea of cancer immunosurveillance, they undoubtedly dampened 
interest towards it for the next two decades. 
Reviving history 
In the 1990s and early 2000s, a collection of new experiments examining tumorigenesis 
in immunodeficient mice, either induced or genetically-defined, restored enthusiasm for the 
concept of immune-mediate suppression of cancer.  Animals lacking the cytokine interferon- 
(IFN-) demonstrated an increased incidence of carcinogen-induced and spontaneous tumors 
(Street et al., 2001; Street et al., 2002).  Similar results were observed for animals unable to 
respond to IFN- either because they lacked a subunit of the IFN- receptor IFNGRI or a 
component involved in signaling downstream of the receptor Stat-1 (Kaplan et al., 1998; 
Shankaran et al., 2001).  Furthermore, enhanced susceptibility to carcinogen-induced and 
spontaneous tumors was also observed in mice deficient for the cytolytic effector molecule 
perforin (Smyth et al., 2000a; Smyth et al., 2000b; van den Broek et al., 1996).  A 
comprehensive list of studies involving tumor incidence in immunodeficient animals can be 
found in (Dunn et al., 2006; Swann and Smyth, 2007). 
These new studies were supported by a greater understanding of immunology, including 
knowledge of the caveats present in experiments involving nude mice.  In addition, the new 
technological breakthrough of constructing gene-targeted mice made the use of animals with 
numerous researcher-defined immune deficiencies possible (Thompson et al., 1989).  Work with 
these gene-targeted immunodeficient mice, although not without caveats themselves, has not 
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only led to a resurgence of activity in tumor immunology, but has laid the groundwork by 
identifying specific immune components involved in cancer immunosurveillance. 
 
III. THE CURRENT PERSPECTIVE ON CANCER IMMUNE SURVEILLANCE 
In the following section, I will discuss the types of tumor antigens that are recognized by 
cytotoxic T cells and what we know of how the adaptive immune system is activated in response 
to these antigens in cancer.  Then, in the next section, I will describe how the anti-cancer 
response can be circumvented or blocked by tumor cells and by the host’s own immune system 
resulting in tolerance to cancer.  As there has been considerable progress in the area of tumor 
immunology over the years, these sections will not be an exhaustive review of the field’s 
literature, but rather an account that highlights what I see to be the most salient features of the 
immune response to cancer. 
Tumor antigens 
As cancer develops, tumor cells display genetic instability and acquire numerous gene 
mutations (Leary et al., 2008; Sjoblom et al., 2006; Weir et al., 2007).  These genetic events 
either directly or indirectly, through cell signaling modifications and epigenetic changes, result in 
gene expression alterations.  Both the mutant gene products and the alternatively expressed genes 
can yield peptide antigens that the immune system can in turn utilize to recognize cancer (Finn, 
2008; Novellino et al., 2005; Stevanovic, 2002b).  I will start by mentioning some of the 
methodologies used to identify tumor antigens.  Then, I will describe the types of tumor antigens 
that have been identified, and finish by discussing considerations when targeting each antigen 
type therapeutically. 
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Identification 
The identification of immunogenic, non-viral neo-antigens and self-antigens in cancer 
patients, either endogenous or after vaccination, has provided concrete evidence in support of 
cancer immunosurveillance.  The methodologies employed to identify these tumor antigens have 
evolved considerably over the last four decades (Stevanovic, 2002b).  The earliest reliable assay 
for human tumor antigen identification utilized serological analysis for B cell antibody responses 
by mixed hemadsorption assay with established cancer cell lines (Carey et al., 1976).  This 
technique, also called autologous typing, eliminated the confounding variable of reactivity to 
histocompatibility antigens and allowed determination of antigen specificity in tumor versus 
normal cells.  This general approach was subsequently improved upon in the development of 
SEREX, a method utilizing cDNA libraries from fresh tumor specimens, which avoids artifacts 
produced in the in vitro propagation of tumor cells (Sahin et al., 1997).  The libraries were 
generated in lambda-phage vectors and expressed in E. coli.  The resulting recombinant protein 
was transferred onto nitrocellulose membranes and screened for cross-reactivity to antibodies in 
human sera.  SEREX has resulted in the rapid discovery of numerous tumor antigens that elicit 
humoral, or B cell, immune responses in cancer patients. 
While the immune system is known to integrate T cell and B cell responses, antibody 
cross-reactivity to tumor antigens was insufficient to prove the existence of cellular immune 
responses to these or associated antigens.  Many technical advances in immunology have 
allowed the identification of tumor antigens presented by either MHC class I or MHC class II 
molecules that elicit T cell responses in cancer patients (Finn, 2008; Stevanovic, 2002a).  The 
ability to propagate human T cells in culture for extended lengths of time was one of these 
advances (Morgan et al., 1976).  This procedure facilitated the cloning of MAGE1, the first gene 
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discovered to encode a tumor antigen recognized by cytotoxic T lymphocytes (van der Bruggen 
et al., 1991).  In addition, the establishment of in vitro growth conditions for dendritic cells has 
allowed the creation of cell lines that can recapitulate antigen cross-presentation in culture 
(Sallusto and Lanzavecchia, 1994).  These dendritic cell lines, combined with proteomic 
methods, have been used to survey peptides eluted from MHC molecules for their ability to 
stimulate T cells in culture, providing the capacity to identify tumor antigens with high-
throughput efficiency (Kao et al., 2001).  Furthermore, the development of peptide-MHC 
tetramers has allowed the identification and characterization of antigen-specific T cells within a 
population containing diverse antigen specificity (Altman et al., 1996).  Using peptide-MHC 
tetramers, researchers have been able to screen peripheral blood from cancer patients for T cells 
reactive to known or putative tumor antigens (Lee et al., 1999a). 
Classification 
Cancer antigens can be broadly classified as tumor-specific antigens (TSAs) or tumor-
associated antigens (TAAs) (Table 1).  TSAs are derived from proteins to which the host 
immune system is naïve, and so, from an immunological perspective, are unique to tumor cells.  
TAAs, on the other hand, are derived from non-mutant proteins that are over-expressed, 
inappropriately expressed, or even expressed at normal levels in cancer.  Therefore, TAAs 
represent self-antigens that the immune system recognizes to differentially target tumor cells and 
normal host tissues.  By increasing avidity, or the concentration of possible interactions, antigen-
MHC class I complexes with relatively low affinity for T cell receptors (TCRs) can be 
recognized more potently by the immune system; thus, the basis of immune reactivity to TAAs. 
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Both TSAs and TAAs can be further divided into subclasses (Table 1) (Novellino et al., 
2005).  Tumor-specific antigens include cancer-testis antigens, mutant peptides, and viral 
antigens.  Cancer-testis antigens (sometimes referred to as germline antigens or oncofetal 
antigens) are peptides shared between tumor and germ cells or placenta.  As these antigens, such 
as MAGE1, TRAG3, and NY-ESO-1, are normally only expressed in immune privileged sites, 
their mis-expression in tumors is considered foreign to the immune system.  Mutant peptides can 
be generated by point mutation, aberrant splicing or gene fusion, and so are often thought of as 
altered-self antigens.  Due to the genetic instability of tumor cells, mutant peptides as a class are 
common in cancer, but individual mutant peptides do not often overlap between distinct tumors 
or even discrete cells in a single tumor (Segal et al., 2008).  Despite being rare, a handful of 
shared mutant peptides have been identified in cancer, deriving from obligatory mutant proteins, 
such as K-RAS and BCR-ABL (Gjertsen et al., 1997; Wagner et al., 2003).  Finally, cancers with 
viral etiology express truly foreign viral antigens.  This subclass includes peptides from the E6 
and E7 proteins of human papillomavirus in cervical cancer and EBNA-1 from Epstein-Barr 
virus in Burkitt’s lymphoma (Finn, 2008). 
Tumor-associated antigens comprise differentiation antigens and over-expression 
antigens.  Differentiation antigens define a specific cell lineage and are shared between tumor 
and the normal tissue from which the tumor derives.  The majority of known differentiation 
antigens are melanocyte/melanoma antigens, such as Tyrosinase, GP100 and MART-1, but 
others have been identified in epithelial cancers, including PSA in prostate cancer and CEA in 
colon cancer (Novellino et al., 2005).  Over-expression antigens are generally ubiquitously 
expressed across tissue types, but, as the name suggests, expressed at high levels in tumor 
relative to normal tissue.  Many commonly over-expressed proteins in cancer have yielded 
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antigens that fall into this subclass, including hTERT, p53, Cyclin B1and ERBB2.  Many of 
these are barely detectable in normal tissues and so provide great differential in immune 
reactivity (Kao et al., 2001). 
Considerations for targeting tumor antigens with immune therapy 
Experimental immune therapies against both tumor-specific antigens and tumor-
associated antigens are being pursued in pre-clinical and clinical trials.  While the specific 
strategies being employed will be discussed in a later section, I will discuss some of the 
advantages and disadvantages to targeting particular antigen classes or sub-classes here.  The 
major considerations when choosing tumor antigens to pursue include: (1) the selectivity of the 
antigen to tumor compared to normal tissue, (2) the prevalence of the tumor antigen across 
cancer patients, (3) the dependency of cancer to the tumor antigen’s expression, and (4) the 
extent to which the patient’s immune system is tolerized or unresponsive to the antigen. 
By virtue of being categorized as neo-antigens, tumor-specific antigens are not expressed 
in normal tissues surveyed by the immune system and thus offer absolute specificity for tumor 
cells.  With this in mind, cancer-testis antigens and viral antigens would certainly be good targets 
when applicable, particularly because these antigens are also commonly found in certain cancers.  
Unfortunately, few cancer-testis antigens have been identified outside of melanoma and viral 
antigens are only relevant to a minority of cancer types (Novellino et al., 2005).  Furthermore, as 
previously mentioned, most mutant proteins are limited to the individual tumors from which they 
were originally identified (Segal et al., 2008). 
Fortunately, there are two scenarios in which mutant proteins would be appropriate to 
target.  One is in the case of commonly found mutant proteins that are obligatory in cancer, such 
as peptides containing a codon 12 point mutation in K-RAS or the BCR-ABL fusion gene 
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product (Gjertsen et al., 1997; Wagner et al., 2003).  In this situation, it would be important to 
consider the patients’ MHC haplotypes as this is an important determinant of whether an antigen 
is presented and could considerably limit the applicability of a specific therapy.  The second 
circumstance involves the use of individualized therapy, such as when a patient’s own cancer is 
used to induce immunity in himself/herself (Gruijl et al., 2008).  Individualized therapy will be 
described further later, but it should be noted here that mutant peptides are not the only subclass 
of tumor antigen involved with this therapy. 
Concerning selectivity for cancer and prevalence across cancer types, tumor-associated 
antigens are characterized contrary to mutant peptides.  TAAs represent the majority of known 
tumor antigens and are common among cancer types and tumors of the same variety.  Thus, 
therapies devised against specific TAAs are likely to be widely applicable.  Unfortunately, 
though, as TAAs are self-antigens, the risk of autoimmunity is clearly present when targeting this 
class of antigens.  In fact, autoimmunity has been observed after immune therapy against 
differentiation antigens in melanoma both in the clinic and in experimental model systems 
(Dudley et al., 2002; Overwijk et al., 2003; Yee et al., 2000).  Targeting TSAs, however, does 
not necessary escape this risk.  Inducing immune reactivity to a specific antigen may activate 
additional reactivity to unspecified antigens linked in expression through the occurrence of 
epitope, or determinant, spreading (Anderson et al., 2000; Pilon et al., 2003).  Despite this, in 
some cases, researchers have reported successful anti-tumor immunity, even when targeting 
TAAs, in the absence of overt autoimmunity in model systems (Eck and Turka, 2001; Morgan et 
al., 1998; Vierboom et al., 1997).  Considering the model systems used, however, these 
conclusions need to be examined more rigorously. 
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Tumor cells can evade immune responses directed at a particular antigen by decreasing 
expression of that antigen.  This phenomenon has been observed in experimental model systems 
when the expression of antigens under immune pressure was dispensable for cancer progression 
(Khong and Restifo, 2002).  Thus, to circumvent this potential resistance mechanism, tumor 
antigens targeted for therapy should be evaluated on the basis of the relative survival benefit they 
confer on cancer.  Research regarding various cancers’ dependency on specific mutant gene 
products and signaling pathways is ongoing (Ding et al., 2008; Jones et al., 2008; Leary et al., 
2008; Wood et al., 2007).  Some insights into this dependency have, however, been elucidated, 
such as the requirement for activated K-ras in non-small cell lung cancer (Fisher, 2001).  This 
strategy of targeting antigens to which tumors are dependent is consistent with the general tactic 
of exploiting cancer’s vulnerabilities (Luo et al., 2009). 
The consideration of established tolerance to tumor antigens is very important in immune 
therapy, but not one that can be strictly applied based on currently available data.  Before cancer 
initiation, the host may be considered tolerant to tumor-associated antigens, as these self-antigens 
exist in the absence of immune reactivity.  On the other hand, the host is naïve to tumor-specific 
antigens at this time, so this group of antigens is likely to be appropriate for prophylactic 
immune therapy.  After cancer establishment, however, immune reactivity to both TAAs and 
TSAs is suppressed.  The specific mechanisms governing immune tolerance to cancer have been 
described and will be discussed later in the chapter, in addition to the potential for breaking 
tolerance to cancer.  In brief, immune tolerance is still being activity investigated and, at present, 
it is unclear how best to overcome these mechanisms. 
  - 29 - 
Activating adaptive immunity against cancer 
An effective adaptive immune response to cancer necessitates cross-presentation of tumor 
antigens by mature dendritic cells to CD8
+
 T cells to promote the generation of cytotoxic 
function.  This activity is supported by CD4
+
 helper cells, which are also stimulated in response 
to tumor antigen cross-presentation.  Here, I will describe how antigen-presenting cells (APCs), 
dendritic cells in particular, and CD4
+
 T helper cells contribute to CD8
+
 T cell activation in the 
context of cancer (Table 2).  Activating anti-tumor immunity, however transient its function may 
be, serves as a guide in the development of immune therapies against cancer. 
Dendritic cell activation 
Studies of how dendritic cells (DCs), the link between innate and adaptive immunity, are 
activated in response to damaged and dying cells have been important in supporting the idea of 
cancer immunosurveillance.  Cell death is a prominent feature of mutant tumor cells and can 
result from detrimental gene mutations, nutrient deprivation, or successful anti-cancer therapy.  
Dendritic cells phagocytose dying tumor cells and cross-present tumor antigens to lymphocytes.  
The activation state of DCs during cross-presentation determines whether productive anti-tumor 
immunity or immune tolerance will be generated.  Activated dendritic cells are characterized by 
expression of the co-stimulatory molecules B7-1 and B7-2, increased MHC class II antigen 
presentation and the generation of immune-stimulatory cytokines (Murphy et al., 2008). 
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The study of pattern-recognition receptors (PRRs), like toll-like receptors (TLRs), and 
their associated ligands, pathogen-associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPs), has been an intense and rapidly growing in the field of 
immunology over the last decade and a half (Kono and Rock, 2008; Medzhitov and Janeway, 
2000; Tesniere et al., 2008).  Associated with this area’s rapid growth came much controversy, 
particularly concerning the source and nature of the ligands that activate adaptive immunity as 
well as the relative importance of different PRRs in this process.  It suffices to say, though, that it 
is now established that dying somatic cells can induce immune reactivity leading to adaptive 
immunity in the absence of foreign microbes.  In addition, it was long thought that programmed 
cell death, or apoptosis, was a sterile death that did not result in immune activation.  This idea 
has been re-evaluated, leading to the notation of two forms of apoptosis, non-immunogenic and 
immunogenic, both of which are still being defined on the molecular level.  Because the type(s) 
of cell death that lead to immune activation are still under contention, I will use general terms, 
such as “dying cell” and “cell death,” to avoid confusion. 
The realization that antigens from dying cells in the absence of foreign microbial 
adjuvants could indeed be recognized by the immune system came with the discovery of “eat 
me” signals – ligands on dying cells that could interact with receptors on phagocytic cells to 
encourage engulfment.  One of these ligands phosphatidylserine (PS) is distributed 
asymmetrically on the inner-leaflet of cell membranes in healthy cells.  PS becomes exposed on 
the outer surface of dying cells and its interaction with PS receptors on phagocytic cells appears 
critical for clearance of dying cells (Fadok, 2001; Hoffmann, 2001).  A second ligand calreticulin 
is upregulated on cell surfaces during stress and damage and found to interact with the LDL-
receptor-related protein LRP on DCs to promote phagocytosis (Gardai et al., 2005).  In addition, 
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calreticulin exposure was found to govern the immunogenity of cancer cell death in response to 
chemotherapy (Obeid et al., 2007).  Because calreticulin is also on the surface of healthy cells, it 
was discovered that integrin-associated protein CD47 on viable cells interacts with SIRP on 
DCs and acts dominant to calreticulin-LRP engagement as a “don’t eat me” signal (Gardai et al., 
2005).  Thus, phagocytosis of dying tumors cells involves both exposure of “eat me” signals and 
abrogation of “don’t eat me” signals and can be enhanced by chemotherapy to support immune 
activation. 
The discovery of damage-associated molecular patterns or “danger” signals that 
promoted dendritic cell maturation and antigen cross-presentation after phagocytosis further 
supported the notion that tumor cells could induce a productive adaptive immune response.  
Even prior to the identification of these signals, it was already observed that dying tumor cells 
and cell debris could induce DC maturation and the generation of cytotoxic T lymphocytes 
(Gallucci et al., 1999; Shi et al., 2000).  Since then, a number of “danger” signals that stimulate 
pattern-recognition receptors, including Toll-like receptors (TLRs)-2 and -4, have been found to 
be derived from dying and distressed cells (Kono and Rock, 2008; Tesniere et al., 2008).  The 
first of these molecules identified that could function in DC activation were heat shock proteins, 
either surface-bound or released from dying normal and tumor cells (Basu et al., 2000; Binder et 
al., 2000; Feng et al., 2003).  Subsequently, a chromatin-associated protein HMGB1, uric acid 
crystals, and other “danger” signals have been recognize to support DC maturation and antigen 
cross-presentation in response to dying cells (Apetoh et al., 2007; Scaffidi et al., 2002; Shi et al., 
2003; Tesniere et al., 2008).  Studies of these “danger” signals and the response to them through 
pattern-recognition receptors are helping researchers to gain insight into the immune-stimulatory 
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component of chemotherapy and radiotherapy treatment for cancer and the potential to activate 
adaptive immunity through PRR stimulation (Table 2). 
CD4
+
 T cell help 
Whether or not CD4
+
 T cells are essential for cellular immunity is being debated, but, 
regardless, T cell help is certainly highly significant to CD8
+
 T cell activation and function 
(Bevan, 2004; Kennedy and Celis, 2008; Knutson and Disis, 2005).  Naïve CD4
+
 T lymphocytes 
are activated by T cell receptor (TCR) engagement with cognate antigens presented by MHC 
class II molecules on dendritic cells and associated stimulatory signals.  When these T cells are 
activated, they differentiate to assume one of many effector cell phenotypes that can greatly 
influence the strength and direction of an immune response.  The developmental path taken by 
CD4
+
 T cells depends on the microenvironment, including the co-stimulatory signals and the 
cytokine milieu present, in which these cells are activated.  The details of these signals and the 
fate of CD4
+
 T cell development are beyond the scope of this chapter; instead, we will focus here 
specifically on the T helper 1 (Th1) cell subset and its role in supporting cytotoxic T cell (CTL) 
activity against cancer.  Consistent with Th1 cells’ role in cancer is the fact that many of known 
tumor antigens are presented by MHC class II molecules and are encoded by genes that also 
produce MHC class I presented tumor antigens (Novellino et al., 2005). 
T helper 1 cells are thought to assist cellular immune responses in four ways: (1) 
activation of APCs, (2) provision of cytokines that directly support CTL survival and function, 
(3) maintenance of CD8
+
 T cell memory and (4) support of CTL effector function through direct 
contact.  As previously mentioned, the state of dendritic cell activation when cross-presenting 
antigens to naïve CD8
+
 T cells determines if immune activation or tolerance is produced.  In 
addition to pattern-recognition receptor signaling described above, CD4
+
 T cells can directly 
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activate dendritic cells that also cross-present antigen to CD8
+
 T cells to induce cytotoxic T cell 
generation (Bennett et al., 1997; Cassell and Forman, 1988).  Signaling via CD40 on DCs by 
interaction with CD40L on activated CD4
+
 T cells directly mediates DC stimulation.  In fact, 
dendritic cell activation followed by CTL priming can be reproduced with cross-linking 
antibodies to CD40 and abrogated by blocking antibodies to CD40L (Bennett et al., 1998b; 
Ridge et al., 1998; Schoenberger et al., 1998).  Moreover, agonistic CD40 antibodies are being 
investigated as an immune therapy against cancer in animal models and in pre-clinical/clinical 
trials (van Mierlo et al., 2004; van Mierlo et al., 2002; Vonderheide et al., 2007). 
Aside from DC licensing, T helper 1 cells produce cytokines, such as interleukin-2 (IL-2) 
and interferon- (IFN-), that effect cytotoxic T cell function.  IL-2 directly supports 
proliferation of CTLs after initial priming and is required for expansion of CD8
+
 memory cells 
(Chen et al., 1990; Gao et al., 2002; Williams et al., 2006).  In addition, IFN- has a potent effect 
on enhancing peptide processing and MHC class I antigen presentation (Früh and Yang, 1999; 
Yang et al., 1992).  Through this function, IFN- can augment cross-presentation by dendritic 
cells and boost recognition of target tumor cells by CTLs (Lugade et al., 2008).  Furthermore, 
direct contact between Th1 cells and CTLs via co-stimulatory molecules has been shown to 
promote CTL proliferation, survival and cytolytic function (Giuntoli et al., 2002; Kennedy and 
Celis, 2008).  The in vivo details of this phenomenon are still being examined.  As CD4
+
 T cell 
help has been shown in many contexts to enhance cytotoxic T cell activity against tumors, the 
mechanisms employed by Th1 cells are currently being investigated for cancer immune therapy 
(Kennedy and Celis, 2008). 
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IV. IMMUNE TOLERANCE TO CANCER 
Despite evidence for immune surveillance of cancer by T lymphocytes, the fact that 
tumors develop, progress, and persist is indicative of ineffective immunity.  Immune evasion by 
tumors has been hypothesized to explain why the immune system is not adequate to eliminate 
cancer (Table 3).  Alternatively, tolerance to cancer can occur due to immune regulatory 
mechanisms, which normally function to protect against autoimmunity and/or collateral damage 
during pathogenic responses (Table 3).  Strategies used for immune suppression are mediated by 
cell surface receptors, soluble factors and immune regulatory cells.  I will describe some 
examples of each of these in the following section. 
Immune suppression mediated by direct contact 
Evading recognition 
One approach tumors use to avert immune attack is to prevent immune recognition.  
Since cytotoxic T cells recognize their targets via tumor antigens presented on MHC class I 
molecules, downregulation of antigen expression or presentation would block detection (Chang 
and Ferrone, 2006; Khong and Restifo, 2002).  Consistent with this notion, was the observation 
that expression of genes encoding differentiation antigens correlated inversely with histological 
grade of melanoma (Hofbauer et al., 1998a; Hofbauer et al., 1998b).  Furthermore, an inverse 
correlation was also noted between the expression of melanocyte differentiation antigens and 
spontaneous cytotoxic T cell reactivity (Jager et al., 1996).  In line with these correlations are 
experiments in mouse models that result in loss of tumor antigens either spontaneously or after 
immune therapy (Khong and Restifo, 2002). 
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Reduced levels of MHC class I antigen presentation have been found in many human 
cancers, as well (Cabrera et al., 1996; Korkolopoulou et al., 1996).  Low levels of antigen 
presentation are also associated with increased malignancy (Vitale et al., 1998).  The molecular 
basis of reduced antigen presentation was elucidated to be due either to decreased expression of 
MHC class I molecules or to defects in the antigen presentation machinery (APM).  Loss of 
function mutations in 2-microglobulin, which makes up half of the MHC class I complex, have 
been identified in human cell lines (Hicklin et al., 1998; Restifo et al., 1996).  In addition, 
reduced expression of APM proteins, such as transporter associated with antigen processing 1 
(TAP1) and TAP2, has also been observed (Restifo et al., 1993; Sanda et al., 1995; Vitale et al., 
1998).  In many circumstances, however, exposure of tumor cell lines to IFN- re-established 
levels of antigen presentation.  Moreover, exogenous expression of TAP1 in tumor cells, despite 
having reduced levels of other APM components, reinstated recognition by T cells, as well 
(Alimonti et al., 2000).  Interestingly, ectopic TAP1 expression has also been shown to restore 
immunogenicity to IFN--insensitive murine sarcoma cell lines (Shankaran et al., 2001). 
Instead of thwarting immune recognition by altering antigen presentation on tumor cells, 
the complementary TCR-CD8 complex on cytotoxic T cells can be modified.  T cell receptors 
associated with the co-receptor CD8 can bind to cognate peptide-MHC class I complexes with 
much greater affinity than in the absence of CD8 (Holler and Kranz, 2003).  Furthermore, TCR 
co-signaling with p56-Lck, the intracellular kinase linked to CD8, enhances T cell activation 
(Abraham et al., 1991; Xu and Littman, 1993).  Dissociation of TCR and CD8 was observed in 
tumor-infiltrating lymphocytes (TILs) with reduced effector function from patient samples, 
despite maintaining normal levels of TCR and CD8 expression (Demotte et al., 2008).  Analysis 
of T cells with reduced function after prolonged antigen stimulation revealed that the TCRs, 
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instead, co-localized with galectin-3.  Extracellular galectin-3 is thought to form a lattice around 
the TCR, blocking its association with CD8.  Consistently, treatment with N-acteyllactosamine 
(LacNAc), a competitive inhibitor of galectin-3, restored CD8
+
 T cell effector function (Demotte 
et al., 2008).  Thus, galectin-3, besides having many other functions, can alter recognition of 
tumor cells by T cells and effect T cell function (Dumic et al., 2006).  Galectin-3 is secreted by 
activated T cells themselves, a self-regulatory mechanism, and by tumor cells, and is found in 
high concentration in sera from cancer patients (Joo et al., 2001; Liu and Rabinovich, 2005). 
Death receptors 
Cytotoxic T lymphocytes can kill tumors by expressing ligands that interact with death 
receptors on target cells (Russell and Ley, 2002).  When engaged, death receptors, such as Fas 
(Apo-1/CD95) and tumor necrosis factor-related apoptosis inducing ligand-receptors (TRAIL-
R), signal downstream with the help of adaptor molecules to activate a series of proteases, called 
caspases, that lead to apoptosis of the targeted cell (Danial and Korsmeyer, 2004).  Tumors can 
circumvent this death signal by decreasing expression or mutational inactivation of death 
receptors.  In fact, somatic mutations in Fas, TRAIL-R1, and TRAIL-R2 have been identified in 
a number of human cancers of non-hematopoietic origin (Lee et al., 1999b; Lee et al., 1999c; 
Park et al., 2001; Shin et al., 1999).  In addition, alterations in components downstream of death 
receptors have also been discovered in human cancer.  Chromosomal loss of genomic regions 
containing initiator caspases in the extrinsic death pathway have been identified, as well as, 
inactivating mutations (Park et al., 2002).  High expression of anti-apoptotic protein cFLIP, 
which functions proximal to cell surface death receptors, has also been demonstrated in human 
cancer (Irmler et al., 1997).  Furthermore, in animal models, tumor cell lines transduced to over-
express cFLIP escape T cell immunity in vivo (Medema et al., 1999).  Lastly, somatic mutations 
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in death receptors and downstream components have been found associated with advanced and 
metastatic disease (Shin et al., 2002). 
Induced apoptosis via death ligands and receptors have also been discovered to work in 
reverse; tumor can commandeer this system to induce death of attacking lymphocytes.  Activated 
lymphocytes normally elevate expression of Fas and reduce expression of intracellular inhibitors 
of apoptosis when they become activated as a means to quell their own immune response after 
clearance of pathogens (Krammer et al., 2007).  Thus, they are primed to respond to death 
ligands.  Indeed, when this mechanisms is altered, such as by somatic mutations of death 
receptors, lymphoma can occur (Grønbæk et al., 2003; Lee et al., 2001).  Expression of FasL, the 
ligand for Fas death receptor, has been observed in non-hematopoietic human cancers (Hahne et 
al., 1996; Niehans et al., 1997; O'Connell et al., 1998).  In addition, tumor areas with higher FasL 
expression were associated with reduced numbers of tumor-infiltrating lymphocytes and 
increased death of these lymphocytes compared to areas with low FasL (Bennett et al., 1998a).  
Furthermore, FasL-expressing human cell lines can kill a T lymphocyte cell line in vitro, in a 
manner that can be blocked by soluble Fas receptor or anti-sense knock-down of Fas in the T 
cells (Niehans et al., 1997; O'Connell et al., 1996). 
The expression of death ligands by cancer as a counter-attack to cytotoxic T cells, 
however, has been contested based on criticism of detection methods and assays used in the 
discovery of FasL expression on non-hematopoietic tumors (Restifo, 2000).  With the use of 
intron-spanning primers for reverse transcriptase-polymerase chain reaction (RT-PCR) and 
short-term cultures of surgical specimens to eliminate contaminating lymphocytes, researchers 
found no expression of FasL in melanoma, directly refuting previous data (Chappell et al., 1999).  
Furthermore, to make sense of previous in vitro T cell killing data, melanoma cells not 
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expressing FasL were shown to cause antigen-specific T cell death upon TCR engagement (Zaks 
et al., 1999).  This apoptosis, called activation-induced cell death (AICD), also functions through 
FasL engagement of Fas, but with both ligand and receptor originating from the T cells.  T cell 
apoptosis then occurs through Fas ligation by FasL on the same cell, suicide, or by a neighboring 
T cell, fratricide (Krammer et al., 2007). 
Co-signaling molecules 
The B7 family of co-signaling molecules is important in regulating T cell activation and 
tolerance (Greenwald et al., 2005).  The prototypical members, B7-1 (CD80) and B7-2 (CD86), 
are primarily expressed on hematopoietic cells and bind both CD28 and CTLA-4 receptors on T 
cells to stimulate or inhibit T cell activity, respectively.  CTLA-4 is currently a major target in 
immunotherapy trials against cancer and will be discussed further in section V of this chapter.  
More recently discovered B7 molecules include PD-L1 (B7-H1), PD-L2 (B7-DC), ICOSL (B7-
H2), B7-H3, and B7x (B7-H4) and have wider expression patterns, including expression on non-
immune cells.  In particular, immunostaining of patient samples has revealed higher expression 
of PD-L1, B7-H3, and B7x in tumors than in surrounding normal tissue (Boorjian et al., 2008; 
Dong et al., 2002; Gao et al., 2009; Zou and Chen, 2008).  Moreover, elevated PD-L1 staining 
was specifically associated with advanced grade and poor prognosis.  I will describe PD-L1 and 
its corresponding receptor PD-1 further as these have received the most attention of the recently 
identified B7 molecules.  It is clear, though, that the other B7 molecules also have roles in 
generating and maintaining tolerance to cancer (reviewed in (Seliger et al., 2008; Zou and Chen, 
2008)). 
Mice lacking either PD-1 or PD-L1 exhibit T cell hyperactivity and autoimmune disease, 
underscoring the importance of these molecules in controlling immune reactivity (Latchman et 
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al., 2004; Nishimura et al., 1999).  Engagement of PD-1 on T cells by PD-L1 results in inhibition 
of T cell proliferation and cytokine production (Freeman et al., 2000).  PD-L1 over-expression 
on tumors also causes apoptosis of T cells in vitro and promotes the growth of tumors in mice 
(Dong et al., 2002; Iwai et al., 2002).  Conversely, blocking antibodies to PD-L1 result in T cell-
mediated immune rejection of tumors in animal models (Strome et al., 2003; Wei et al., 2008).  
Moreover, PD-L1 is upregulated on tumor-associated myeloid cells, blockade of which also 
promotes T cell activation (Curiel et al., 2003).  Consistent with these data, PD-1 deficient 
transgenic T cells can reject transplanted tumors in mice under conditions which PD-1 proficient 
T cells are unable to do so (Blank et al., 2004).  To make things more complicated, both PD-L1 
and PD-1 can interact with additional molecules.  Specifically, like PD-L1, PD-L2 also engages 
PD-1 to regulate T cell responsiveness (Latchman et al., 2001).  Furthermore, B7-1 has been 
shown to interact with PD-L1 on T cells to suppress function (Butte et al., 2007).  Thus, PD-L1 
not only acts as a ligand, but as a receptor, mediating signals downstream of itself (Keir et al., 
2008). 
Soluble factors involved in immune suppression 
Transforming growth factor- 
Transforming growth factor- (TGF-), a prototypical family of molecules that possess 
pleiotropic function, has been studied extensively in various contexts (reviewed in (Li et al., 
2006; Massagué, 2008)).  In cancer, TGF- has roles in tumor suppression, angiogenesis, 
metastasis and, most relevant here, immune suppression.  Concerning this latter function, mice 
deficient for TGF-1, the predominant isoform expressed by immune cells, exhibit multi-focal 
inflammatory disease and tissue necrosis resembling autoimmune disease (Kulkarni et al., 1993; 
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Shull et al., 1992).  This mutant phenotype was ameliorated in animals with additional deficiency 
for either MHC class I or class II (Kobayashi et al., 1999; Letterio et al., 1996).  Specifically, 
TGF-1’s role in suppressing effector T cell responses was significant as in vivo antibody 
depletion of CD8
+
 or CD4
+
 T cells also suppressed autoimmunity in TGF-1 null mice. 
Tumor cells and stromal cells in the tumor microenvironment can secrete TGF- to 
mediate immune suppression.  In fact, a highly immunogenic tumor cell line over-expressing 
TGF-1 failed to instigate CTL cytolytic activity in vitro and in vivo despite maintaining MHC 
class I expression (Torre-Amione et al., 1990).  Conversely, CD8
+
 T cells insensitive to TGF-1, 
as a result of expressing a dominant-negative TGF- receptor dnTGF--RII, expanded to greater 
numbers in vivo and eradicated transplanted tumors that that produced TGF- (Gorelik and 
Flavell, 2001).  Specifically, TGF- can influence CD8+ T cell effector function by repressing 
transcription of enzymes involved in cytolysis and cytokines.  Neutralization of TGF- by 
ectopic expression of a soluble TGF--RII trap in transplanted tumors restored effector gene 
expression in tumor antigen-specific cytotoxic T cells in mice (Thomas and Massagué, 2005).  In 
addition, cytokine secretion from CD8
+
 melanoma-infiltrating lymphocytes derived from patients 
was also blocked by TGF- treatment (Ahmadzadeh and Rosenberg, 2005). 
In addition to production by tumors, TGF- secreted by the immune system also plays an 
important role in immune tolerance to cancer.  TGF- mediated the ability of T regulatory cells 
(or Tregs, described further later) to suppress CD8
+
 T cell cytolytic activity in vivo using a 
transplant tumor model.  Transfer of Tregs along with tumor-specific cytotoxic T cells abrogated 
tumor rejection, but expression of dnTGF--RII in these CTLs yielded tumor clearance despite 
the presence of Tregs (Chen et al., 2005). 
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Signal transducer and activator of transcription-3 
Like TGF-, signal transducer and activator of transcription 3 (Stat-3) also has diverse 
roles in cancer.  Stat-3 is activated by cytokines and growth factors receptors, many of which are 
aberrantly activated or mutated in tumors.  Not only can Stat-3 promote tumorigenesis in a cell 
autonomous fashion, it can mediate immune evasion by inhibiting immune responses to cancer 
(reviewed in (Yu et al., 2007)).  Constitutive Stat-3 activation in tumor cells results in 
transcriptional repression of pro-inflammatory cytokines and chemokines (e.g. IFN-, IL-12, 
CXCL10) and induction of immunosuppressive factors (e.g. IL-10, VEGF, IL-6).  Blocking Stat-
3 signaling in murine tumor cells, either with dominant-negative Stat-3 or with anti-sense 
oligonucleotides, results in derepression of pro-inflammatory molecules and chemo-attractants 
and subsequent immune cell infiltration into transplanted tumors (Burdelya et al., 2005; Wang et 
al., 2004).  Furthermore, in human melanoma cells bearing mutant B-RAF
V600E
, blocking 
oncogenic mitogen-activated protein kinase (MAPK) signaling via drug inhibition or RNAi, 
resulted in reduced production of immunosuppressive cytokines.  Although Stat-3 RNAi did not 
produce an additive effect, MAPK inhibition did not always result in reduced Stat-3 activation, 
suggesting that secretion of immunosuppressive cytokines may be regulated by many oncogenic 
pathways (Sumimoto, 2006). 
Stat-3 signaling in tumors produces a cascade of Stat-3 activation through the immune 
system.  In fact, tumor-infiltrating leukocytes often exhibit constitutive Stat-3 signaling 
themselves.  Specifically, immunosuppressive molecules secreted by tumors activate Stat-3 in 
dendritic cells to block maturation (Wang et al., 2004).  Hematopoietic cells in which Stat-3 has 
been genetically ablated display greater activation and tumor reactivity.  Moreover, transplanted 
tumors are rejected in these mice, although the tumor themselves are proficient for Stat-3 
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(Kortylewski et al., 2005).  Furthermore, T regulatory cells were under-represented in tumor-
infiltrating lymphocytes of animals with Stat-3 deficient hematopoietic cells, suggesting a 
potential role for Stat-3 in Treg maintenance or function.  Interestingly, CD4
+
 T cells have been 
shown to produce IL-10 and TGF- when deficient for suppressor of cytokine signaling 3 
(SOCS3), a negative regulator of Stat-3 (Kinjyo, 2006). 
Other soluble immune suppressive factors 
There are other soluble factors that regulate anti-tumor T cell function.  Enzymes that 
produce or degrade these molecules are often upregulated in the tumor microenvironment.  
Indoleamine 2,3-dioxygenase (IDO), which catabolizes the essential amino acid tryptophan, is 
expressed by tumor cells, surrounding stroma cells, and cancer-associated dendritic cells 
(reviewed in (Katz et al., 2008; Prendergast, 2008)).  The potent role of IDO in effector T cell 
suppression was first shown by treating pregnant mice with an IDO inhibitor, which resulted in T 
cell-dependent immune rejection of their fetuses (Munn, 1998).  In addition to tryptophan 
degradation, enzymes that catabolize (L)-arginine, such as arginase and nitric-oxide synthase 
(NOS), inhibit T cell proliferation and function (reviewed in (Bronte and Zanovello, 2005; 
Rodríguez and Ochoa, 2008)).  Arginase and NOS are expressed by tumor cells, tumor-
associated macrophages, and myeloid-derived suppressor cells (described further later).  In 
addition, cyclooxygenase 2 (COX2) and its downstream product prostaglandin E2 (PGE2) are 
produced in cancer and promote the expression of IDO and arginase (Braun, 2005; Rodriguez, 
2005).  Furthermore, PGE2 induces the generation of both myeloid-derived suppressor cells and 
T regulatory cells and inhibition of COX2 promotes anti-tumor immunity (Baratelli et al., 2005; 
Sharma et al., 2005; Sinha et al., 2007; Stolina et al., 2000).  Moreover, adenosine is expressed 
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by tumors under hypoxic conditions and produced by T regulatory cells to suppress T cell 
signaling and effector activity (reviewed in (Sitkovsky et al., 2008)). 
Cellular mediators of immune suppression 
The cells of the immune system influence each other greatly both through indirect soluble 
factors and through direct interaction of cell surface receptors and ligands.  As described above, 
tumor cells can harness these communication lines to influence immune reactivity itself.  That 
said, the soluble and surface-bound molecules normally function within the immune system, as it 
regulates itself.  Here, I will describe two of many cellular regulators of the immune system, T 
regulatory cells and myeloid suppressor cells.  These and other immune cells can restrict anti-
tumor cytotoxic T cell function through some of the mechanisms already mentioned. 
T regulatory cells 
In section III, I described the role of CD4
+
 T cells in supporting adaptive immunity, but 
CD4
+
 T cells can have immunosuppressive roles, as well.  The identities and functions of many 
of these and other lymphocytic immune suppressive populations are still being elucidated.  Here, 
I will focus specifically on CD4
+
CD25
+
 T regulatory cells (Tregs), now well known to be a 
central regulator of autoimmunity and peripheral tolerance (reviewed in Sakaguchi et al., 2008). 
Tregs are specifically identified by expression of the transcription factor Foxp3, which 
represses expression of genes directly involved in T cell activity (Marson et al., 2007; Schubert 
et al., 2001; Zheng et al., 2007).  Spontaneous mutation of Foxp3 was found to be the cause of 
neonatal autoimmune syndromes scurfy and IPEX, in mouse and humans, respectively (Bennett 
et al., 2001; Brunkow et al., 2001; Wildin et al., 2001).  In addition, targeted deletion of Foxp3 in 
mice also resulted in autoimmune disease and early lethality, confirming the critical role of 
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Foxp3 in immune regulation (Fontenot et al., 2003).  Furthermore, adoptive transfer of either 
CD4
+
CD25
+
 Tregs or CD4
+
CD25
-
 T cells transduced to express Foxp3 rescued animals from 
disease.  Moreover, specific deletion of Foxp3-expressing Tregs in adult mice also led to 
autoimmunity, supporting a essential role for T regulatory cells throughout life (Kim et al., 2007; 
Lahl et al., 2007).  Based on the requirement for Tregs in maintaining peripheral tolerance, it is 
not surprising that there is now ample evidence for T regulatory cell participation in tolerance to 
cancer. 
Expanded populations of T regulatory cells have been found within tumors, in tumor-
draining lymph nodes, and in peripheral blood of patients with various types of cancer (Ichihara 
et al., 2003; Liyanage et al., 2002; Ormandy et al., 2005; Viguier et al., 2004; Woo et al., 2001).  
Tregs from these patients were found to constitutively express the inhibitory co-signaling 
molecule CTLA-4 and produce immunosuppressive cytokines TGF- and IL-10.  When isolated 
from patient tumors, Tregs inhibited proliferation and cytokine secretion of autologous CD4
+
 and 
CD8
+
 T lymphocytes in vitro, demonstrating their ability to suppress adaptive immune effectors 
(Ormandy et al., 2005; Viguier et al., 2004; Woo et al., 2002).  Furthermore, high numbers of 
tumor-infiltrating Foxp3
+
 T regulatory cells in patients with ovarian cancer predicted reduced 
survival compared to patients with low Treg numbers (Curiel et al., 2004).  Conversely, in breast 
cancer, complete responders after neoadjuvant chemotherapy exhibited a reduced number of 
tumor-infiltrating Tregs and increased cytotoxic T cell responses in tumors (Ladoire et al., 2008). 
In animal models, the functional relationship between T regulatory cells and suppressed 
anti-tumor immunity has been further investigated.  The first demonstration of this association 
was through the use of monoclonal antibodies against the IL-2 receptor -chain CD25, which 
depletes Tregs based on their relatively high expression of CD25.  Depletion in mice before or a 
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day after tumor cell inoculation led to tumor rejection that was dependent on either CD8
+
 T cells 
or NK cells (Onizuka et al., 1999; Shimizu et al., 1999).  Since then, Treg depletion via CD25-
specific antibodies has been found to similarly enhanced anti-tumor immunity in other transplant 
tumor models (Zou, 2006).  Furthermore, denileukin diftitox, or ONTAK, a fusion protein of IL-
2 and active domains of diphtheria toxin, has been used with the aim of depleting Tregs in 
patients with solid tumors.  The limited number of clinical trials with ONTAK, however, has 
shown mixed results in patients (Attia et al., 2005; Barnett et al., 2005; Dannull, 2005). 
Other methods to affect Tregs, that exploit cell-surface receptors besides CD25, have also 
been used in mice with potential for clinical application.  These strategies include anti-CTLA-4 
antibody blockade and agonistic antibodies against the glucocorticoid-induced tumor necrosis 
factor receptor (TNF-R) family-related protein GITR and OX40 of the TNF-R superfamily.  
These therapies have all demonstrated some ability to block suppressive Treg activity and 
promote anti-tumor CTL activity in various mouse models (Ko et al., 2005; Shimizu et al., 2002; 
Sutmuller et al., 2001; Takahashi et al., 2000; Vu et al., 2007).  The functional purpose of these 
treatments, though, remain under question as each of the antibodies can directly promote T cell 
effector function in addition to limiting T regulatory cell function.  Low-dose cyclophosphamide 
has also been used to reduce Treg-mediated immune suppression (Ercolini, 2005; Turk, 2004).  It 
is, however, yet another example of a treatment regimen with multi-functional mechanisms of 
action (Loeffler et al., 2005). 
T regulatory cell accumulation in and around tumor sites can occur due to trafficking of 
natural (thymus-derived) Tregs or conversion of non-Treg cells into Tregs in the periphery.  
Involvement of chemokine ligands and receptors has been demonstrated in both mice and 
humans (Curiel et al., 2004; Tan et al., 2009).  Thus, an alternative or additive strategy to 
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depleting or blocking Tregs would be to inhibit migration of Tregs into tumor sites.  In addition, 
immunosuppressive cytokines have been shown to support the generation of Tregs, offering 
another avenue for intervention (Sakaguchi et al., 2008; Zou, 2006).  In fact, TGF- produced by 
existing Tregs can support the conversion of non-Treg CD4
+
 T cells into new Tregs (Andersson 
et al., 2008). 
T regulatory cells have been suggested to exert immune suppressive function in three 
general ways.  First, because Tregs express high levels of the CD25, direct competition for IL-2 
can limit anti-tumor effector T cell survival and proliferation, particularly in the tumor 
microenvironment (Antony et al., 2006; Zhang et al., 2005).  Second, Tregs may directly kill 
cross-presenting antigen-presenting cells or effector T cells via granzymes and/or perforin, 
although more studies are needed to understand this further (Cao et al., 2007; Gondek et al., 
2005; Grossman et al., 2004; Zhao, 2006).  Finally, described through a number of means and 
involving both direct contact and cytokines, Tregs can suppress T cell activity or induce myeloid 
cells to become suppressive of T cell activity (Chen et al., 2005; Sakaguchi et al., 2008; Zou, 
2006).  The relative importance of these immunosuppressive mechanisms to Treg function and 
the contexts in which each become relevant are still under investigation. 
Myeloid-derived suppressor cells 
In addition to immune suppressive cells of T cell origin, there are many immune 
regulatory cells of myeloid origin.  Included in this group are immature antigen-presenting cells 
since antigen presentation without proper co-stimulatory and inflammatory signals can lead to 
tolerance to the presented antigens.  Many of these myeloid/dendritic cell-like immune 
suppressors are still poorly defined, including IDO
+
 DCs, B7x
+
 DCs, CD11b
+
CD11c
+
 myeloid 
cells, and plasmacytoid DCs(Rabinovich et al., 2007; Zou, 2005).  Myeloid-derived suppressor 
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cells (MDSCs, also called myeloid suppressor cells MSCs), however, have been better described, 
at least in mice. 
MDSCs are a heterogenous population of myeloid cells that are generally defined as 
CD11b
+
Gr1
+
 in mice.  In humans, there are no specific markers for MDSCs, but cells with 
similar characteristics and the ability to negatively effect effector T cell function have been 
described (Filipazzi et al., 2007; Rodriguez et al., 2009; Schmielau and Finn, 2001).  Like T 
regulatory cells, myeloid-derived suppressor cells can inhibit anti-tumor T cell responses in 
many ways (Rodríguez and Ochoa, 2008).  First, MDSCs express arginase and NOS (particularly 
the inducible form NOS2, or iNOS), which catabolize L-arginine, as previously mentioned 
(Bronte et al., 2003).  Arginase, in particular, along with the cationic amino acid transporter 2B, 
limits the extracellular concentration of L-arginine in the tumor microenvironment.  L-arginine 
starvation, in turn, reduces the expression of TCR-associated CD3 chain, altering the ability of 
effector T cells to interact with their target cells (Rodriguez et al., 2003).  Decreased CD3 chain 
expression in tumor-infiltrating lymphocytes is also associated with MDSCs in cancer patients 
(Kuang et al., 2008; Zea et al., 2005).  In addition, MDSCs suppress T cell proliferation as 
reduced levels of L-arginine affect cell cycle progression (Rodriguez et al., 2007). 
Second, elevated levels of arginase and iNOS are found in human cancer patients and are 
associated with increased levels of nitrotyrosine (Bronte and Zanovello, 2005; Ekmekcioglu et 
al., 2000).  Under low L-arginine due to high arginase, iNOS mediates production of reactive 
oxygen species and peroxynitrite resulting in tyrosine nitration.  This can suppress anti-tumor T 
cell activity presumably by inhibiting T cell activation, which requires protein phosphorylation.  
In a three-dimensional human prostate cancer culture system, tumor-infiltrating lymphocytes had 
reduced level of nitrotyrosine and could respond to stimulation only after treatment with arginase 
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and NOS inhibitors.  Similar results were observed in a transgenic mouse model of prostate 
cancer after arginase and NOS inhibition (Bronte, 2005).  In addition to blocking signaling, 
tyrosine nitration can alter the ability of T cells to recognize their targets.  Tolerized CD8
+
 T 
cells were shown to have tyrosine nitration of their TCR-CD8 complex after contact with 
MDSCs in a process dependent on reactive oxygen species (Nagaraj et al., 2007).  Consistent 
with this, MDSCs have been described to induce CD8
+
 T cell tolerance in a manner dependent 
on MHC class I presentation of T cell-specific antigen (Kusmartsev et al., 2005). 
Finally, subpopulations of CD11b
+
Gr1
+
 MDSCs are capable of inducing expansion of 
natural T regulatory cells and generation of Tregs by conversion of non-Treg cells in mice 
(Huang, 2006; Serafini et al., 2008).  Many different immune regulatory cell populations are 
usually found together in the tumor microenvironment.  IL-1 and PGE2 are thought to produce 
inflammation around tumors that promote the recruitment of immunosuppressive immune cells.  
Thus, inhibiting inflammation by IL-1R genetic ablation or COX2 inhibition in mice reduces the 
accumulation of MDSC and Tregs in the tumor microenvironment (Bunt et al., 2007; Sharma et 
al., 2005; Sinha et al., 2007).  Moreover, surgical resection of tumors in mice decreases MDSC 
numbers, restoring them to normal levels, and promotes anti-tumor immunity (Salvadori et al., 
2000).  Besides recruitment of MDSCs, IL-13, produced predominantly by natural killer T cells 
and functioning through IL-4R and Stat-6, has been found to polarize macrophages to a tumor-
promoting phenotype characteristic of MDSCs (Sinha, 2005).  Furthermore, likely as a means of 
auto-regulation, IFN- produced by effector T cells can activate myeloid-derived suppressor cells 
(Gallina et al., 2006). 
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V. IMMUNE THERAPY AGAINST CANCER 
Immunological methods for treating cancers hold great promise, yet most 
immunotherapeutic strategies have yet to demonstrate great efficacy.  This is likely a result of 
our limited understanding of the mechanisms controlling immune tolerance to cancer.  Despite 
this weakness, strategies to activate immunity towards cancer are continuing to be employed and, 
from these attempts, we are gaining knowledge of how to improve cancer immune therapies. 
Vaccines against cancer 
Vaccines used against cancer include both prophylactic vaccines and therapeutic vaccines 
(Lollini et al., 2006; Purcell et al., 2007).  Prophylactic vaccines used to protect against cancer 
have generally been limited to diseases with viral etiology.  Because the prevalence of oncogenic 
viruses in healthy individuals is relatively low, there are only few examples of preventative 
vaccines against cancer.  These include formulations to block Hepatitis B and human 
papillomavisus (HPV) infections, which have been successful in reducing the risk of liver cancer 
and cervical cancer, respectively (Chang et al., 1997; Garland et al., 2007).  It is important to 
mention, however, that both these vaccines likely induce B cell antibody responses to antigens 
on the surface of viral particles, rather than robust T cell responses to virus infected cells.  In 
fact, in individuals with pre-existing HPV infection, the same vaccine that protects against the 
infection is unable to significantly eliminate HPV-infected cells or reduce viral load (Hildesheim 
et al., 2007).  This information should not discourage the use of therapeutic vaccines against 
cancer, though, as there are likely context-dependent factors involved in this outcome. 
Therapeutic vaccines come in many forms and have evolved tremendously over the 
years.  In general, these vaccines have two components:  tumor antigen(s) and an immune-
stimulating component.  Tumor antigens can be defined, through the use of peptides or genes 
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encoding the antigens, or unknown, such as in the use of damaged cancer cells.  As I have 
described in section III, many different types of antigens have been identified in cancer and 
considerations must be made when selecting these for use in cancer immune therapy.  The 
immune-stimulating component can include adjuvants, cross-linking antibodies, cytokines, and 
viruses with the goal of activating dendritic cells that will present the associated tumor antigens 
to the immune system.  Adjuvants stimulate pattern-recognition receptors (PRRs) on antigen-
presenting cells, as previously mentioned, and have included heat shock proteins and other toll-
like receptor agonists (Belli, 2002; Ishii and Akira, 2007; Janetzki et al., 2000).  In addition, to 
simulate CD4
+
 T cell help, both recombinant CD40L and an agonistic antibody against CD40 
have been used in clinical trials (Vonderheide et al., 2007; Vonderheide et al., 2001).  Cytokines 
used in vaccination, include IL-12, IL-21, among others, and serve to promote anti-tumor 
immunity by multi-faceted means (Cebon et al., 2003; Skak et al., 2008).  Moreover, due to the 
natural immunogenicity of viral pathogens, recombinant viruses expressing tumor antigen genes 
have been exploited as cancer vaccines (Eder et al., 2000; Harrop et al., 2006; Marshall et al., 
2000; Rosenberg et al., 2003).  Furthermore, researchers and clinicians have also employed 
combinations of these immunostimulatory agents (Ahonen, 2004; Arlen, 2006).  Despite 
observing changes in anti-tumor immunity with these vaccines, however, all attempts have 
resulted in little or no clinical objective response in patients (Rosenberg et al., 2004).  That said, 
many clinical trials involve patients that have failed to respond to other therapies and so likely 
bear highly aggressive cancer. 
In addition to single agent vaccines, whole cell vaccines are also being applied in pre-
clinical and clinical trials (Gruijl et al., 2008).  Expression of the cytokine granulocyte-
macrophage colony-stimulating factor (GM-CSF) is currently used together with irradiated 
  - 53 - 
tumor cells in a formulation called GVAX (Eager and Nemunaitis, 2005).  The exact functions of 
GM-CSF are still being elucidated, but this cytokine has been found to potently recruit antigen-
presenting cells and promote anti-tumor immunity in mouse model systems (Dranoff, 2002; 
Jinushi et al., 2008).  Irradiated autologous cancer cells biopsied from patients are transduced to 
express GM-CSF and used to induce immunity in that same patient.  This personalized treatment 
has been used against a number of cancer types (Salgia, 2003; Soiffer, 2003; Soiffer et al., 1998).  
Furthermore, as antigens from these whole tumor cell vaccines were found to be cross-presented 
by host dendritic cells, researchers and clinicians have moved on to use allogenic cell lines, 
bearing potentially unmatched MHC molecules, that can be made to more efficiently express 
transgenes.  These allogenic cancer cell lines are also irradiated and transduced to express GM-
CSF and can be produced in bulk to provide a standard treatment for many patients (Emens et 
al., 2004; Higano et al., 2008; Small et al., 2007).  Irradiated autologous tumor cells have also 
been mixed with irradiated cell lines expressing GM-CSF, even with additional expression of 
CD40L, to achieve cross-presentation of patient-specific tumor antigens (Dessureault et al., 
2007; Nemunaitis et al., 2006). 
Finally, mature dendritic cells, the most potent antigen-presenting immune cells, bearing 
tumor antigens themselves have been utilized as vaccines (Koski et al., 2008; Melief, 2008).  
Peptide-pulsed DCs induced stronger immune responses in cancer patients than peptides alone 
and viruses expressing the tumor antigen (Connerotte et al., 2008).  DCs have been derived from 
both monocytes and CD34
+
 progenitor cells for vaccine trials, although CD34
+
 cell-derived DCs 
have been shown to be more effective at inducing T cell responses (Banchereau et al., 2001; 
Ferlazzo et al., 1999; Schuler-Thurner, 2002).  Recently, a phase III clinical trial utilizing 
autologous DCs expressing GM-CSF and tumor antigen for prostate cancer was completed with 
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some success (Small, 2006).  Despite this, FDA approval for this vaccine was denied in part 
owing to the inability to standardize autologous vaccine formulations (Gruijl et al., 2008).  More 
standard DC vaccines have been used in the form of allogeneic cells, despite not having the 
capacity to prime T cells via syngeneic MHC molecules.  In theory, this could strongly stimulate 
CD4
+
 T cell help via allo-reactivity to potentially support anti-tumor cytotoxic T cell responses.  
Allogeneic DC vaccines, however, have failed to perform better than autologous DCs.  
Nonetheless, an interesting approach to achieve both cross-presentation of MHC class I tumor 
antigen presentation and strong CD4
+
 T helper cell induction via allogeneic MHC reactions has 
been with the use of fused hybrid cells between autologous tumor cells and allogeneic DCs 
(Trefzer et al., 2004; Trefzer and Walden, 2003). 
Adoptive T cell therapy 
Cancer vaccines must compete with established immune suppressive factors to overcome 
tolerance in cancer patients, which explains why it has not been easy to develop vaccines for 
cancer.  Furthermore, many endogenous tumor reactive T cells may be anergic or deleted and so 
less able to response to immune activating signals.  Thus, rather than inducing an immune 
response, passive immune therapy involves the transfer of already activated immune cells or 
molecules into cancer patient for therapy.  Transferred cells can be effector CD4
+
 or CD8
+
 T 
lymphocytes and transferred molecules are generally B cell antibodies.  I will mention 
therapeutic antibody administration later when I describe combination cancer therapies.  Here, I 
will describe the current use and future potential of adoptive T cell transfer therapy. 
Adoptive cell transfer (ACT) therapy involves the ex vivo culture and expansion of 
tumor-infiltrating lymphocytes (TILs) derived from a patient and transfer back into the same 
patient for therapy.  ACT was made possible by the use of high levels of IL-2, a T cell growth 
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factor, to culture human TILs.  This culture method allowed clinicians to greatly expand TILs 
while maintaining the lymphocytes’ ability to lyse autologous target cells in an antigen-specific 
manner (Dudley et al., 2003; Muul et al., 1987).  Initial randomized trials using ACT therapy in 
combination with IL-2 resulted in no significant difference in efficacy compared to IL-2 
treatment alone in either melanoma or renal cancer (Dréno et al., 2002; Figlin et al., 1999).  A 
similar clinical trial with gastric cancer, however, did result in prolonged survival with ACT 
(Kono et al., 2002).  Interestingly, these patients were treated with a low-dose chemotherapy 
regimen in addition to ACT compared to chemotherapy alone. 
A breakthrough in ACT therapy came with the use of non-myeloablative, 
lymphodepleting chemotherapy.  Patients receiving a regimen consisting of cyclophosphamide 
and fludarabine for 7 days prior to T cell transfer and IL-2 supplementation demonstrated in vivo 
expansion and persistence of antigen-specific T cells and resulted in cancer regression and 
autoimmunity (Dudley et al., 2002).  Use of this pre-conditioning regimen with ACT has since 
resulted in 51% of patients with metastatic melanoma demonstrating objective clinical response 
in therapy (Dudley et al., 2005).  This strategy was preceded by studies in mice where 
cyclophosphamide treatment increased the effectiveness of adoptive anti-tumor T cell transfer 
presumably by removing immunosuppressive T lymphocytes (Berendt and North, 1980; North, 
1982).  Recently, a multi-faceted rationale for lymphodepletion has been elucidated in mouse 
models, although other factors could be at play, as well.  First, lymphodepletion reduces immune 
suppressive T regulatory cells, which are often expanded in the presence of cancer (Antony et al., 
2005).  Second, lymphodepletion allows for homeostatic proliferation of transferred T cells and 
eliminates lymphocytes that might compete with anti-tumor T cells for important cytokines 
(Dummer, 2002; Gattinoni, 2005).  Finally, damaged cells and structures that block microbial 
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infection serve as natural adjuvants to boost immunity (Paulos et al., 2007).  More effective 
immune depletion strategies that result in myeloablation are currently being investigated (Dudley 
et al., 2008). 
The efficacy of ACT therapy with associated pre-conditioning in clinical trials is ample 
evidence of its potency as a cancer treatment (June, 2007; Rosenberg et al., 2008).  Its success, 
however, has been largely limited to metastatic melanoma, thus far.  Nevertheless, it is hopeful 
that the effectiveness of ACT will translate to other cancer types, particularly with research on T 
cell modifications that can improve efficacy.  One limitation of the current approach for ACT is 
the ability to isolate tumor-infiltrating lymphocytes for ex vivo expansion.  Thus, an alternative is 
gene modification of autologous peripheral blood lymphocytes (PBLs) to express T cell 
receptors specific for target tumor antigens.  Success with this procedure has been demonstrated 
in both mouse models and human patients (Clay et al., 1999; Morgan et al., 2006; Weinhold et 
al., 2007).  Furthermore, researchers are making efforts to eliminate the need for MHC-
dependent recognition of target antigens by using chimeric monoclonal antibody single-chain 
variable fragments (scFvs) fused to the intracellular signaling domains of the TCR complex 
(Gross et al., 1989).  In addition to modification of T cell-target cell recognition, T cells are 
being modified to improve their effector activity, survival, proliferation, and tumor-homing 
capacity (Kershaw et al., 2005).  For example, human T cells transduced to express co-
stimulatory ligands that are normally expressed on APCs can stimulate themselves and 
surrounding T lymphocytes to achieve a more potent anti-tumor response (Stephan et al., 2007).  
Furthermore, small interfering RNAs (siRNAs) targeting Fas have been used to improve the 
survival of human CTLs (Dotti et al., 2005).  The use of engineered T cells will surely expand 
the use of adoptive cell transfer therapy. 
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In addition to autologous ACT therapy for metastatic melanoma, allogeneic ACT has also 
proven efficacious under some circumstances.  As minor histocompatibility antigens can elicit 
potent T cell responses, allogeneic donor lymphocytes have demonstrated, although initially 
inadvertently, the ability to facilitate remission of cancer in some patients with leukemia and 
lymphoma.  Allogeneic ACT has since been used intentionally with the realization that donor 
lymphocytes could function in the capacity of graft-versus-host (GVH) to eliminate malignant 
cells (Kolb, 2008). 
Non-specific immune modulation 
A number of immune therapy treatments assume the existence of endogenous anti-tumor 
responses and so seek to boost these non-specifically or to block inhibition of these responses.  
Current strategies include the use of pro-immunity cytokines (in the absence of gene or peptide 
vaccination), such as IL-2.  Also being investigated are methods of blocking immune suppressive 
factors, such as TGF-, and inhibitory molecules, such as PD-1.  As there are numerous 
formulations for non-specific immune modulation, I will limit the following description to the 
blockade of the inhibitory CTLA-4 co-signaling molecule. 
As I mentioned previously, CD28 and CTLA-4 on T cells both bind co-signaling ligands 
B7-1 and B7-2, generally provided by APCs.  Signaling through CD28 promotes T cells 
activation, while CTLA-4 ligation results in inhibitory signaling.  CTLA-4 has much greater 
affinity than CD28 for co-signaling ligands and so CTLA-4 also functions to compete with co-
stimulation (Collins et al., 2002).  Furthermore, CTLA-4 blocks the formation of lipid-rafts and 
microclusters resulting in impaired TCR signaling (Schneider et al., 2008).  Because of CTLA-
4’s negative effect on T cells activation, blocking CTLA-4 with monoclonal antibodies was 
perceived to be a viable therapeutic strategy for cancer patients.  CTLA-4 blockade has 
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demonstrated efficacy in improving anti-tumor T cell responses and facilitating tumor rejection 
in mouse cancer models (Kwon et al., 1997; Leach et al., 1996; Shrikant et al., 1999).  The 
effectiveness of this treatment, however, depended on tumor stage, as anti-tumor effects were not 
enhanced with CTLA-4 blockade in mice with advanced lesions (Sotomayor et al., 1999; Yang et 
al., 1997).  Furthermore, since enhanced immunity relies on a pre-existing anti-tumor response, 
the natural immunogenicity of tumors also posed a challenge.  Thus, CTLA-4 blockade has since 
been combined with GM-CSF producing cancer cell vaccines with improved results in mouse 
models (Hurwitz et al., 2000; van Elsas et al., 1999).  Furthermore, this combination mediates 
increased anti-tumor immunity in patients with a reduction in adverse side effects (Hodi et al., 
2008; Melero et al., 2009).  Clinical trials of CTLA-4 blockade via two different humanized 
antibodies are currently underway against a variety of cancers (Peggs et al., 2008; Weber, 2007). 
As T regulatory cells constitutively express CTLA-4, it is unclear if CTLA-4 antibody 
blockade also affects this immunosuppressive population.  Antibody blockade of CTLA-4 on 
Tregs has yielded abrogated suppressive activity towards T cells, but this result has been debated 
(Quezada, 2006; Takahashi et al., 2000).  More convincingly, Tregs were found to require 
CTLA-4 to maintain peripheral tolerance as evidenced by fatal autoimmune disease in animals 
with Treg-specific CTLA-4 deficiency (Wing et al., 2008).  Additional CTLA-4 deficiency in 
other lymphocytes enhanced the disease, however, indicating that CTLA-4 functions on many 
cell types to regulate immunity. 
Combination therapy 
As I have mentioned at the beginning of this chapter, there are multiple components to 
cancer that have coordinated functions in facilitating malignant progression.  Based on this, the 
use of single agents or combination therapies aimed at altering multiple components of cancer, 
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rather than a single part, is likely to be advantageous in cancer therapy.  In fact, many treatments 
intended to target cancer cells have important immune components that add to their 
effectiveness, including chemotherapies, radiation therapy, and targeted therapies based on 
antibodies. 
The primary goal of conventional anti-cancer therapies, such as chemotherapies and 
radiation therapy, is to directly kill tumor cells that exist in the presence of many sources of 
cellular stress (Luo et al., 2009).  Many of these agents, however, also promote anti-tumor 
immunity (Zitvogel et al., 2008b).  For example, chemotherapy-induced death of tumor cells 
results in calreticulin exposure and release of HMGB1 promoting dendritic cell activation and 
tumor antigen cross-presentation (Apetoh et al., 2007; Obeid et al., 2007).  Furthermore, ionizing 
radiation enhances MHC class I antigen presentation and, thus, improved CTL recognition of 
target tumor cells (Garnett et al., 2004; Reits et al., 2006).  More directly, low-dose 
cyclophosphamide treatment reduces T regulatory cell-mediated immune suppression (Ercolini, 
2005; Turk, 2004).  In addition, the anti-metabolite gemcitabine decreases the number of 
myeloid-derived suppressor cells (Ko et al., 2007).  Furthermore, as previously mentioned, 
immune depletion with chemotherapy and radiation augments the efficacy of adoptive T cell 
transfer therapy (Dudley et al., 2008).  Efforts to further understand these pleiotropic effects and 
capitalize on synergistic interactions are in progress (Zitvogel et al., 2008a). 
A number of monoclonal antibodies have been approved for cancer therapy.  These 
include Herceptin, which targets the HER2 oncogene found predominantly in breast cancer, and 
Erbitux, which binds the epidermal growth factor receptor (EGFR) in a number of malignancies 
(Carter, 2001).  Binding of target proteins by these antibodies can block oncogenic signaling or 
mediate cell death by antibody cross-linking.  In addition, tumor cells bound by antibodies can 
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be killed via immune mechanisms, antibody-dependent cell-mediated cytotoxicity (ADCC) or 
complement-dependent cytotoxicity (CDC).  ADCC relies on recognition of the antibodies 
bound to tumor cells by Fc receptors on innate immune cells, such as natural killer cells, 
macrophages, neutrophils, and eosinophils.  Tumor cells are then killed via perforin/granzymes 
or other lytic enzymes depending on the immune cell type.  CDC involves recognition of 
antibodies by complement proteins that initiate a biochemical cascade resulting in osmotic lysis 
of tumor cells (Murphy et al., 2008).  The immune system’s role in the effectiveness of targeted 
monoclonal antibodies has been demonstrated in model systems and its role in the clinic is being 
investigated (Carter, 2001) 
 
VI. MOUSE MODELS OF CANCER FOR TUMOR IMMUNOLOGY 
Model antigens 
Many model T cell antigens have been used in cancer immunology studies, as well as, 
more general immunological research (Table 4).  Some of these antigens are derived from human 
or mouse tumors, whereas others come from foreign sources, ranging from chickens to viruses, 
or are synthetically produced.  The attraction of utilizing these defined antigens come from the 
various reagents that are available with which to investigate antigen-specific immune responses.  
As the identities of these antigens are known, peptides can be synthesized for use in stimulating 
antigen-specific T cells, detecting endogenous T cell responses via tetramer/Dimer staining, or 
vaccinating animals.  Additional reagents, such as viruses or cell lines, expressing these antigens 
are often available, as well.  Furthermore, T cell clones that specifically recognize these antigens 
presented by particular MHC molecules have also been developed.  In many cases, the T cell 
receptors (TCR) of these T cell clones have been used to make TCR transgenic mice that 
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produce large numbers of antigen-specific T cells.
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Mouse cancer models 
Model antigens have been engineered into mouse tumor cell lines, if not already naturally 
expressed, in order to study immune reactivity and therapy to tumors.  These lines vary in the 
type of cancer they represent, such as melanoma (B16), colon cancer (CT26), and breast cancer 
(4T1).  These cell lines are either transplanted subcutaneously or orthotopically into syngeneic 
mice to generate in vivo cancer.  Although widely used, such tumor models present a number of 
complications.  Tumor cell injection results in tissue damage, death to transplanted cells, and an 
acute burden of tumor antigens that is likely to be highly immunogenic.  In addition, transplanted 
cells are commonly injected under the skin, an organ that is surveyed by Langerhans cells, a 
dendritic cell subset described to be relatively potent at activating immune responses (Merad et 
al., 2008).  Moreover, transplanted tumors are unlikely to possess a realistic tissue 
microenvironment due to their ectopic location and rapid growth rate, which can influence 
immune therapy and facilitate tumor rejection.  Thus, to better understand the role of the immune 
system in cancer development, many groups have developed and/or used spontaneous cancer 
models in the mouse for the study of cancer immunology. 
Spontaneous cancer models used in cancer immunology have generally been animals that 
are germline deficient for tumor suppressor genes and/or that express oncogenes in tissue-
restricted patterns (Gendler and Mukherjee, 2001).  In addition, model tumor antigens are then 
expressed via (another) transgene in a tissue-restricted pattern or derived from the oncogenic 
transgene.  For example, two human tumor-associated antigens, CEA and MUC1, have been 
engineered to be expressed in transgenic mice (Clarke et al., 1998; Eades-Perner et al., 1994; 
Rowse et al., 1998).  Anti-tumor immunity and immune therapy in CEA transgenics have been 
studied in various contexts, including spontaneous breast cancer, colon cancer, and lung cancer 
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(Greiner et al., 2002; Thompson et al., 1997; Zeytin et al., 2004).  Tumor immunology in the 
MUC1 transgenic mouse has been examined in the context of pancreatic cancer and mammary 
cancer (Chen et al., 2003; Mukherjee et al., 2003).  Since the defined tumor antigens in these 
transgenic mice are expressed across many tissues, these models represent cancer bearing tumor-
associated antigens that do not offer a wide differential specificity between tumor and normal 
tissue. 
Two commonly used spontaneous cancer models are the RIP-Tag2 and TRAMP mice, 
both of which expressed SV40 large T antigen.  RIP-Tag2 express T antigen via the rat insulin 
promoter and develop insulinomas, tumors of the pancreatic -islet cells (Hanahan, 1985).  
TRAMP mice, on the other hand, utilize the rat probasin promoter and develop prostate cancer 
(Greenberg et al., 1995).  Various defined antigens have been studied in the context of these 
spontaneous tumor models, including epitopes of T antigens and of Influenza’s hemagglutinin 
(HA) engineered to be expressed similarly to T antigen (Anderson et al., 2007; Drake et al., 
2005; Lyman et al., 2004).  Since both oncogenic T antigen and these cancers’ associated tumor 
antigens are expressed in a tissue-restricted manner, the level of antigen expression is likely to be 
similar between tumor and normal tissue.  Thus, these models most closely represent cancer 
bearing differentiation antigens, particularly because antigen expression likely precedes tumor 
formation. 
In addition to spontaneous mouse cancer models, a few efforts have been made to 
generate conditional cancer models with associated tumor antigens that are regulated in a Cre-
loxP-dependent fashion.  The first of these utilized a ubiquitous promoter regulated by a floxed 
attenuator element to regulate expression of SV40 small and large T antigens (Willimsky and 
Blankenstein, 2005).  Cre delivered via Adenovirus through the tail vein to the liver induced 
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liver cancer with high efficiency.  In addition, through aberrant splicing or deletion of the 
attenuator, animals spontaneously developed focal tumors in various tissues.  In these animals, 
prophylactic vaccination against T antigen protected animals from both spontaneous and Cre-
induced tumor development.  This result is similar to what one might expect of a tumor-specific 
antigen in which neither central nor peripheral tolerance in the absence of cancer restricts 
antigen-specific T cells.  The utility of this model, however, is not only limited by the formation 
of spontaneous tumors, but also the dependence on SV40 T antigens as oncogenes. 
A second conditional cancer model in mice also aims to generate tumors bearing tumor-
specific expression of a defined antigen (Huijbers et al., 2006).  In this model, the cancer-testis 
antigen P1A is expressed in melanoma driven by coordinated expression of oncogenic H-ras and 
loss of tumor suppressors p16
Ink4a
 and p19
Arf
.  The group has yet to examine immune reactivity 
to these tumors due to incompatibility between the tumor antigen and the MHC haplotype 
expressed in the animals generated.  The use of genetic mutations relevant to human cancer in 
this model, however, is a step forward in the faithful recapitulation human disease.  Knowledge 
of the mutations that promote the development of different types of cancer in humans combined 
with the ability to specifically alter gene function in mice has allowed many laboratories to 
develop mouse models of various tumor types (Frese and Tuveson, 2007).  A new allele that 
achieves conditional expression of a model antigen has recently been developed to be compatible 
with various Cre-loxP-dependent mouse cancer models (Cheung et al., 2008).  This new model 
of an over-expressed self-antigen in cancer is described in Chapter 2.  
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ABSTRACT 
Maximizing the potential of cancer immunotherapy requires model systems that closely 
recapitulate human disease to study T cell responses to tumor antigens and to test 
immunotherapeutic strategies.  We have created a new system that is compatible with Cre-loxP-
regulatable mouse cancer models in which the SIY antigen is specifically over-expressed in 
tumors, mimicking clinically-relevant tumor-associated antigens.  To demonstrate the utility of 
this system, we have characterized SIY-reactive T cells in the context of lung adenocarcinoma, 
revealing multiple levels of antigen-specific T cell tolerance that serve to limit an effective anti-
tumor response.  Thymic deletion reduced the number of SIY-reactive T cells present in the 
animals.  When potentially self-reactive T cells in the periphery were activated, they were 
efficiently eliminated. Inhibition of apoptosis resulted in more persistent self-reactive T cells, but 
these cells became anergic to antigen stimulation.  Finally, in the presence of tumors over-
expressing SIY, SIY-specific T cells required a higher level of costimulation to achieve 
functional activation.  This system represents a valuable tool in which to explore sources 
contributing to T cell tolerance of cancer and to test therapies aimed at overcoming this 
tolerance. 
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INTRODUCTION 
Mouse models have been a mainstay of cancer immunology research.  The mouse has 
been used to probe the function of cells and molecules that influence the ability of tumor-reactive 
T cells to kill or to otherwise become functionally suppressed, or tolerized (Dunn et al., 2004; 
Rabinovich et al., 2007; Swann and Smyth, 2007).  These studies have largely relied on 
chemically-induced and spontaneous tumors in immunodeficient mice or on transplanted tumors.  
Such systems are limited because they fail to reproduce the complex interactions that exist 
among an emerging tumor, its microenvironment and the multiple elements of an intact immune 
system.  More recently, genetically-engineered cancer models with tissue-specific expression of 
known antigens have been used to study T cells reactive to tumor antigens (Anderson et al., 
2007; Drake et al., 2005; Huijbers et al., 2006; Muller-Hermelink et al., 2008; Nguyen et al., 
2002; Willimsky and Blankenstein, 2005).  Interestingly, these studies have led to divergent 
findings on T cell reactivity and tolerance to tumors, leading to the question of whether to 
attribute these differences to the immunobiology of specific tissues, the type of cancer under 
study, and/or the pattern in which antigens are expressed. 
Tumor antigens are characterized as either tumor-specific (TSAs) or tumor-associated 
(TAAs).  TSAs are derived from proteins to which the host immune system is naïve, such as 
mutant, germ cell-restricted, or viral proteins.  TAAs, on the other hand, are derived from wild-
type somatic proteins over-expressed or inappropriately expressed in tumors (e.g. CEA, ERBB2, 
hTERT, MUC1, P53).  Experimental immune therapies for both TSAs and TAAs are being 
pursued as neither is clearly a more effective anti-cancer target (Dudley et al., 2005; June, 2007; 
Rosenberg et al., 2008).  Targeting TSAs might appear preferable because this provides absolute 
selection for tumor cells; however, TSA expression is often limited to the individual tumors from 
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which they were originally identified (Novellino et al., 2005).  Conversely, TAAs are commonly 
shared among tumor types and represent the majority of known tumor antigens (Stevanovic, 
2002).  Thus, therapies developed to TAAs may be applicable to patients across cancer types. 
Lung cancer is the leading cause of cancer death worldwide.  This is due to its high 
incidence and the failure of existing therapies to effectively treat advanced disease.  Thus, there 
is great need to develop effective novel therapeutic strategies for lung cancer.  Relative to other 
tumor types (e.g. melanoma, ovarian and prostate cancer) little is known about the immune 
response to lung cancer or the potential for immunotherapy for this cancer type (Fukuyama et al., 
2006; Fukuyama et al., 2007; Mizukami et al., 2006; Raez et al., 2005; Woo et al., 2002).  To 
begin to explore the immune response to lung cancer antigens and to build systems for testing 
immunotherapeutic strategies to treat lung cancer in humans, we have created a mouse model in 
which the well-characterized T cell antigen SIYRYYGL (Udaka et al., 1996) is over-expressed 
in autochthonous lung cancer.  Based on analysis of T cells reactive to SIYRYYGL in this 
context, we have uncovered multiple levels of immune tolerance that limits an effective T cell 
response against a tumor-associated antigen (Figure S1). 
 
RESULTS 
Generation of R26
LSL-LSIY
 
To create a flexible system in which tumor-specific T cell responses could be carefully 
monitored during tumor progression, we used gene targeting to introduce a fusion of Firefly 
luciferase and SIYRYYGL (SIY) into the ubiquitously-expressed Rosa26 locus (Soriano, 1999) 
(Figure S2).  Expression of luciferase-SIY fusion protein (termed LSIY) is controlled by a Lox-
STOP-Lox, such that efficient expression can only be achieved following Cre-mediated excision 
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of the STOP element (Jackson et al., 2001; Tuveson et al., 2004).  The Rosa26-Lox-STOP-Lox-
Luciferase-SIY allele is hereafter referred to as R26
LSL-LSIY
.  We chose the synthetic peptide 
SIYRYYGL because many complementary reagents exist making it a tractable model antigen 
(Udaka et al., 1996) (Table S1).  SIY was fused to luciferase to facilitate detection and 
quantification of antigen expression in vitro and in vivo.  Cre-inducible expression from a 
ubiquitous promoter makes R26
LSL-LSIY 
compatible with various mouse cancer models that bear 
Cre-regulated tumor-predisposition genes (Frese and Tuveson, 2007). 
Adenovirus-Cre (Ad-Cre) infection of R26
LSL-LSIY/+
 mouse embryonic fibroblasts (MEFs) 
yielded strong induction of luciferase activity (>10
3
-fold over unrecombined MEFs), validating 
Cre-dependent regulation.  Interestingly, in the absence of Ad-Cre, we consistently observed 
slightly elevated luciferase activity (~3-fold) in R26
LSL-LSIY/+
 MEFs compared to controls (Figure 
1A).  This result suggests that R26
LSL-LSIY
 expresses LSIY at low levels. 
2C mice express a dominant TCR (recognized by the clonotypic antibody 1B2) that 
reacts with SIY bound by H-2K
b
 haplotype MHC class I (Kranz et al., 1984; Saito et al., 1984; 
Sha et al., 1988; Udaka et al., 1996).  To test for LSIY expression in vivo, the fate of potentially 
self-reactive 2C T cells was assessed in R26
LSL-LSIY
;2C mice.  CD8
+
1B2
+
 cells were severely 
reduced in peripheral blood of these mice relative to R26
+/+
;2C controls (Figure 1B).  
Furthermore, the proportion of thymic 1B2
+
 cells, in particular the CD8
+
CD4
-
 fraction, was 
diminished in R26
LSL-LSIY/+
;2C mice.  These data imply negative-selection of SIY-reactive cells 
during T cell development, or central tolerance, in R26
LSL-LSIY
 mice. 
R26
LSL-LSIY
 exhibits Cre-dependent over-expression 
Central tolerance could occur due to thymus-restricted or ubiquitous, somatic antigen 
expression.  Various tissues were surveyed to distinguish between these possibilities.  Luciferase 
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activity was 3-30-fold higher in both thymic and extra-thymic tissues of R26
LSL-LSIY/+
 mice 
relative to background levels in controls (Figure 1C).  By contrast, in R26
1Lox-LSIY/+
 mice, in 
which the STOP element had been deleted by the Meox2-Cre transgene (Tallquist and Soriano, 
2000), a 10
4
-10
5
-fold increase in reporter activity was detected in all tissues examined (Figure 
S2A; Figure 1C).  These results show that R26
LSL-LSIY
 exhibits low-level, ubiquitous expression 
of LSIY. 
To further characterize the consequences of low-level expression from R26
LSL-LSIY
, we 
assessed 2C cell reactivity to R26
LSL-LSIY/+
 cells.  Naïve 2C cells exhibited dose-dependent 
activation (measured by CD25 surface-expression) and proliferation upon co-culture with 
R26
LSL-LSIY/+
, but not with R26
+/+
, splenocytes (Figure S3A,B).  Additionally, transfer of CFSE-
labeled 2C cells into R26
LSL-LSIY/+
 mice led to progressive dilution of CFSE and upregulation of 
CD44, a cell-adhesion molecule associated with T cell activation (Figure 1D; Figure S3C).  
These data establish that low-level LSIY expression from R26
LSL-LSIY
 is sufficient to stimulate 2C 
cells in vitro and in vivo. 
Incomplete central tolerance in R26
LSL-LSIY
 mice 
Because we detected CD8
+
 T cells bearing 2C-TCR in blood and peripheral lymphoid 
organs of R26
LSL-LSIY/+
;2C mice, central tolerance to SIY must be incomplete (Figure 1B; data not 
shown).  To eliminate the possibility of an artifact of 2C transgenic mice, we infected R26
LSL-
LSIY/+
 and control mice, that have normal TCR repertoires, with Influenza virus engineered to 
express SIY (WSN-SIY) (Li et al., 1993; Shen et al., 2008).  Seven days after pulmonary WSN-
SIY infection of R26
+/+
 mice, robust induction of SIY-specific CD8
+
 T cells in lungs and 
lymphoid tissues was evident by staining with SIY-loaded H-2K
b
 DimerX reagent (Figure 2A; 
data not shown).  We also detected SIY-reactive T cells in lungs of WSN-SIY-infected R26
LSL-
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LSIY/+
 mice, albeit at significantly lower levels compared to controls (Figure 2A).  (SIY-reactive T 
cells were not detectable in uninfected mice (data not shown)). 
Because SIY-reactive T cells in R26
LSL-LSIY
 mice could be self-reactive, we probed the 
activity of these cells induced by WSN-SIY and found they were functional.  When single-cell 
suspensions from lungs of WSN-SIY-infected mice were stimulated in vitro with SIY, a 
comparable fraction of cells secreted IFN- in both R26+/+ and R26LSL-LSIY/+ cultures (Figure 2B).  
Furthermore, by assaying in vivo cytotoxicity (Figure S4) in WSN-SIY-infected mice, we found 
SIY-specific cytolysis in proportion to SIY-reactive T cells induced in R26
LSL-LSIY/+
 mice (Figure 
2C).  As we observed long-term health without autoimmunity in WSN-SIY-infected R26
LSL-LSIY/+
 
mice, we investigated SIY-reactive T cell fate.  Upon boosting with DC2.4.LSIY cells (a 
dendritic cell line expressing high levels of costimulatory molecules B7-1 and B7-2 (Shen et al., 
1997), modified to additionally express LSIY), we did not detect surviving SIY-reactive T cells 
in WSN-SIY-infected R26
LSL-LSIY/+
 mice. In contrast, memory cells were evident in WSN-SIY-
infected wild-type mice (Figure 2D).  Together, these results demonstrate that central tolerance 
to SIY is incomplete in R26
LSL-LSIY
 mice and a transient, but functional, T cell response to SIY 
can be initiated. 
Antigen over-expressing tumors progress normally 
R26
LSL-LSIY
 is a novel system in which over-expression of a self-antigen is induced, 
representing clinically-relevant tumor-associated antigens in human cancer (Novellino et al., 
2005).  Given the importance of TAAs as targets for cancer immunotherapy, R26
LSL-LSIY
 in Cre-
inducible cancer models provides a powerful tool to study T cell-tumor interactions.  To explore 
the utility of this system, we used a model of human lung adenocarcinoma in which oncogenic 
K-ras is expressed from its endogenous locus after intranasal Ad-Cre administration (Jackson et 
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al., 2001; Tuveson et al., 2004).  In this K-ras
LSL-G12D
 model, focal activation of oncogenic K-ras 
leads to epithelial hyperplasia, which progresses to adenoma and adenocarcinoma over a defined 
time course resembling human non-small cell lung cancer (NSCLC). 
We generated K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice and induced lung cancer in these animals 
and controls using Ad-Cre.  K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice developed lung tumors 
histologically indistinguishable from their K-ras
LSL-G12D/+
;R26
+/+
 littermates when examined at 
various times after Ad-Cre (Figure 3A; data not shown).  Tumors dissected from K-ras
LSL-
G12D/+
;R26
LSL-LSIY/+
 mice consistently had 10
3
-10
4
-fold higher luciferase activity than those from 
K-ras
LSL-G12D/+
;R26
+/+
 mice, suggesting that LSIY expression was maintained in established 
tumors (Figure 3B).  Luciferase activity was also detectable in large tumors several months after 
tumor initiation via in vivo bioluminescence imaging (Figure 3C). 
Histological examination of tumors from K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 and K-ras
LSL-
G12D/+
;R26
+/+
 mice at 8, 12, and 16 weeks post-Ad-Cre revealed no evidence of an active anti-
tumor T cell response in either genotype (Figure 3A; data not shown).  Furthermore, flow 
cytometry of lungs and lymphoid tissues of K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice failed to detect 
SIY-reactive T cells either early after tumor initiation (within 12 days) or 3-4 months later during 
tumor progression (data not shown).  Because this does not eliminate the possibility of an 
immune response below detection or at an unexamined time, we explored the effects that such a 
response might have had.  Specifically, we compared tumor burdens and sizes between K-ras
LSL-
G12D/+
;R26
LSL-LSIY/+
 and Kras
LSL-G12D/+
;R26
+/+
 littermates, but no significant differences were 
observed (Figure 3D).  These data suggest that although SIY-reactive T cells are elicited in 
WSN-SIY-infected R26
LSL-LSIY/+
 mice (Figure 2), a response is not generated against SIY-over-
expressing lung tumors. 
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Tumors maintain antigen presentation 
Tumor-specific down-regulation of antigen presentation has been proposed as a 
mechanism to evade recognition by T cells (Algarra et al., 2004; Khong and Restifo, 2002; 
Pardoll, 2003).  To measure MHC class I in tumors, lung tumor cell lines were derived from Ad-
Cre-infected K-ras
LSL-G12D/+
;p53
fl/fl
;R26
LSL-LSIY/+
 mice and R26
+/+
 controls (Figure S5A,B).  By 
flow cytometry, we detected comparably low levels of H-2K
b
, which was induced 40-fold by 
IFN- treatment in all lines (Figure S5C).  This indicates that antigen presentation is functional in 
tumors.  Furthermore, we induced and examined lung tumors in mice on a 2C transgenic 
background.  Tumors in K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
;2C mice were highly infiltrated by 
lymphocytes in contrast to tumors induced in K-ras
LSL-G12D/+
;R26
+/+
;2C  controls, demonstrating 
that antigen presentation by SIY-over-expressing tumors is sufficient to recruit 2C cells in vivo 
(Figure S5D).  These observations imply that loss of SIY presentation is unlikely to account for 
the unproductive immune response to SIY-over-expressing tumors. 
Naïve cells recognize but do not respond effectively to lung tumors 
Our data indicate that SIY-reactive T cells are present in K-ras
LSL-G12D/+
; R26
LSL-LSIY/+
 
animals, but fail to react to SIY-over-expressing lung tumors.  There are several non-exclusive 
explanations for this observation.  For example, neither tumor initiation nor progression may be a 
sufficient stimulus to induce T cell responses to tumor-associated antigens (Pardoll, 2003).  
Alternatively, peripheral tolerance to self-antigen may inhibit responses to over-expressed 
antigens in tumors (Redmond and Sherman, 2005).  Finally, tumors over-expressing antigen 
could be actively suppressing reactive T cells (Rabinovich et al., 2007; Zitvogel et al., 2006).  
Because the low numbers of endogenous SIY-specific T cells in R26
LSL-LSIY
 mice impedes 
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analyses, we investigated these possible mechanisms by transferring donor 2C cells into tumor-
bearing and control animals. 
Naïve 2C cells became activated and proliferated in tumor-bearing K-ras
LSL-G12D/+
;R26
LSL-
LSIY/+
 animals, similar to our observation in tumor-free R26
LSL-LSIY/+
 mice (Figure 4A,B; Figure 
S3C; Figure S1F).  Only in tumor-bearing K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice, however, were 2C 
cells enriched in lung-draining mediastinal lymph nodes relative to non-draining mesenteric 
lymph nodes (Figure 4C).  2C cells are likely retained in mediastinal lymph nodes where SIY 
antigen presentation is increased due to SIY-over-expressing lung tumors. 
Despite accumulation in high SIY areas, 2C cells did not infiltrate tumors, although 2C 
cells were detectable in lungs by flow cytometry (Figure 4C; data not shown).  Consistent with 
the absence of tumor-infiltrating lymphocytes, K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice displayed no 
decrease in tumor burden, size, or number relative to K-ras
LSL-G12D/+
;R26
+/+
 mice analyzed 4 
weeks after 2C transfer (Figure 4D).  These data demonstrate that 2C cells do not hinder tumor 
growth.  Moreover, 2C cells were not detectable in any mice at this time-point whether they bore 
tumors or not (data not shown).  These data indicate that 2C cells activated in R26
LSL-LSIY
 mice do 
not form memory cells, as was observed in WSN-SIY-infected R26
LSL-LSIY
 mice, potentially due 
to peripheral tolerance where persistent weak TCR stimulation leads to apoptosis (Redmond and 
Sherman, 2005).  Therefore, in the presence of self-antigen, SIY-reactive T cells become 
activated and divide, but do not significantly kill tumor cells or persist. 
SIY-reactive T cells are not cytotoxic in R26
LSL-LSIY
 mice 
Failure of T cells to kill SIY-over-expressing tumors could be due to a general defect in 
SIY-specific cytotoxicity or to a direct inhibition of T cells by tumors.  To assess 2C cell 
functionality, we assayed in vivo cytotoxicity examining the ability of 2C cells to kill non-
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malignant target cells (Figure S4; Figure 5A).  As shown in Figure 5C panel 1, DC2.4.LSIY 
vaccination stimulated 2C cells to become highly cytotoxic in wild-type animals, a positive 
control for SIY-specific cytotoxicity.  As a negative control, naïve 2C cells transferred into 
R26
+/+
 without vaccination do not become activated and, thus, only displayed low SIY-specific 
cytolysis. 
The assay was applied to tumor-free R26
LSL-LSIY/+
 mice.  Despite inducing activation 
markers and proliferating, 2C cells exhibited no more cytotoxicity in these animals than 2C cells 
in R26
+/+
 mice, indicating that self-antigen-induced activation fails to yield full effector function 
(Figure 4A,B; Figure 5B).  In tumor-bearing K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 animals, SIY-specific 
cytotoxicity was similarly defective (Figure 5B).  These data demonstrate generalized 
impairment in T cell cytotoxicity to antigenic targets, rather than specific inhibition of 
tumoricidal activity in R26
LSL-LSIY
 mice. 
TAA-over-expressing tumors suppress T cell cytotoxicity 
Peptide presentation without costimulation often yields unproductive activation and T 
cell deletion, analogous to our own observations (Hernandez et al., 2001).  To determine whether 
DC2.4.LSIY could provide the necessary costimulation to functionally activate 2C cells in 
animals in which SIY is a self-antigen, naïve 2C cells were transferred into R26
LSL-LSIY/+
 animals 
concurrently with DC2.4.LSIY vaccination (Figure 5A).  With this treatment, 2C cells exhibited 
high levels of SIY-specific cytotoxicity in tumor-free animals, despite low-level ubiquitous SIY 
(Figure 5B,C).  This result demonstrates that self-antigen presented with ample costimulation can 
yield functional activation of potentially self-reactive T cells. 
When 2C cells were transferred into tumor-bearing K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice with 
DC2.4.LSIY vaccination, however, only marginal induction of SIY-specific cytotoxicity was 
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observed (Figure 5B,C).  Thus, although costimulation enabled 2C cells to become highly 
cytotoxic to self-antigen in tumor-free animals, it failed to similarly induce SIY-specific 
cytotoxicity in the presence of tumors over-expressing SIY.  Importantly, 2C transfer and 
DC2.4.LSIY vaccination of tumor-bearing K-ras
LSL-G12D/+
;R26
+/+
 mice resulted in robust SIY-
specific cytotoxicity (Figure 5B).  This result strongly supports a mechanism by which tumors 
induce suppression of immune responses towards antigens over-expressed in those tumors.  
Furthermore, we observed comparably low cytotoxicity in mediastinal lymph nodes draining 
tumor-bearing lungs and mesenteric lymph nodes not draining tumors suggesting that tumor-
induced inhibition of TAA-specific T cells occurs systemically (Figure 5C; data not shown). 
Functional activation of TAA-reactive T cells requires stronger costimulation 
The balance of immune stimulatory and inhibitory factors determines whether immune 
reactivity or tolerance is generated.  Therefore, we reasoned that stronger immunological stimuli 
might induce SIY-specific cytotoxicity in tumor-bearing R26
LSL-LSIY/+
 mice.  DC2.4.LSIY 
vaccination failed to expand endogenous SIY-reactive T cells to detectable levels in R26
LSL-LSIY/+
 
mice (data not shown) whereas WSN-SIY was more potent (Figure 2).  Thus, we used WSN-SIY 
instead of DC2.4.LSIY to vaccinate naïve 2C cell recipients (Figure 5A). In contrast to the case 
with DC2.4.LSIY vaccination, WSN-SIY vaccination caused 2C cells to exhibit high SIY-
specific cytotoxicity in both tumor-free and tumor-bearing R26
LSL-LSIY/+
 mice (Figure 5D).  This 
result indicates that the threshold costimulation required to induce SIY-specific cytotoxicity is 
increased in the presence of SIY-over-expressing tumors.  Despite being highly cytotoxic, 
however, 2C cells did not seem to exert a significant anti-tumor effect in WSN-SIY-infected K-
ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice, although the number of animals tested was small (data not 
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shown).  This phenomenon is likely a result of the relatively brief lifespan of 2C cells in R26
LSL-
LSIY
 mice. 
SIY-reactive T cells blocked from death succumb to anergy 
We have shown that SIY-reactive T cells can be functionally activated in tumor-bearing 
R26
LSL-LSIY/+
 mice, but as these cells are short-lived, T cell death remains an obstacle to effective 
anti-tumor immunity.  To overcome this barrier, we over-expressed anti-apoptotic Bcl2 by 
infecting SIY-stimulated 2C cells with a retrovirus carrying Bcl2 and EGFP (MIG-Bcl2).  By 
observing enrichment of EGFP
+
 cells in culture, we confirmed that Bcl2-over-expressing 2C 
cells had enhanced survival over uninfected cells when deprived of IL-2 (Charo et al., 2005) 
(Figure 6A).  When MIG-Bcl2-infected 2C cells were transferred into R26
LSL-LSIY/+
 and R26
+/+
 
mice, Bcl2-over-expressing cells again became enriched over uninfected cells in both genotypes 
(Figure 6B).  Despite this enrichment, 2C cells in R26
LSL-LSIY/+
 mice were still significantly 
reduced and decreased over time compared to 2C cells in R26
+/+
 recipients, suggesting that 
induction of both intrinsic and extrinsic apoptotic pathways account for loss of 2C cells. 
Next, we examined the function of persisting Bcl2-over-expressing 2C cells.  Upon in 
vitro SIY stimulation of splenocytes recovered from 2C recipients, we observed that 2C cells 
from R26
LSL-LSIY/+
 mice had impaired IFN- secretion compared to controls (Figure 6C).  
Therefore, although Bcl2 over-expression can partially protect 2C cells from apoptosis in the 
presence of self-antigen, additional mechanisms act to induce anergy in these cells. 
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DISCUSSION 
We have described a novel system that allows inducible expression of a defined antigen 
in mice to mimic tumor-associated antigens (TAAs) in human cancer.  We have characterized T 
cells reactive to the SIY TAA in lung adenocarcinoma and uncovered multiple levels of immune 
tolerance that limit an effective response against TAAs (model depicted in Figure S1).  Due to 
low-level antigen expression, SIY-reactive T cells were subjected to central tolerance, 
eliminating the majority of potentially tumor- and self-reactive T cells during development.  In 
the periphery, SIY-reactive cells that escaped thymic selection died soon after activation, likely a 
mechanism to limit auto-reactivity.  Self-reactive T cells that were transiently blocked from 
apoptosis became anergic.  Finally, in mice bearing autochthonous SIY-over-expressing lung 
tumors, strong immunological stimuli were required to activate transferred 2C cells to become 
highly cytotoxic toward targets.  This is noteworthy because a weaker vaccine was able to impart 
cytotoxic activity on self-reactive T cells only in the absence of SIY-over-expressing tumors.  
Thus, in the context of a tumor-associated antigen, reactive T cells must overcome 
developmental negative selection, peripheral self-tolerance, and tumor-induced inhibition as 
barriers to effective anti-tumor immunity. 
Our data suggest that neither prophylactic nor therapeutic vaccines to TAAs will be 
effective in preventing or treating lung cancer.  Protection provided by prophylactic vaccination 
against an antigen relies on formation and maintenance of memory cells that can respond 
efficiently to tumors bearing that antigen (Lollini et al., 2006).  In R26
LSL-LSIY
 animals, where SIY 
is a self-antigen, we have demonstrated that SIY-reactive T cells do not persist and cannot result 
in immunological memory or protection to SIY (Figure 2D; data not shown).  In contrast, when 
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targeting antigens to which the host is not tolerant, prophylactic vaccines protect against even 
large numbers of potentially tumorigenic cells (Willimsky and Blankenstein, 2005). 
Therapeutic vaccines boost immune responses to tumor antigens in patients with 
established cancers (Lollini et al., 2006).  To be effective, this requires both the presence of 
antigen-specific T cells and the ability to properly activate these cells.  Based on our model, both 
elements are hampered in the context of TAAs.  We have shown that central tolerance results in 
significant diminution of SIY TAA-specific T cells (Figure 1C,D).  Additionally, we have 
demonstrated that DC2.4.LSIY vaccination yields only marginal induction of SIY-specific 
cytotoxicity in mice bearing tumors over-expressing SIY (Figure 5).  Furthermore, although 
WSN-SIY can endow 2C cells with high cytotoxicity, activated 2C cells are anergized and die in 
the presence of self-antigen (Figure 2D; Figure 6).  Our data are consistent with observations 
from human trials in which therapeutic vaccines have resulted in only rare cases of objective 
clinical response (Rosenberg et al., 2004).  Importantly, therapeutic vaccines may still be 
effective in combination with other therapeutic strategies (Schlom et al., 2007). 
Immune ignorance of tumors, immune avoidance by tumors, and active suppression of 
anti-tumor immunity are the prevailing explanations for defective T cell responses in cancer 
(Dunn et al., 2004; Pardoll, 2003; Rabinovich et al., 2007).  Loss of antigen expression or 
presentation is often described as a means of immune avoidance (Algarra et al., 2004; Khong and 
Restifo, 2002).  We have demonstrated sustained LSIY expression in lung cancer, even at 
advanced stages (Figure 3B,C).  Moreover, we have shown that antigen presentation was not 
different between R26
LSL-LSIY/+
 lung tumor cell lines and controls (Figure S5).  Furthermore, we 
have demonstrated the inability of 2C cells to efficiently kill non-malignant cells expressing high 
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SIY in SIY-over-expressing tumor-bearing hosts (Figure 5).  These data exclude immune 
avoidance by tumors as a major contributor to deficient anti-tumor T cell responses. 
We cannot exclude the possibility of immune ignorance playing a role in early stages of 
tumorigenesis, but our data argue for active tumor-induced immune suppression.  Inefficient 2C 
cell killing in mice bearing SIY-over-expressing tumors was observed even with coincident 
antigen presentation and costimulation provided by DC2.4.LSIY (Figure 5).  This treatment is 
normally immune-activating and, moreover, is capable of overcoming self-tolerance in tumor-
free R26
LSL-LSIY/+
 mice.  This implies that even if tumors are naturally ignored in our model, 
tumor-induced T cell suppression can dominate over immune-stimulatory signals. 
There are many mechanisms by which SIY-reactive T cells may be suppressed in K-
ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice (Rabinovich et al., 2007; Zitvogel et al., 2006).  Suppression can 
occur by contact with tumors or by intermediaries, but since we observe systemic antigen-
specific T cell suppression, direct contact between T cells and tumors is unlikely to be the 
dominant mechanism.  Tumor suppression by intermediaries may involve cellular and/or soluble 
inhibitors of T cell cytotoxicity.  These factors may be present normally to limit self-reactivity, 
but are increased in animals with self-antigen over-expressing tumors and thus induce greater 
suppression of antigen-reactive T cells.  Consistent with this idea, we have shown that high 
levels of costimulation provided by WSN-SIY were required to effectively induce cytotoxicity in 
2C cells (Figure 5). 
We immunophenotyped animals to screen for potential cellular mediators of T cell 
suppression.  Two putative immunosuppressive populations, Gr1
+
CD11b
+
 myeloid suppressor 
cells and CD4
+
CD25
+
FoxP3
+
 T regulatory cells, were reproducibly expanded in lungs and 
lymphoid tissues of tumor-bearing mice relative to tumor-free mice (Figure S6).  Interestingly, 
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both immune cell types are overrepresented in NSCLC patients and appear to mediate systemic 
immune suppression (Almand et al., 2000; Perrot et al., 2007; Woo et al., 2001).  Further studies 
are needed to determine if either of these cell types are playing a causal role in tumor-induced T 
cell suppression in our model. 
Melanoma, ovarian and prostate cancers are more often treated with immunotherapy in 
the clinic than other cancers.  This may reflect an inherent susceptibility of these cancers to 
immune attack or simply our limited experience in using the immune system to treat other 
cancers.  Our observations of tolerance in the presence of tumors are similar to those made in 
TRAMP mice in which prostate-specific expression of SV40 TAg leads to spontaneous prostate 
cancer (Anderson et al., 2007; Drake et al., 2005).  In contrast to our model, however, priming 
with a DC vaccine yielded more effective T cells that significantly reduced tumor burden in 
TRAMP mice (Anderson et al., 2007).  Interestingly, T cell tolerance was not observed in a 
mouse model of insulinoma also driven by SV40 TAg (Nguyen et al., 2002).  To learn more 
about tumor-immune interactions, it will be important to compare immune responses among 
different cancer types and even among tumors bearing different oncogenic alterations as 
particular pro-oncogenic events have been described to specifically modulate immune responses 
(Zitvogel et al., 2006).   
Numerous Cre-regulated oncogenes and tumor suppressor genes have been generated in 
the context of human cancer models (Frese and Tuveson, 2007).  Because R26
LSL-LSIY
 is 
expressed ubiquitously and independent of oncogenic events, our model tumor antigen can be 
studied in several cancer models to gain greater understanding of context-dependent effects on 
anti-tumor immunity.  Data derived from these studies will help define the best strategies to 
successfully stimulate the immune system to recognize and eliminate cancers of different origins. 
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METHODS 
Mice.  2C mice were provided by J. Chen, Trp53
flox
 mice by A. Berns, and Meox-Cre and Rag2
-
 
mice were purchased from Jackson Laboratories.  K-ras
LSL-G12D
 mice were generated in our 
laboratory (Jackson et al., 2001; Tuveson et al., 2004).  R26
LSL-LSIY
 mice and controls used were 
either pure 129S4/SvJae or enriched on C57BL/6 for 3-13 generations.  Donor 2C cells for 
transfer experiments were from pure C57BL/6 2C;Rag2
-/-
 mice and recipients were always 
C57BL/6 enriched.  To induce tumors, mice were infected with Adenovirus-Cre intra-nasally as 
previously described (Jackson et al., 2001).  WSN-SIY was provided by J. Chen and infections 
were done by intra-nasal instillation similar to Adenovirus-Cre.  For tumor studies, lung 
histology was prepared and analyzed by Bioquant Image Analysis software as previously 
described (Jackson et al., 2005).  Animal studies were approved by MIT’s Committee for Animal 
Care and conducted in compliance with Animal Welfare Act Regulations and other federal 
statutes relating to animals and experiments involving animals and adheres to the principles set 
forth in the 1996 National Research Council Guide for Care and Use of Laboratory Animals 
(institutional animal welfare assurance number, A-3125-01). 
 
Cells.  MEFs were derived from e13.5 embryos and grown as previously described (Tuveson et 
al., 2004).  KP/KPLSIY cell lines were derived from K-ras
LSL-G12D/+
;p53
flox/flox
 mice (Jackson et 
al., 2005) 16 weeks post-Ad-Cre.  Individual tumors were plucked from lungs, minced, 
trypsinized and cultured in MEF growing media until lines were established.  DC2.4.LSIY cells 
were generated by infection of DC2.4 cells (Shen et al., 1997) with a lentivirus bearing 
Luciferase-SIY and selection of a single positive clone.  In vitro activated 2C cells were made by 
stimulating 2C splenocytes/lymphocytes suspensions with 1μg/mL SIY in DMEM-10 full 
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medium overnight, then culturing with 10ng/mL mIL-2 (R&D Systems cat#402-ML) for 6 days.  
Bcl2 over-expression was achieved by spin-infecting in vitro activated 2C cells twice (at days 3 
and 4 of activation) with a pMSCV-IRES-GFP retrovirus carrying Bcl2, prepared as described 
(Schmitt et al., 2000). 
 
Luciferase detection.  Cells were lysed with Passive Lysis Buffer (Promega cat#E1941) and 
assayed with Luciferase Assay Reagent (Promega cat#E1501) according to manufacturer’s 
instructions.  Tissues and tumors were mechanically disrupted before lysis and tissue debris was 
pelleted before assay.  In vivo bioluminescence imaging was performed on a NightOWLII 
LB983 (Berthold Technologies).  Mice were shaved and intra-peritoneally injected with Beetle 
Luciferin (Promega cat#E1602) within 20 minutes prior to imaging. 
 
Cell transfer and DC vaccination.  Single-cell suspensions from lymph nodes and spleens of 
2C;Rag2
-/-
, R26
1Lox-LSIY/+
 and R26
+/+
 mice were used for 2C transfer, in vivo cytotoxicity assay’s 
target and control cells, respectively.  Cells were counted by hemocytometer, resuspended in 
RPMI and transferred into recipients via tail vein.  For CFSE-labeling, cells were resuspended at 
4-6x10
6
 cells/mL RPMI with 5% fetal calf serum containing 5μM (or 1μM for control cells in in 
vivo cytotoxicity assay) CFSE (Molecular Probes cat#C1157) for 10 minutes at 37
o
C.  Cells were 
then washed twice in RPMI with 5% fetal calf serum, followed by washes in serum-free RPMI 
before intravenous transfer into recipients.  3x10
6
 cells were injected for naïve 2C transfer, 
12x10
6
 cells for in vitro activated 2C, and 6x10
6
 cells each of CFSE-labeled target and control in 
vivo cytotoxicity cells. DC2.4.LSIY cells were washed and resuspended in RPMI for intra-
peritoneal vaccination with 5x10
5
 cells/mouse. 
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Cell isolation.  Single-cell suspensions from lymph nodes, spleen and thymus were generated by 
mechanical disruption.  For lung preparations, tissue samples were minced and digested at 37
o
C 
for 30 minutes in 125U/mL of collagenase-typeI (Gibco) in phosphate-buffered saline before 
mechanical disruption and passage through a 70μm-pore filter (BD Falcon).  Peripheral blood 
was collected by tail tip bleeds into 40μL of 50mM EDTA to prevent coagulation.  Red blood 
cells were lysed with an aqueous solution containing 0.83% NH4Cl, 0.1% KHCO3, and 
0.000037% Na2EDTA at pH 7.2-7.4.  Single-cell suspensions were passed through a 35μm-pore 
cell-strainer cap (BD Falcon) before culture, intravenous transfer, or staining for flow cytometry. 
Reagents and flow cytometry.  SIYRYYGL peptide was synthesized by MIT’s Biopolymers 
Laboratory.  Recombinant murine Interferon- (cat#315-05) was purchased from PeproTech Inc.  
The following antibodies were purchased from BD Pharmingen: CD4 (H129.19), CD8 (53-
6.7), CD11b (M1/70), CD16/CD32 (2.4G2), CD25 (7D4 and PC61), CD44 (IM7), CD69 
(H1.2F3), CD107a (1D4B), Gr-1 (RB6-8C5), H-2Kb (AF6-88.5), and IgG1 (X56).  
Phycoerythrin-conjugated and unconjugated DimerX I reagents were purchased from BD 
Pharmingen and prepared according to manufacturer’s instructions.  Intracellular Foxp3 staining 
was performed with FITC--mouse/rat Foxp3 staining set from eBioscience and secreted IFN- 
capture/detection was performed with Mouse IFN- Secretion Assay Detection kit (order#130-
090-516) from Miltenyi Biotec, according to manufacturers’ instructions.  Biotinylated 1B2 
monoclonal antibody was provided by J. Chen.  Streptavidin-allophycocyanin and streptavidin-
phycoerythrin conjugates were purchased from BD Pharmingen.  Cells were read on a 
FACSCalibur (BD Biosciences) and analyzed using Flowjo 8.1 software (Tree Star Inc).  Dead 
cells were excluded by 1μg/mL propidium iodide staining (Sigma). 
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ABSTRACT 
Adoptive cell transfer (ACT) therapy for cancer has demonstrated efficacy in clinical 
trials, particularly for the treatment of metastatic melanoma.  There is great potential in 
broadening the application of ACT to treat other cancer types, but the threat of severe 
autoimmunity may limit its use.  Immunosuppressive agents can be used to reduce autoimmune 
side effects, but this would undoubtedly also diminish immune reactivity against tumors.  Studies 
in model systems have demonstrated successful induction of anti-tumor immunity against self-
antigens without detrimental effects on normal somatic tissue.  These results are likely due to 
preferential recognition of tumor over normal tissue by activated T cells.  We previously 
described the generation of a mouse model system in which a defined self-antigen is highly over-
expressed in cancer.  Here, we applied adoptive T cell transfer therapy combined with 
lymphodepletion pre-conditioning to treat autochthonous lung tumors in this system.  With this 
treatment, we can overcome peripheral tolerance, successfully inducing large number of 
functional anti-tumor T cells.  Furthermore, these T cells are able to effect lung tumor over-
expressing self-antigen.  Importantly, despite large numbers of potentially self-reactive T cells, 
we do not observe overt autoimmunity.  In addition, we have potentially identified LAG-3 as an 
additional factor that serves to limit anti-tumor T cell activity. 
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INTRODUCTION 
Cancer immune therapy highlights new potential in the treatment of cancer.  In particular 
adoptive cell transfer (ACT) therapy has received great attention due to its success in treating 
some patients with metastatic melanoma (Dudley et al., 2005).  There is, however, a strong 
correlation between autoimmunity and the effectiveness of immune therapy against cancer (Yee 
et al., 2000).  When lineage-specific differentiation antigens are targeted by cytotoxic T 
lymphocytes (CTLs), as in ACT therapy for melanoma and prostate cancer, self-reactivity is 
tolerable.  On the other hand, autoimmunity against essential tissues, such as to lung or pancreas, 
would not be acceptable.  Thus, to expand the applicability of immune therapy to cancer of vital 
organs, we must learn more about the rules governing the balance between anti-tumor immunity 
and autoimmunity. 
Effective immune therapy against self-antigens in cancer has been demonstrated without 
resulting in autoimmunity in some animal models (Eck and Turka, 2001; Morgan et al., 1998; 
Vierboom et al., 1997).  In other cases, detrimental autoimmunity has resulted (Ludewig et al., 
2000).  Whether or not autoimmunity is induced likely depends on the features of the therapy as 
well as the differential specificity of target antigens for tumors versus somatic tissue.  For 
example, non-specific immune modulation, such as with the use of anti-CTLA-4 blocking 
antibodies, results in autoimmune symptoms in patients at high frequencies (Attia et al., 2005; 
Peggs et al., 2008).  Furthermore, self-antigens that are highly over-expressed in cancer, but have 
relatively low expression in somatic tissue, such as peptides from p53 and cyclin B1, are 
attractive targets for tumor antigen-directed immune therapy (Egloff et al., 2006; Theobald et al., 
1995). 
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Immune therapy has been used successfully to slow the growth and even eradicate 
established tumors in transplant models (Hanson et al., 2000; Overwijk et al., 2003).  
Conversely, autochthonous tumors have proven more difficult to treat and reports of successful 
immune therapy against established lesions are rare (Hurwitz et al., 2000; Nguyen et al., 2002).  
Transplanted cells are commonly injected under the skin, an organ that is surveyed by 
Langerhans cells, a dendritic cell subset described to be relatively potent at activating immune 
responses (Merad et al., 2008).  Furthermore, tumor cell injection results in tissue damage, death 
to transplanted cells, and an acute burden of tumor antigens that is likely to be highly 
immunogenic.  Moreover, transplanted tumors are unlikely to possess a realistic tissue 
microenvironment due to their ectopic location and rapid growth rate, which can influence 
immune therapy.  Thus, to better recapitulate the state of immune tolerance that exists in human 
cancer, immune therapy necessitates evaluation in autochthonous cancer. 
Previously, we described a novel allele R26
LSL-LSIY
 that allows inducible expression of a 
defined antigen SIYRYYGL (SIY) in mice to mimic an over-expressed self-antigen in human 
cancer (Cheung et al., 2008).  In the context of autochthonous lung cancer, SIY-reactive T cells 
encounter multiple barriers to effective anti-tumor immunity.  Here, we investigated adoptive T 
cell transfer with lymphodepletion pre-conditioning, an essential component for successful 
therapy, in R26
LSL-LSIY
 mice (Dudley et al., 2002; North, 1982).  We examined the ability of 
lymphodepletion to support transferred T cells reactive to a self-antigen and we determined the 
capacity of these T cells to influence self-antigen over-expressing tumors.  Furthermore, we 
explored the conditions governing heterogeneous response to immune therapy. 
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RESULTS 
Established B16-LSIY tumors can be controlled without overt autoimmunity 
B16-F10 melanoma, a poorly immunogenic cell line syngeneic to C57BL/6 mice, 
expresses a number of melanocyte differentiation antigen genes and has been used widely as an 
experimental tumor model.  Adoptive transfer of pmel-1 transgenic cytotoxic T lymphocytes 
(CTLs) specific for melanocyte antigen gp10025-33 causes regression of established B16-F10 
tumors and treatment is enhanced in mice with prior non-myeloablative immunodepletion 
(Gattinoni, 2005; Overwijk et al., 2003).  CTL-mediated tumor killing, however, is associated 
with autoimmune melanocyte destruction in the skin and eye (Overwijk et al., 2003).  Although 
autoimmunity to tumor differentiation antigens in non-essential tissues can be tolerated, 
autoimmune reactivity to self-antigens expressed ubiquitously in vital organs can be fatal.  Thus, 
we wanted to determine if we could achieve effective anti-tumor immunity against a self-antigen 
over-expressed in tumors without fatal autoimmunity in mice. 
First, we assessed if transplanted B16-F10 cells could be controlled in mice receiving 
lymphodepleting radiation followed by adoptive transfer of activated T cells specific for a tumor 
over-expression antigen as was demonstrated with transfer of T cells reactive to melanocyte 
differentiation antigens (Gattinoni, 2005).  SIY is an H-2K
b
-restricted self-antigen expressed 
ubiquitously at low levels in R26
LSL-LSIY
 mice (Cheung et al., 2008).  We generated a SIY over-
expressing B16-F10 line B16-LSIY and a control line B16-0 by retroviral infection of B16-F10 
cells with a MSCV-based vector expressing Luciferase-SIY (LSIY) or an empty vector, 
respectively, followed by drug selection.  B16-LSIY cells exhibit high-level luciferase activity 
that is decreased by approximately 10-fold after subcutaneous in vivo passage (Figure S1).  B16-
LSIY cells have equally reduced luciferase after 19 days in either R26
+/+
, R26
LSL-LSIY/+
, or 
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R26
1Lox-LSIY/+
 hosts suggesting that LSIY, the puromycin resistance gene product, or both are 
immunogenic in the context of a transplanted cell line despite peripheral self-tolerance in R26
LSL-
LSIY/+
 and R26
1Lox-LSIY/+ 
mice.  Regardless of the reduction of LSIY expression in these lines, in 
vivo passaged B16-LSIY lines still retain considerable reporter expression and so the parental 
lines were, therefore, utilized further. 
Animals were challenged subcutaneously with 2x10
5
 B16-LSIY or B16-0 cells and 
tumors were allowed 10 days to grow before treatment.  Treated animals received 5 Grays total 
body lymphodepleting irradiation (IR) several hours prior to intra-peritoneal vaccination with 
5x10
5
 DC2.5.LSIY cells (DC) and intravenous adoptive transfer of 1-1.5x10
7
 in vitro activated 
2C cells (2C).  B16-LSIY tumors in untreated R26
LSL-LSIY/+
 mice and B16-0 tumors in IR/DC/2C-
treated R26
LSL-LSIY/+
 mice grew progressively until animals were sacrificed.  B16-LSIY tumors in 
IR/DC/2C-treated R26
LSL-LSIY/+
 mice, however, exhibited significantly stunted growth, increasing 
only 3.5-fold in the 10 days following treatment (Figure 1A).  Flow cytometry analysis of 
inguinal lymph nodes revealed preferential accumulation of 1B2
+
 cells, which identifies the 2C T 
cell receptor (TCR), in ipsilateral lymph nodes draining B16-LSIY tumors, but not a B16-0 
tumor, compared to contralateral lymph nodes.  Furthermore, 2C cells were found in varying 
proportions in B16 tumors 5 days after treatment by flow cytometry (Figure S2).  This result 
indicates that adoptive T cell transfer boosted by vaccination and preceded by lymphodepletion 
can reduce growth of transplanted melanoma tumors by targeting an over-expressed self-antigen.  
Inhibition of tumor growth was SIY-specific and did not result in overt autoimmunity. 
We also examined B16-LSIY tumors in R26
+/+
 mice where SIY represents a tumor-
specific neo-antigen.  B16-LSIY tumors in untreated R26
+/+
 mice had reduced growth compared 
to those in R26
LSL-LSIY/+
 hosts demonstrating there is endogenous immune reactivity to B16-LSIY 
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tumors in the absence of peripheral self-tolerance.  Furthermore, when R26
+/+
 mice bearing B16-
LSIY tumors were treated with IR/DC/2C, most tumors regressed (Figure 1A).  One B16-LSIY 
tumor that did progress, albeit slowly over the 10 days following treatment, failed to exhibit 
luciferase activity indicating that loss of antigen expression allowed this tumor to escape immune 
attack (Figure S1).  None of the other explanted tumors examined, regardless of host or treatment 
conditions, had lost antigen expression.  Thus, these data suggest that immune therapy targeting 
a tumor-specific antigen is more effective than targeting a tumor over-expression antigen, but 
such a potent response can lead to tumor escape variants (Khong and Restifo, 2002). 
Lymphodepletion, vaccination, adoptive transfer function together to limit tumor growth 
To determine the individual contributions of lymphodepletion, vaccination, and 
transferred T cells in limiting B16-LSIY tumor growth in R26
LSL-LSIY
 mice, we treated animals 
with IR, DC, and 2C in combination, with IR and 2C without DC, with DC and 2C without IR, 
or with IR alone.  We observed that tumors grew similarly whether mice received DC/2C dual-
therapy or were left untreated, demonstrating that adoptive transfer of tumor-reactive T cells 
even with a weak vaccine is ineffective in this context without lymphodepletion (Figure 1B).  
Furthermore, we found similarly reduced tumor growth whenever animals received total body 
irradiation treatment either as a monotherapy or in combination.  This may suggest induction of 
endogenous immunity or an effect on tumors unrelated to immune response and will require 
further investigation.  2C following IR resulted in slightly less tumor growth then IR alone and 
the combination of DC and 2C following IR yielded the least tumor growth (Figure 1B).  The 
ability of self-antigen-presenting dendritic cells to boost the activity of effector CTLs has been 
described (Lou et al., 2004).  Thus, each component was needed to maximize the effectiveness of 
immune therapy in this context. 
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Adoptively transferred 2C cells persist better and are functional after lymphodepletion 
Previously, we demonstrated that activated 2C cells were short-lived in R26
LSL-LSIY
 mice, 
dying rapidly so that they were barely detectable after a week in vivo.  Ectopic expression of the 
anti-apoptotic protein Bcl2 extends viability transiently, but 2C cells become anergic to antigen 
stimulation in this context (Cheung et al., 2008).  Lymphopenia in immunodepleted mice 
increases the persistence of anti-tumor T cells (Gattinoni, 2005; Wang, 2005).  Furthermore, 
ablation of lymphocytic suppressor cells and release of natural adjuvants by total body 
irradiation supports anti-tumor T cell function (Antony et al., 2005; North, 1982; Paulos et al., 
2007).  Thus, we sought to determine if lymphodepletion could enhance 2C cell viability and 
function in R26
LSL-LSIY
 mice. 
Tumor-free R26
LSL-LSIY/+
 mice and R26
+/+
 littermates received in vitro activated 2C cells 
with DC.2.4.LSIY vaccine either with or without prior immunodepletion and were analyzed 
following treatment.  Analysis of inguinal lymph nodes of R26
LSL-LSIY/+
 mice revealed on average 
5-6 times more 2C cells 7 days after treatment in treated versus untreated mice (Figure 2A).  On 
day 15 after treatment, 2C cell number was maintained in treated R26
LSL-LSIY/+
 mice such that on 
average they numbered more than 15 times that in untreated.  Thus, lymphodepletion does 
indeed enhance 2C viability in SIY-expressing mice.  Lymphodepletion, however, does not 
eliminate all sources of peripheral self-tolerance, as 2C cells are maintained at even higher 
numbers in R26
+/+
 mice, with and without treatment (Figure 2A).  Interestingly, we did not 
observe a significant reduction in Foxp3
+
CD25
+
CD4
+
 T regulatory cells, a potent mediator of 
peripheral tolerance, after sub-lethal total body irradiation (Figure S3).  It is unclear if Tregs are 
resistant to irradiation or if they divide rapidly to recover, although the relatively small decline in 
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number at days 4 and 7 after lymphodepletion might suggest the former.  This matter will require 
further investigation. 
We then inquired about the function of persisting 2C cells in tumor-free R26
LSL-LSIY/+
 
mice.  Upon in vitro stimulation with SIY peptide, a significant fraction of 2C cells recovered 
from splenocytes of IR/DC/2C-treated R26
LSL-LSIY/+
 mice 6 days after treatment were able to 
secrete IFN- (Figure 2B).   A variable proportion of 2C cells recovered from treated R26LSL-
LSIY/+
 animals maintained the ability to secrete IFN- upon antigen stimulation for at least 2 
weeks (data not shown).  In addition, 2C cells from treated R26
+/+
 mice also secreted IFN- upon 
SIY stimulation, but untreated R26
LSL-LSIY/+
 mice never demonstrated cytokine secretion beyond 
background levels (Figure 2B).  We went on to examine 2C function in mice by an in vivo 
cytotoxicity assay (Cheung et al. 2008).  Despite reduced numbers of functional 2C cells in 
IR/DC/2C-treated R26
LSL-LSIY/+
 mice compared to R26
+/+
 mice, comparable levels of target cell 
cytolysis were observed in treated mice 2 weeks post-treatment (Figure 2C).  Not surprisingly, 
untreated R26
LSL-LSIY/+
 mice had low levels of in vivo SIY-specific cytotoxicity.  Therefore, 
lymphodepletion treatment enhances the survival and maintains the function of 2C cells 
transferred into animals expressing SIY self-antigen. 
K-ras
G12D
-driven lung tumors further support 2C persistence and function 
Previously, we demonstrated a higher threshold of stimulation to functionally activate 
SIY-reactive T cells in the context of autochthonous lung tumors over-expressing SIY (Cheung 
et al., 2008).  Tumor-induced tolerance was only investigated in the context of naïve 2C cells, so 
we wondered if SIY over-expressing lung tumors would negatively affect activated 2C cells 
transferred into lymphodepleted mice.  We infected K-ras
LSL-G12D/+
;R26
+/+
 and K-ras
LSL-
G12D/+
;R26
LSL-LSIY/+
 mice intra-tracheally with an Adenovirus vector carrying Cre (Ad-Cre) to 
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generate autochthonous lung tumors that do not express and those that over-express SIY self-
antigen, respectively (Jackson, 2001).  We then treated tumor-bearing R26
+/+
 and R26
LSL-LSIY/+
 
mice with 5 Gy total body irradiation followed by DC2.4.LSIY vaccination and transfer of 
activated 2C cells.  When we examined these mice 2 weeks after treatment, we noticed that a 
high proportion of CD8
+
 T cells staining positive for 1B2 in lungs, lung draining lymph nodes 
(LNs) and non-draining LNs of R26
+/+
 mice (Figure 3A).  These 1B2
+
CD8
+ 
cells likely represent 
a greater population than is found in tumor-free R26
+/+
 mice, but we have yet to perform a direct 
comparison. 
Interestingly, in tumor-bearing R26
LSL-LSIY/+
 mice 2 weeks after treatment, the proportion 
of 1B2
+
CD8
+
 cells found in the lungs is comparable to that in tumor-bearing R26
+/+
 mice (Figure 
3A).  This population exhibits great variability, but continues to be significant 3 weeks post-
treatment in lungs of R26
LSL-LSIY/+
 mice, whereas 1B2
+
CD8
+
 cells are considerably diminished in 
untreated mice (Figure 3B).  In addition, a higher proportion of 2C cells is found in the tumor-
draining LN of tumor-bearing R26
LSL-LSIY/+
 mice than in non-draining LNs, although this 
accumulation is variable (Figure 3A).  The distribution of 2C cells in lymph nodes of tumor-
bearing R26
+/+
 mice, however, does not exhibit this bias.  Furthermore, we noted a correlation 
between SIY over-expressing tumor burden and 2C T cell accumulation.  Specifically, reduced 
tumor burdens were found in R26
LSL-LSIY/+
 mice with lower proportions of 1B2
+
CD8
+
 T cells in 
their lung-draining LNs (data not shown).  We observed a similar preference of 2C cells for 
lymph nodes draining SIY over-expressing tumors when studying B16-LSIY tumors (Figure S2). 
To test for 2C function after lymphodepletion, we examined the ability of recovered cells 
to produce IFN- after in vitro SIY stimulation.  Similar proportions of 2C cells recovered 2 
weeks following treatment from lymph nodes of tumor-bearing and tumor-free R26
LSL-LSIY/+
 mice 
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secreted IFN- upon antigen stimulation (Figure 3C; Figure 2B).  At 3 weeks post-treatment, 2C 
cells from tumor-bearing R26
LSL-LSIY/+
 mice continued to be functional (Figure 3C).  Although the 
proportion of IFN--secreting cells was higher in R26+/+ mice, this disparity did not differ 
between tumor-free and tumor-bearing mice (Figure 3C; Figure 2B).  Thus, rather than having a 
negative effect of activated 2C cells, lung tumors over-expressing SIY self-antigen in 
lymphodepleted animals appear to further support persistence and function of transferred 2C 
cells. 
Autochthonous SIY over-expressing lung tumors are effected by 2C ACT after 
lymphodepletion 
Since functional 2C cells are maintained at high numbers and accumulate in lungs of lung 
tumor-bearing R26
LSL-LSIY/+
 mice after lymphodepletion treatment, we sought to determine 
whether this combination immune therapy could be effective against autochthonous lung tumors.  
We infected K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice with Ad-Cre intra-tracheally to generate SIY over-
expressing lung tumors.  At 18 weeks post-infection, we divided tumor-bearing animals into 3 
groups to be treated with 10
7
 in vitro activated 2C cells plus DC2.4.LSIY vaccine (DC/2C), 5 Gy 
sub-lethal total body irradiation only (IR), or a combination of activated 2C cells and vaccine 
preceded by lymphodepleting radiation (IR/DC/2C).  Animals received a single dose of 
treatment and were analyzed 3 weeks later.  To quantitatively assess the effects of therapy, we 
performed luciferase assays on whole lung lysates after bronchoalveolar lavage (BAL) to reduce 
biases caused by variable tumor distributions, which would influence surface counts and 
assessment of tumor burden by histological sections.  Lungs of tumor-bearing R26
LSL-LSIY/+
 mice 
treated with IR/DC/2C exhibited a statistically significant reduction of 66% in luciferase activity 
(** p <0.005 by Student’s t test) when compared to mice treated with DC/2C (Figure 3D).  IR-
  - 154 - 
treated animals had an intermediate level of luciferase activity, but because an untreated control 
group was not included in this experiment we cannot conclude if IR alone reduced luciferase or 
if DC/2C somehow increased luciferase.  In addition, we cannot determine at this time if a 
reduction in luciferase activity reflects a decrease in tumor burden, a decrease in luciferase 
expression by tumor cells, or a combination of the two, as we were unable to effectively assess 
tumor burden.  Furthermore, if reduced luciferase does indeed mirror decreased tumor burden, 
whether or not this is an antigen-specific phenomenon remains to be determined, as we could not 
examine R26
+/+
 tumor burden by luciferase assay.  In the future, longitudinal studies should be 
performed to assess tumor burden prior to and after treatment in order to address these 
uncertainties. 
LAG-3 upregulation may contribute to heterogeneous T cell function 
Activated 2C cells transferred into tumor-bearing R26
LSL-LSIY/+
 mice after 
lymphodepletion pre-conditioning persist, retain function, and potentially influence tumors over-
expressing SIY.  We have, however, observed considerable variability in each of these 
measurements, particularly when compared to tumor-bearing R26
+/+
 mice when applicable 
(Figure 3A,C).  These results suggest the involvement of immune suppressive mechanisms that 
function in an antigen-specific manner.  Many inhibitory molecules have been described to limit 
T cell function.  Thus, we have started to examine expression of candidate inhibitory receptors.  
CTLA-4, upregulated by activated T cells, blocks co-stimulatory molecule CD28 and inhibits 
TCR signaling (Peggs et al., 2008).  We stained 2C cells from tumor-bearing mice after 
IR/DC/2C treatment for CTLA-4, but failed to observe an increase in surface expression of this 
molecule in cells from R26
LSL-LSIY/+
 mice compared to R26
+/+
 mice (data not shown). 
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 Next, we examined the expression of LAG-3, another negative regulator of T cell 
homeostasis (Grosso et al., 2007; Workman and Vignali, 2005).  We found increased staining for 
LAG-3 on 2C cells derived from lungs of tumor-bearing R26
LSL-LSIY/+
 mice, but not on 2C cells 
from R26
+/+
 mice (Figure 4).  Individual lymphodepleted animals yielded heterogeneous levels 
of LAG-3 expression consistent with the heterogeneity in 2C cell persistence and function.  We 
have not, however, been able to correlate these measurements.  Interestingly, 2C cells in lung 
draining lymph nodes from either genotype had consistently low levels of LAG-3 (Figure 4).  
LAG-3 upregulation may represent a contributor to 2C cell heterogeneity in tumor-bearing 
R26
LSL-LSIY/+
 mice. 
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DISCUSSION 
We have demonstrated for the first time that adoptive T cell transfer influences 
established autochthonous tumors that over-express a ubiquitous self-antigen.  Lymphodepletion 
pre-conditioning had an essential role in therapeutic efficacy, allowing the persistence of 
functional self-antigen reactive T cells.  In addition, tumors in lymphodepleted animals further 
supported the persistence of these T cells.  Moreover, treated mice do not exhibit overt signs of 
autoimmunity.  It is likely that the differential expression of self-antigen in tumors and somatic 
tissues contributes to the observation of anti-tumor immunity in the absence of autoimmunity.  
Furthermore, self-reactive T cells were found to exhibit heterogeneity in population size and 
function despite lymphodepletion, suggesting the existence of additional immune tolerizing 
factors.  We discovered variable upregulation of the LAG-3 inhibitory molecule on self-reactive 
T cells that might contribute to the observed immune suppression. 
Recently, we described a novel allele R26
LSL-LSIY
 in mice that allows inducible expression 
of a defined antigen SIYRYYGL (SIY) to mimic tumor-associated antigens (TAAs) in human 
cancer (Cheung et al., 2008).  In R26
LSL-LSIY
 mice, SIY is a self-antigen expressed at low-levels in 
somatic tissues throughout the animal.  Upon Cre-mediated recombination of the allele, SIY 
expression is increased tremendously, copying the expression of known TAAs, such as p53 and 
cyclin B1 (Egloff et al., 2006; Theobald et al., 1995).  This system is compatible with the many 
Cre-loxP-regulated mouse cancer models available, which closely recapitulate important features 
of human cancer (Frese and Tuveson, 2007).  We characterized SIY-reactive T cells in the 
context of K-ras
G12D
-driven lung adenocarcinoma, revealing multiple levels of immune tolerance 
that together serve to limit an effective response against SIY (Jackson, 2001). 
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Previously, we demonstrated that activated 2C cells were short-lived in R26
LSL-LSIY
 mice, 
dying rapidly so that they were barely detectable after a week in vivo.  Ectopic expression of the 
anti-apoptotic protein Bcl2 extended viability transiently, but 2C cells became anergic to antigen 
stimulation in this context.  In contrast, we have shown here that lymphodepleting radiation prior 
to T cell transfer enhances that persistence 2C cells that retains functionality.  Moreover, we 
demonstrated tumor-induced tolerance earlier, such that in the presence of autochthonous lung 
tumors over-expressing self antigen, naïve T cells reactive to self-antigen could not be induced to 
become highly cytotoxic when boosted with a weak vaccine.  A stronger vaccine, in the form of 
a replicating Influenza virus, was required to overcome this tumor-induced tolerance.  Here, 
rather than having a negative effect of SIY-reactive T cells, we observe that the presence of 
tumors actually enhances the persistence of activated 2C cells and their homing to the tumor site 
when hosts are lymphodepleted. 
Total body sub-lethal irradiation has profound consequences on 2C cell survival, 
function, and anti-tumor effects in R26
LSL-LSIY
 mice.  It is not clear at this time exactly how pre-
conditioning produces all of these results, but rationales for this phenomenon have been 
elucidated.  The generation of immunological space for homeostatic T cell proliferation and the 
elimination of lymphocytes that consume supportive cytokines have been found to have potent 
roles in the effects of lymphodepletion (Dummer, 2002; Gattinoni, 2005).  Furthermore, the 
elimination of lymphocytic suppressor cells, such as T regulatory cells, by lymphodepletion has 
also been demonstrated (Antony et al., 2005; North, 1982).  Interestingly, T regulatory cells are 
not significantly reduced in number after irradiation of tumor-free mice in our hands (Figure S3).  
Release of lipopolysaccharides, potent immune adjuvants, from gut microbes has also been 
shown to mediate the effects of lymphodepletion, as well (Paulos et al., 2007).  Furthermore, 
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non-cytotoxic doses of radiation have been demonstrated to upregulate Fas death receptor and 
MHC class I antigen presentation on tumor cells (Chakraborty et al., 2003; Garnett et al., 2004).  
Moreover, low-dose ionizing radiation has been shown to enhance innate immune cell activity 
(Ren et al., 2006).  Finally, it is possible that low dose radiation can alter the tumor 
microenvironment to be immune supportive.  Many of these possibilities may account for our 
observation of efficacy with 5 Gy total body irradiation treatment alone on B16-LSIY tumors 
(Figure 1B). 
Further experiments are needed to investigate the actual effect of 2C ACT with prior 
lymphodepletion on autochthonous lung tumors.  Longitudinal studies will allow us to determine 
whether tumors are losing antigen expression or actually being killed and whether the effects we 
observe are SIY specific.  Moreover, additional studies are required to determine if LAG-3 
upregulation correlates with decreased SIY-reactive T cell number or function and whether 
additional inhibitory molecules are involved.  Longitudinal studies will be helpful with respect to 
this detail, as well.  If expression of LAG-3 or other inhibitory molecules correlate with reduced 
therapeutic efficacy in tumor-bearing R26
LSL-LSIY
 mice, we may be able to apply blocking 
antibodies to enhance immune therapy (Blackburn et al., 2009; Grosso et al., 2007; Keir et al., 
2007). 
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METHODS 
Mice.  2C mice were provided by J. Chen and Rag2
-
 mice were purchased from Jackson 
Laboratories.  R26
LSL-LSIY
 and R26
1Lox-LSIY
 mice were generated in our laboratory (Cheung et al., 
2008).  K-ras
LSL-G12D
 mice were also generated in our laboratory (Jackson, 2001; Tuveson et al., 
2004).  Donor 2C cells for transfer experiments were from pure C57BL/6 2C;Rag2
-/-
 mice and 
all recipients and controls used were also on pure C57BL/6 background.  To induce tumors, mice 
were infected with Adenovirus-Cre intra-tracheally.  Non-myeloablative immunodepleting 
irradiation was performed with 5 Grays (500 rads) total body irradiation upon exposure of 
animals to 
137
Cesium in a Gammacell 40 irradiator.  Irradiation was always performed within 6-
14 hours prior to T cell transfer or vaccination.  Animal studies were approved by MIT’s 
Committee for Animal Care and conducted in compliance with Animal Welfare Act Regulations 
and other federal statutes relating to animals and experiments involving animals and adheres to 
the principles set forth in the 1996 National Research Council Guide for Care and Use of 
Laboratory Animals (institutional animal welfare assurance number, A-3125-01). 
 
Cell lines.  B16-F10 cells were purchased from ATCC.  B16-LSIY and B16-0 derivatives were 
generated by infection of B16-F10 parental cells with amphotropic pseudotyped retroviruses 
made with sub-cloned pMSCV-LSIY-puro and empty pMSCV-puro transfer vectors, followed 
by puromycin selection.  Melanoma tumors were generated by subcutaneous injection of 2x10
5
 
B16-LSIY or B16-0 cells into C57BL/6 mice.  Tumor masses were measured by calipers and 
volumes were determined by assuming an ellipsoid shape; volume = (4/3)*pi*x*y*z, with x, y, 
and z being the widths of each perpendicular axis.  Tumor-bearing mice were treated with 
therapy on day 10 after tumor innoculation and sacrificed within 3 weeks after challenge.  
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DC2.4.LSIY cells were previously described (Cheung et al., 2008). DC2.4.LSIY cells were 
washed and resuspended in RPMI for intra-peritoneal vaccination with 5x10
5
 cells/mouse.  
Single-cell suspensions from lymph nodes and spleens of 2C;Rag2
-/-
, R26
1Lox-LSIY/+
 and R26
+/+
 
mice were used for 2C transfer, in vivo cytotoxicity assay’s target and control cells, respectively.  
Cells were counted by hemocytometer, resuspended in RPMI and transferred into recipients via 
tail vein. 1.5x10
7
 of CFSE-labeled target and control cells were injected per mouse for the in vivo 
cytotoxicity, which has been previously described (Cheung et al., 2008).  In vitro activated 2C 
cells were made by stimulating 2C splenocytes/lymphocytes suspensions with 1μg/mL SIY in 
DMEM-10 full medium overnight, then culturing with 10ng/mL mIL-2 (R&D Systems cat#402-
ML) for 6 days.  1-1.5x10
7
 in vitro activated 2C cells were injected for adoptive T cell transfer 
therapy. 
 
Luciferase detection.  In vivo passaged B16-LSIY and B16-0 cells were explanted and cultured 
in DMEM-10 full medium for a maximum of 5 days before assay.  Cells were trypsinized, 
washed, and lysed with Passive Lysis Buffer (Promega cat#E1941).  Assayed were performed 
with Luciferase Assay Reagent (Promega cat#E1501) according to manufacturer’s instructions.  
Tumor-bearing lungs were minced before lysis and tissue debris was pelleted before assay. 
 
Cell isolation.  Single-cell suspensions from lymph nodes, spleens, and B16 tumors were 
generated by mechanical disruption.  For lung preparations, tissue samples were minced and 
digested at 37
o
C for 30 minutes in 125U/mL of collagenase type I (Gibco) in phosphate-buffered 
saline before mechanical disruption and passage through a 70μm-pore filter (BD Falcon).  Red 
blood cells were lysed with an aqueous solution containing 0.83% NH4Cl, 0.1% KHCO3, and 
  - 169 - 
0.000037% Na2EDTA at pH 7.2-7.4.  Single-cell suspensions were passed through a 35μm-pore 
cell-strainer cap (BD Falcon) before culture, intravenous transfer, or staining for flow cytometry. 
 
Reagents and flow cytometry.  SIYRYYGL peptide was synthesized by MIT’s Biopolymers 
Laboratory.  Recombinant murine interleukin-2 (cat#402-ML) was purchased from R&D 
Systems, Inc.  The following antibodies were purchased from BD Pharmingen: CD4 
(H129.19), CD8 (53-6.7), CD16/CD32 (2.4G2), CD25 (7D4 and PC61), CD107a (1D4B), 
CTLA-4 (UC10-4F10-11), IgG1 (X56), and LAG-3 (C9B7W).  Intracellular Foxp3 staining 
was performed with FITC--mouse/rat Foxp3 staining set from eBioscience and secreted IFN- 
capture/detection was performed with Mouse IFN- Secretion Assay Detection kit (order#130-
090-516) from Miltenyi Biotec, according to manufacturers’ instructions.  Biotinylated 1B2 
monoclonal antibody was provided by J. Chen.  Streptavidin-allophycocyanin and streptavidin-
phycoerythrin conjugates were purchased from BD Pharmingen.  Cells were read on a 
FACSCalibur (BD Biosciences) and analyzed using Flowjo 8.1 software (Tree Star Inc).  Dead 
cells were excluded by 1μg/mL propidium iodide staining (Sigma). 
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CHAPTER 4: 
 
Overview and Future Directions 
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APPLYING R26
LSL-LSIY
 
In Chapter 2 of this thesis, I described the generation of a new model system R26
LSL-LSIY
 
that recapitulates a self-antigen SIY that becomes over-expressed in cancer.  We have identified 
many sources of tolerance faced by SIY-reactive T cells, which collectively limit anti-tumor 
immunity, in the context of a mouse model of lung adenocarcinoma.  With this new model, one 
can now explore the specific mechanisms that contribute to tolerance in the context of 
autochthonous cancer.  In addition, R26
LSL-LSIY
 can be used as a platform to examine therapeutic 
strategies currently in clinical and pre-clinical trials as well as to explore novel immune 
therapies.  Finally, as R26
LSL-LSIY
 is independent of specific oncogenes/tumor suppressor genes 
and specific tissue types, tumor-associated antigens can be studied in other Cre-loxP-inducible 
mouse cancer models. 
Elucidating mechanisms of tolerance 
In the Introduction, I described several means by which tumors can evade immunity and 
tolerance to cancer can be mediated.  We have already detected an expansion of myeloid 
suppressor cells and T regulatory cells in tumor-bearing mice compared to tumor-free mice, 
described in Chapter 2.  In addition, we observed upregulation of the inhibitory molecule LAG-3 
on SIY-reactive T cells in tumor-bearing R26
LSL-LSIY
, described in Chapter 3.  Furthermore, we 
have preliminary evidence of other immune regulatory factors, including additional immune cell 
types and inhibitory molecules, which could potentially be mediating tolerance to lung tumors.  
Despite our observations, we have not yet demonstrated that any of these mechanisms are 
actually contributing to immune tolerance to cancer.  Thus, R26
LSL-LSIY
 can be applied specifically 
for this purpose and to determine the relative contributions of individual immune suppressive 
agents. 
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Many groups have developed reagents to facilitate the interrogation of immune 
suppressive factors.  To interrogate specific cell populations or proteins, genetic tools have been 
developed which one can utilize to acutely delete the factor in question.  For example, we have 
initiated experiments with Foxp3-DTR transgenic and knock-in mice, which will deplete T 
regulatory cells upon administration of diphtheria toxin (DT) to mice, described in Appendix 1 
(Kim et al., 2007; Lahl et al., 2007; Quezada et al., 2008).  In addition, conditional alleles can be 
used to delete genes coding for specific factors or to specifically express DTR in defined cell 
types to be subsequently depleted with DT administration (Buch et al., 2005).  In addition to 
genetic tools, blocking antibodies have been widely used.  In Appendix 1, we described our 
efforts to deplete T regulatory cells, which express high levels of CD25, with a CD25-specific 
antibody (Zou, 2006).  Moreover, contingent upon additional experiments discussed in Chapter 
3, we can potentially use blocking antibodies to LAG-3 to improve T cell expansion and function 
in the context of adoptive cell transfer and immunodepletion (Grosso et al., 2007).  Furthermore, 
one can manipulate T cells to over-express, reduce expression, or block function of specific gene 
products to interrogate T cell-intrinsic molecules (Kershaw et al., 2005).  For example, 
expression of short hairpin (sh)-RNAs to LAG-3 or T cell-specific gene knockout of LAG-3 will 
also allow interrogation of LAG-3 function in limiting anti-tumor T cell function. 
Evaluating immune therapies for cancer 
Many immune therapies for cancer are currently being tested in clinical trials and, likely, 
more in pre-clinical trials.  Although, immune therapies have been used successfully against 
established tumors in transplant models, the likelihood of such wide success in clinical trials in 
low.  Transplanted tumors results in tissue damage, death to transplanted cells, and an acute 
burden of tumor antigens that is likely to be highly immunogenic.  In addition, the 
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microenvironment of the tumors are unlikely to be realistic due to the ectopic location and rapid 
growth rate of the transplanted tumor cells, which can influence immune therapy.  Thus, to better 
recapitulate the state of immune tolerance that exists in human cancer, immune therapy 
necessitates evaluation in autochthonous cancer.  Genetically-modified mouse cancer models, to 
which R26
LSL-SIY
 is compatible, closely recapitulate many aspects of human cancer (Frese and 
Tuveson, 2007).  As described in Chapter 3, we have evaluated adoptive cell transfer therapy 
with lymphodepletion pre-conditioning in lung tumor-bearing R26
LSL-SIY
 mice.  Whereas 
subcutaneous, SIY-expressing melanoma tumors were relatively easy to control, autochthonous 
lung tumors demonstrated a wide-ranging response.  Furthermore, we have identified LAG-3 as 
a potential contributor to heterogeneous T cell function.  Studies such as this will not only help in 
predicting the efficacy of cancer immune therapies in the clinic, but also facilitate the 
identification of additional points of intervention that may be useful for combination therapies. 
Discovering context-dependency in immune reactivity and tolerance 
An open question in cancer immunology concerns the immunogenicity of antigens 
among tissue sites.  For example, the skin has been described as a particularly immunogenic site, 
while the lung has been labeled immune suppressive (O'Mara and Allen, 2004).  Direct 
comparison of individual studies on tumor tissue microenvironments can be misleading due to 
many variables.  For example, two transgenic tumor models both based on oncogenic SV40 large 
T antigen have demonstrated divergent findings relating to immune tolerance.  In RIP-Tag2 
mice, which develop spontaneous insulinomas, tumor reactive T cells are not tolerized despite 
large tumor burdens and mice remain responsive to therapeutic vaccination (Nguyen et al., 
2002).  In contrast, tumor-reactive T cells in TRAMP mice, which develop prostate cancer, 
become dysfunction and vaccination is only effective in boosting T cell activity briefly 
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(Anderson et al., 2007).  The difference in tolerance induction between the models could be 
related to the tissue in which the cancer arises.  Alternatively, the difference may be attributable 
to the strain background or model antigens being investigated as T cells reactive to an antigen 
derived from a glycoprotein of lymphocytic choriomeningitis virus (LCMV-GP) is used in RIP-
Tag2 mice while T cells reactive to an epitope of T antigen is TRAMP mice. 
R26
LSL-LSIY
 offers researchers the ability to compare the same tumor antigen within two or 
more different tumor microenvironments.  As R26
LSL-LSIY
 is independent of specific tissue types, 
SIY can be studied as a model tumor-associated antigen in all Cre-loxP-regulated cancer models. 
For example, conditional expression of oncogenic K-ras
G12D
 and mutation/loss of the tumor 
suppressor p53 contributes to both lung adenocarcinoma and soft tissue sarcoma (Jackson, 2005; 
Kirsch et al., 2007).  Thus, comparing tolerance to SIY in these contexts will be informative in 
learning about how tissue microenvironments contribute to tolerance induction and maintenance. 
Another open question is the extent to which driving mutations in tumors influence 
tolerance.  For example, expression of oncogenic K-ras has been found to induce expression of 
various cytokines and chemokines (Ancrile et al., 2008; Ji et al., 2006).  In addition, as 
mentioned in the Introduction, Stat-3, induced downstream of various growth factor receptors, 
establishes an immune suppressive program (Yu et al., 2007).  Since R26
LSL-LSIY
 is expressed 
independently from tumor-predisposing alleles, one could use this system to investigate the 
impact of cancer genetics on immune tolerance. 
 
IMPROVING UPON R26
LSL-LSIY
 FOR MORE ADVANCED CANCER MODELING 
I have described a model system in which a defined antigen SIYRYYGL (SIY) has been 
genetically engineered to represent a self-antigen that is expressed ubiquitously at low levels and 
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presented by H-2K
b
 MHC class I molecules in mice.  Upon Cre expression in somatic cells of 
Cre-loxP-regulated mouse cancer models, oncogene activation and/or tumor suppressor gene 
inactivation is coordinated with over-expression of SIY in tumors (Chapter 2).  This system 
recapitulates what take places with naturally occurring self-antigens that are over-expressed in 
cancer.  One can make efforts to improve aspects of the current system as well as to use this as a 
foundation for constructing new systems. 
Making use of additional antigens 
As described in the Introduction, CD4
+
 T cell help is needed to license dendritic cells 
(DCs) in order for DCs to properly activate CD8
+
 T cell.  CD4
+
 T cells also support an active 
cytotoxic T cell response through cytokines and co-stimulatory molecules and promote the 
formation of functional memory T cells (Bevan, 2004; Kennedy and Celis, 2008).  In R26
LSL-LSIY
 
mice, Firefly luciferase is a protein fusion partner with SIY and, thus, luciferase is over-
expressed in tumors alongside SIY.  It is expected that luciferase contains peptide epitopes that 
can be presented on MHC class II molecules, which are recognized by CD4
+
 T cells.  In fact, 
pulmonary infection of K-ras
LSL-G12D/+
 mice with integrating lentiviruses expressing luciferase 
and Cre results in lung tumors with substantial lymphocytic infiltration, whereas relatively few 
lymphocytes are observed with lentiviruses bearing Cre alone (DuPage and Jacks, unpublished).  
Thus, to examine CD4
+
 T helper cells in the context of tumors over-expressing luciferase-SIY, 
one could clone such T helper cells and identify their cognate MHC class II-restricted antigens.  
With these additional reagents, one can better examine and manipulate the induction of anti-
tumor immunity in R26
LSL-LSIY
 mice.  Furthermore, suppressor lymphocytes could potentially be 
examined with these reagents as T helper cells can be converted into Foxp3
+
CD4
+
 T regulatory 
cells (Andersson et al., 2008).  In addition, one can assess whether natural T regulatory cells to 
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LSIY are generated in the thymus due to LSIY expression there.  Finally, it would also be useful 
to identify addition CD8
+
 T cell clones and their cognate MHC class I-restricted antigens from 
luciferase-SIY. 
Including tumor-specific antigens 
Tumor cells contain numerous antigens that can potentially be recognized by the immune 
system.  These antigens likely fall into both tumor-associated antigen and tumor-specific antigen 
classes, which were described in the Introduction.  Most tumor-specific antigens are not found 
coincident between individual tumors, even if they are from the same type of cancer (Segal et al., 
2008).  Despite this, use of some cancer immune therapies, such as autologous whole tumor cell 
vaccines, can boost immune responses to undefined tumors-specific antigens (Gruijl et al., 2008).  
Furthermore, activation of immune responses to one tumor antigen can result in induced 
reactivity to associated antigens via epitope spreading (Pilon et al., 2003).  Thus, a system in 
which multiple types of antigens can be studied within the same tumor would be useful.  I have 
described a model system utilizing the defined antigen SIY as a tumor-associated antigen in lung 
cancer.  An alternative system has been developed in the lab that makes use of SIY as a tumor-
specific antigen (DuPage and Jacks, unpublished).  In this case, SIY is introduced into mice, 
again as a fusion with luciferase, but via an integrating lentivirus that also carries Cre with it.  
This system results in restriction of SIY expression to cells that will become tumors by way of 
the conditional K-ras
LSL-G12D
 allele.  Neo-antigen expression of SIY results in induction and 
infiltration of endogenous SIY-reactive T cells into tumors, a phenotype of immunogenic tumors 
(DuPage and Jacks, unpublished).  In contrast, when SIY is introduced via lentivirus into R26
LSL-
LSIY
 mice, lymphocytic infiltration into tumors is not observed, indicative of SIY representing a 
self-antigen in this situation (Cheung, DuPage, and Jacks, unpublished).  Thus, with the same 
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lentivirus used to infect K-ras
LSL-G12D/+
;R26
+/+
 and K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice, we can 
generate tumors bearing SIY as a tumor-specific antigen or as a tumor-associated antigen.  
Furthermore, when we use a lentivirus carrying ovalbumin antigens in addition to SIY and Cre to 
infect K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice, we generate a lung tumors with coincident expression of 
tumor-associated antigens (specifically SIY and epitope in luciferase) and tumor-specific 
antigens (specifically known antigens derived from ovalbumin) (Cheung, DuPage, and Jacks, 
unpublished).  With this system one can learn how immune reactivity to one type of tumor 
antigen influences another. 
Studying naturally occurring tumor antigens 
Tumor immunologists have learned a great deal from the use of model antigens.  These 
systems have been attractive because of the many established reagents on hand that can be used 
to interrogate these defined antigens in various contexts.  Defined antigens in mouse cancer 
models, however, may not fully recapitulate naturally occurring tumor antigens, particularly 
when the model antigens are derived from a different species or are synthetic.  R26
LSL-LSIY
 suffers 
from both these short-comings, as luciferase is derived from Firefly and SIY is synthetic, not yet 
found to occur naturally in any species (Whittaker and Eisen, unpublished).  To more faithfully 
recapitulate the immunology of cancers, one can potentially clone CD8
+
 and CD4
+
 T cells from 
tumor-vaccinated mice.  In addition, cognate antigens can be identified by screening T cell 
clones.  This can be achieved with peptides derived from dendritic cells that have engulfed and 
processed tumor antigens.  Furthermore, with nuclear transfer and 4-factor reprogramming 
technology, transgenic T cell receptor (TCR) mice that produce T cells recognizing these 
naturally occurring tumor antigens can be generated. 
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Aside from this unbiased approach to identifying useful tumor antigens and anti-tumor T 
cell clones, one can use our established knowledge of protein products that are mis-expressed or 
commonly mutated in cancer.  I will use our lab’s mouse models of human lung adenocarcinoma 
based on K-ras
G12D
 alone or in combination with mutant or deleted p53 as examples (Jackson, 
2001; Jackson, 2005; Olive et al., 2004; Tuveson et al., 2004).  Using these cancer models, T 
cells reactive to known lung tumor-specific antigens and tumor-associated antigens can be 
generated.  To potentially produce tumor-specific T cells, one can vaccinate naïve animals with 
mutant peptides/genes for our genetically-defined mutations: K-ras
G12D
, p53
R172H
, and p53
R270H
.  
Vaccination should be performed on various genetic backgrounds bearing different MHC class I 
haplotypes to increase the likelihood of mutant epitope presentation.  Furthermore, one can 
utilize our tumor-versus-normal lung tissue gene expression data to choose somatic genes that 
are specifically over-expressed in our models’ lung tumors (Shaw and Jacks, unpublished; 
Sweet-Cordero et al., 2004).  In our p53 point mutant tumors, the tumor suppressor p53 is over-
expressed due to disregulation of a negative feedback loop involving Mdm2 (Jackson, 2005; 
Olive et al., 2004).  In addition to being highly relevant to human cancer, p53 is generally 
undetectable in normal somatic tissues, and, thus, represents an ideal candidate to which to 
generate T cell reactivity.  In fact, both cytotoxic T cell and helper T cell clones specific for un-
mutated epitopes of the tumor suppressor p53 have already been identified (Vierboom et al., 
1997; Zwaveling et al., 2002).  One could apply these T cell clones to examine immune therapy 
and tolerance in various cancer models (Frese and Tuveson, 2007). 
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ABSTRACT 
Immune tolerance thwarts efforts to utilize immune therapy against cancer.  Numerous 
mechanisms have been attributed to the phenomenon of tolerized anti-tumor cytotoxic T cells in 
both mouse and human disease.  T regulatory cells (Tregs) have stood out among these due to 
their critical role in maintaining peripheral tolerance and preventing autoimmune disease.  In 
many studies, depletion of Tregs has yielded increased anti-tumor T cell activity and tumor 
regression when Tregs are lost prior to tumor establishment.  The importance of T regulatory 
cells in maintaining suppression to anti-tumor T cells once cancer is established, however, is still 
an open issue.  We have documented an expansion of Tregs in mice bearing autochthonous lungs 
tumors that correlates with tumor burden.  Furthermore, we have devised a combination 
depletion strategy that yields substantial T regulatory cell depletion for an extended length of 
time.  Finally, we have demonstrated that depletion of T regulatory cells enhances anti-tumor 
cytotoxic T cell function in the presence of established lung cancer. 
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INTRODUCTION 
Expanded populations of T regulatory cells (Tregs) have been found within tumors, in 
tumor-draining lymph nodes, and in peripheral blood of patients with various types of cancer 
(Ichihara et al., 2003; Liyanage et al., 2002; Ormandy et al., 2005; Viguier et al., 2004; Woo et 
al., 2001).  Patient-derived Tregs were found to constitutively express the inhibitory co-signaling 
molecule CTLA-4 and produce immunosuppressive cytokines TGF- and IL-10.  When isolated 
from patient tumors, Tregs inhibited proliferation and cytokine secretion of autologous CD4
+
 and 
CD8
+
 T lymphocytes in vitro, demonstrated their ability to suppress adaptive immune effectors 
(Ormandy et al., 2005; Viguier et al., 2004; Woo et al., 2002).  High numbers of tumor-
infiltrating Foxp3
+
 T regulatory cells predicted reduced survival compared to patients with low 
numbers of Tregs in ovarian cancer (Curiel et al., 2004).  Conversely, in breast cancer, complete 
responders after neoadjuvant chemotherapy exhibited a reduced number of tumor-infiltrating 
Tregs and increased cytotoxic T cell responses to tumors (Ladoire et al., 2008). 
CD4
+
CD25
+
 T regulatory cells are specifically identified by expression of the 
transcription factor Foxp3, which represses genes directly involved in T cell activity (Marson et 
al., 2007; Schubert et al., 2001; Zheng et al., 2007).  Spontaneous mutation of Foxp3 was found 
to be causative in neonatal autoimmune syndromes scurfy and IPEX, in mouse and humans, 
respectively (Bennett et al., 2001; Brunkow et al., 2001; Wildin et al., 2001).  In addition, 
targeted deletion of Foxp3 in mice also resulted in autoimmunity and early lethality, confirming 
the critical role of Foxp3 in immune regulation (Fontenot et al., 2003).  Adoptive transfer of 
either natural CD4
+
CD25
+
 Tregs or CD4
+
CD25
-
 T cells transduced to express Foxp3 rescued 
animals from disease.  Moreover, specific deletion of Foxp3
+
 Tregs in adult mice also led to 
autoimmune disease, supporting an essential role for T regulatory cells in immune suppression 
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throughout life (Kim et al., 2007; Lahl et al., 2007).  Based on the requirement for Tregs in 
maintaining peripheral tolerance, it is not unexpected that there is now a great deal of evidence 
for T regulatory cell participation in tolerance to cancer. 
T regulatory cells are described to exert immune suppressive function in three general 
ways.  First, since Tregs express high levels of CD25, direct competition for IL-2 can limit anti-
tumor effector T cell survival and proliferation, particularly in the tumor microenvironment 
(Antony et al., 2006; Zhang et al., 2005).  Second, Tregs may directly kill cross-presenting 
antigen-presenting cells or effector T cells via granzymes and/or perforin (Cao et al., 2007; 
Gondek et al., 2005; Grossman et al., 2004; Zhao, 2006).  Finally, described through a number of 
means and involving both direct contact and immunosuppressive cytokines, Tregs can suppress 
T cell activity or induce myeloid cells to become suppressive of T cell activity (Chen et al., 
2005; Sakaguchi et al., 2008; Zou, 2006).  The relative importance of these activities and the 
contexts under which each functions are still under investigation. 
In animal models, the functional relationship between T regulatory cells and suppressed 
anti-tumor immunity has been investigated.  The first demonstration of this association was 
through the use of monoclonal antibodies against the IL-2 receptor -chain, CD25, which 
depletes Tregs based on their high expression of CD25.  Depletion in mice before or a day after 
tumor cell inoculation led to tumor rejection that was dependent on either CD8
+
 T cells or natural 
killer cells (Onizuka et al., 1999; Shimizu et al., 1999).  Since then, Treg depletion via CD25-
specific antibodies has been found to similarly enhanced anti-tumor immunity in other transplant 
tumor models (Zou, 2006).  Interestingly, depletion of Tregs in the context of established tumors 
has not been reported to facilitate immune rejection of tumors. 
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RESULTS and DISCUSSION 
T regulatory cells are expanded in tumor-bearing mice 
We examined Foxp3
+
CD25
+
CD4
+
 T regulatory cells (Tregs) in K-ras
G12D
 lung tumor-
bearing mice by flow cytometry (Cheung et al., 2008; Jackson, 2001).  We observed an 
expanded population of Tregs in lungs and lung-draining mediastinal lymph nodes (LNs) in 
tumor-bearing mice compared to age-matched, tumor-free controls (Figure 1A).  The proportion 
of Tregs increased gradually after tumor initiation and, therefore, correlated with tumor 
progression.  Twenty-two weeks after lung tumor initiation, Tregs had doubled on average in 
their representation among CD4
+
 T cells in lungs that bore tumors.  In addition, a slightly 
increased proportion of Tregs in non-draining LNs was observed at this time (Figure 1A). 
We then went on to examine Tregs in an immunogenic lung cancer model in which 
stably-integrating lentiviruses expressing Cre recombinase and tumor antigens are used to infect 
lungs of K-ras
LSL-G12D
 mice (DuPage and Jacks, unpublished).  Cre induces expression of 
oncogenic K-ras and, thus, tumor initiation.  In these same tumor-initiating cells, defined 
antigens fused to Firefly luciferase are also expressed and are, hence, tumor-specific antigens.  In 
K-ras
LSL-G12D
 mice infected with a lentivirus bearing Cre and a Luciferase-SIY fusion (Lv-LSIY-
Cre), we again observed expanded populations of Tregs by flow cytometry.  When counted, this 
amounted to a 4-fold increase in Treg number in mediastinal LNs and a 3-fold increase in lungs 
of Lv-LSIY-Cre tumor-bearing mice over age-matched, tumor-free controls (Figure 1B). 
Low-grade lentivirus-induced, immunogenic lung tumors are infiltrated by high numbers 
of lymphocytes, in contrast to non-immunogenic lung tumors induced by non-integrating 
adenoviruses expressing Cre (DuPage and Jacks, unpublished).  These lymphocytes are 
heterogeneous in type, but tumor antigen-specific CD8
+
 T cells are among the tumor-infiltrates.  
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We speculated that perhaps a higher proportion of T regulatory cells was needed to maintain 
suppression of tumor-specific T cells, as they did not appear to substantially impede progression 
of established tumors.  R26
LSL-LSIY/+
 mice express LSIY ubiquitously at low levels and exhibit 
both central and peripheral tolerance to SIY (Cheung et al., 2008).  We infected K-ras
LSL-
G12D/+
;R26
+/+
 and K-ras
LSL-G12D/+
;R26
LSL-LSIY/+
 mice with Lv-LSIY-Cre to generate matched 
animals with immunogenic and non-immunogenic lung tumors, respectively.  We refer to these 
animals as bearing tumors with tumor-specific antigens (TSAs) or tumor-associated self-antigens 
(TAAs).  When we evaluated these mice 20 weeks after infection, we observed no difference in 
the proportions of T regulatory cells in either bronchoalveolar lavage (BAL) or lung-draining LN 
(Figure 1C).  We then counted Tregs and found more Tregs on average from lungs of animals 
bearing immunogenic tumors than those with non-immunogenic tumors (data not shown).  
Because of the small number of animals analyzed and the variability in numbers of tumors 
induced, we investigated whether this effect could be due to differences in tumor burden.  
Indeed, when we counted the number of tumors on the surface of each lung, we found that tumor 
multiplicity directly correlated with the proportion of Tregs found in their BALs (data not 
shown).  Thus, T regulatory cells expand in lung tumor-bearing mice and the degree of 
expansion correlates with tumor burden rather than with the apparent immunogenicity of tumors. 
DT depletes Tregs in Foxp3-DTR mice, but chronic DT treatment results in resistance 
Depletion of T regulatory cells has resulted in increased anti-tumor T cell responses in 
many mouse cancer models (Zou, 2006).  These anti-tumor responses have led to prevention of 
tumor outgrowth or tumor regression when Tregs were depleted before tumor establishment 
(Onizuka et al., 1999; Shimizu et al., 1999).  Treg depletion as a successful mono-therapy 
leading to tumor regression has not been reported, however, in established tumors 
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(Degl'Innocenti et al., 2008).  One possibility for this result is inefficient depletion of T 
regulatory cells.  Recently, two groups have demonstrated highly efficient Treg depletion using 
genetically-modified mice that express the diphtheria toxin receptor (DTR) under the control of 
the Foxp3 promoter (Kim et al., 2007; Lahl et al., 2007).  Diphtheria toxin (DT) administration 
in these mice resulted in severe autoimmunity similar to mice genetically deficient for Treg 
production.  We acquired a different transgenic Foxp3-DTR that was unpublished at the time, 
generated in Dan Littman’s laboratory, for our experiments (Quezada et al., 2008). 
We examined the efficiency of Treg depletion by DT administration in Foxp3-DTR 
transgenic mice.  Testing various doses of DT, we found saturating level of Treg depletion 24 
hours after a dose of 40ng per mouse (data not shown).  This single dose resulted in ~85% 
depletion of Tregs in lymph nodes and ~75% in the spleen.  In spite of this, when we examined 
the ability to sustain depletion, we discovered resistance after multiple administrations of DT 
(Figure 2A).  After 4 doses administered every other day, we found only ~50% of Tregs were 
being depleted in mesenteric LNs.  In fact, in the spleen, animals had nearly no reduction in Treg 
proportions after just 2 doses and after 4 doses, Tregs were actually almost twice as numerous as 
in undepleted mice (Figure 2A).  This suggests not only resistance to Treg depletion by DT 
administration, but, perhaps, an active mechanism that compensates when Tregs are lost.  We did 
not observe any appreciable changes to Treg population size in the thymus regardless of the 
number of DT treatments. 
-CD25 antibody administration improves long-term Treg depletion efficiency 
Clearly, diphtheria toxin administration alone to deplete T regulatory cells in Foxp3-DTR 
mice would be insufficient for studies on anti-tumor efficacy.  Thus, we sought to combine DT 
administration with -CD25 antibody treatment.  -CD25 antibodies have been widely used to 
  - 194 - 
deplete Tregs in mice as Tregs are known to express high levels of the IL-2 receptor -chain, 
CD25 (Zou, 2006).  We found that a single dose of 250μg -CD25 antibody per mouse was 
optimal, resulting in sustained depletion of ~65% of Tregs in mesenteric lymph nodes and ~50% 
in spleens (Figure 2B).  Interestingly, higher doses resulted in a reduction in depletion efficiency 
(data not shown).  Furthermore, when we examined Tregs that remained in -CD25-treated 
mice, we noticed a significant reduction in the level of CD25 staining on cell surfaces (data not 
shown).  As Tregs function is dependent on IL-2, it is possible that remaining Tregs have 
reduced function (Antony et al., 2006). 
We compared animals a day after a single 40ng/g dose of DT to animals 7 days after 
250μg -CD25 antibody, and we detected similar level of Treg depletion in the mesenteric LNs 
and somewhat better depletion in the spleen with DT.   When the two treatments were combined, 
we observed greater depletion than either treatment alone in both the mesenteric LNs and spleens 
(Figure 2C).  In addition, in some animals, we administered CD25-specific antibody 7 days 
before analysis followed by 3 doses of 40ng/g DT given every other day starting 5 days before 
analysis.  This resulted in a similar degree of Treg depletion as -CD25 antibody followed by a 
single dose of DT when analyzed a day after the last DT treatment, but presumably multiple 
doses yielded reduced Treg numbers for 5 days prior to analysis (Figure 2C).  Thus, we chose 
this combined treatment regimen as we could sustain Treg depletion to ~80% in mesenteric LNs 
of Foxp3-DTR transgenic mice. 
Tumor-specific T cells are more functional after Treg depletion in tumor-bearing mice 
Using this combined method of Treg depletion, we proceeded to determine how this 
would affect T cell activity in tumor-bearing mice.  We crossed Foxp3-DTR transgenic mice to 
K-ras
LSL-G12D/+ 
mice to generated K-ras
LSL-G12D/+
;Foxp3-DTR animals, which we infected with 
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lentiviruses carrying ovalbumin antigens and Cre (Lv-OVA-Cre).  This resulted in lung tumors 
that express ovalbumin antigens as tumor-specific antigens and that can be recognized by CD8
+
 
T cells expressing the OT-I TCR from OT-I transgenic mice (DuPage and Jacks, unpublished).  
We either treated tumor-bearing animals with combined -CD25/DT regimen or with -CD25 
alone or left mice untreated.  All animals also received transfer of 1x10
6
 naive CD45.1
+
 OT-I T 
cells 7 days after the start of treatment and were analyzed 7 days after T cell transfer. 
We found <50% Treg depletion in lung-draining mediastinal LNs of -CD25/DT-treated 
mice compared to untreated animals upon analysis, but only ~20% depletion with -CD25 alone 
(Figure 3A).  When we stimulated mediastinal LNs in vitro with SIINFEKL (SIN) peptide, to 
which OT-I CD8
+
 T cells respond, we discovered that a greater proportion of OT-1 cells 
(detected by the CD45.1 marker) from -CD25/DT-treated mice stained positively for 
intracellular cytokines than from untreated mice.  Specifically, there was a ~60% increase in the 
proportion of IFN-+ cells and nearly a 200% increase in the proportion of TNF-+IFN-+ 
double-positive cells (Figure 3B).  Interestingly, -CD25 alone failed to result in a change in 
cytokine staining, despite having an intermediate level of Treg depletion.  This suggests a 
threshold level of T regulatory cell depletion that is necessary to have an effect on anti-tumor T 
cell activity. 
Anti-tumor T cells are reduced in -CD25 administered mice 
We went on to examine if Treg depletion would allow greater proliferation of anti-tumor 
OT-I T cells.  Rather than detecting a greater proportion of CD8
+
 T cells staining positive for 
CD45.1, we actually observed a reduction of ~40% under both treatment conditions compared to 
untreated mice (Figure 3C).  -CD25/DT combination treatment and -CD25 alone had 
comparable proportions of OT-I cells, indicating that antibody administration alone could cause 
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loss of OT-I cells.  As activated T cells express CD25 on their surfaces, albeit to a lesser extent 
than T regulatory cells, this is not an unexpected finding. 
Finally, we examined how the reduction in OT-I
+
 cells influenced the proportion of CD8
+
 
cells that were capable of effector function towards SIN-presenting targets.  On average, we 
noticed almost equivalent percentages of CD8
+
 cells staining for IFN- after SIN stimulation in 
untreated and -CD25/DT-treated mice (Figure 3D).  TNF-+IFN-+ double-positive cells still 
represented an increased fraction of CD8
+
 cells, though this was less significant now.  In mice 
treated with just -CD25, both IFN-+ and TNF-+IFN-+ double-positive cells were actually 
reduced in proportion compared to untreated mice, suggesting that CD25-specific antibody 
treatment alone could actually be detrimental to anti-tumor activity (Figure 3D).  Taken together, 
although we can achieve substantial T regulatory cell depletion with combined -CD25/DT 
treatment, some of these effects are negated due to the concomitant reduction in anti-tumor 
effector T cell numbers. 
A reagent for improved T regulatory cell depletion 
We hypothesize that the mice we used here were inefficient in Treg depletion because of 
epigenetic silencing of the Foxp3-DTR transgene.  This would allow T regulatory cells that 
expressed low levels or failed to express DTR to have reduced susceptibility to death via 
diphtheria toxin.  As mentioned, two groups have demonstrated highly efficient Treg depletion 
using genetically-modified mice containing Foxp3-driven diphtheria toxin receptor expression 
(Kim et al., 2007; Lahl et al., 2007).  One of these groups targeted the DTR gene to the 3’ end of 
the endogenous Foxp3 gene (Kim et al., 2007).  Thus, in order to decrease or silence expression 
of DTR in these knock-in mice, Tregs would have an associated loss of Foxp3 expression.  As 
Foxp3 is essential for T regulatory cell function as immune suppressors, this method assures 
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efficient depletion of Tregs.  We have since acquired these animals and are currently breeding 
these knock-in animals to K-ras
LSL-G12D/+
 mice for our experiments. 
Considerations in interpreting results of Treg depletion in Foxp3-DTR mice 
The expression of Foxp3 has been demonstrated in epithelial cells.  Foxp3 is described to 
be a cell-autonomous tumor suppressor, directly repressing expression of the growth factor 
receptor ErbB2/Her2 and the E3 ubiquitin ligase complex component Skp2 oncogenes in mouse 
mammary cancer (Zuo et al., 2007a; Zuo et al., 2007b).  In contrast, expression of Foxp3 in 
pancreatic cancer promotes tumor progression in a non-cell-autonomous fashion by suppressing 
the proliferation of anti-tumor T cells, similar to the function of T regulatory cells themselves 
(Hinz et al., 2007).  Regardless of the role of Foxp3 expression in epithelial cells, expression 
itself could render epithelial cells susceptible to diphtheria toxin-induced death in Foxp3-DTR 
mice.  Furthermore, DT-induced death to large number of Tregs could potentially results in an 
immune activating adjuvant effect independent of the effect produced by loss of immune 
suppressive cells.  Both indirect consequences of DT administration in Foxp3-DTR mice can be 
controlled for by transfer of Foxp3
+
 Tregs that do not express DTR.  Possible synergistic effects 
between Treg depletion and DT-induced death of cancer cells or an adjuvant effect of massive 
cell death will be more difficult to rule out. 
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METHODS 
Mice.  OT-I mice were provided by J. Chen, Foxp3-DTR mice were a gift from D. Littman, and 
CD45.1
+
 and Rag2
-
 mice were purchased from Jackson Laboratories.  K-ras
LSL-G12D
 mice were 
generated in our laboratory (Jackson, 2001; Tuveson et al., 2004).  R26
LSL-LSIY
 mice were also 
generated in our laboratory (Cheung et al., 2008).  Donor OT-I cells for transfer experiments 
were from C57BL/6 OT-I;CD45.1
+/+
;Rag2
-/-
 mice and recipients were C57BL/6.  To induce 
tumors, mice were infected with Adenovirus-Cre, Lv-LSIY-Cre, or Lv-OVA-Cre intra-
tracheally.  Animal studies were approved by MIT’s Committee for Animal Care and conducted 
in compliance with Animal Welfare Act Regulations and other federal statutes relating to 
animals and experiments involving animals and adheres to the principles set forth in the 1996 
National Research Council Guide for Care and Use of Laboratory Animals (institutional animal 
welfare assurance number, A-3125-01). 
 
T regulatory cell depletion.  Diphtheria toxin was purchased from Sigma (cat# D0564) and 
dissolved in PBS for injection.  -CD25 antibody (PC61) was produced from a hybridoma cell 
lines purchased from ATCC.  Hybridomas were grown up in spinner flasks in DMEM-10 full 
medium.  PC61 antibodies were prepared collecting and filtering the hybridoma growth media, 
then purifying PC61 via a protein G column.  The antibody concentration was determined by 
spectrophotometer and purified antibody was diluted in PBS to be injected. 
 
Cell isolation.  Single-cell suspensions from lymph nodes, spleen and thymus were generated by 
mechanical disruption.  For lung preparations, tissue samples were minced and digested at 37
o
C 
for 30 minutes in 125U/mL of collagenase type I (Gibco) in phosphate-buffered saline before 
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mechanical disruption and passage through a 70μm-pore filter (BD Falcon). Red blood cells 
were lysed with an aqueous solution containing 0.83% NH4Cl, 0.1% KHCO3, and 0.000037% 
Na2EDTA at pH 7.2-7.4.  Single-cell suspensions were passed through a 35μm-pore cell-strainer 
cap (BD Falcon) before culture, intravenous transfer, or staining for flow cytometry. 
Reagents and flow cytometry.  SIINFEKL peptide was synthesized by MIT’s Biopolymers 
Laboratory.  The following antibodies were purchased from BD Pharmingen: CD4 (H129.19), 
CD8 (53-6.7), CD16/CD32 (2.4G2), CD25 (7D4 and PC61), and CD45.1 (A20).  
Intracellular Foxp3 staining was performed with FITC--mouse/rat Foxp3 staining set from 
eBioscience and intracellular IFN- and TNF staining was performed with BD Cytofix/Cytoperm 
Fixation/Permeabilization kit, according to manufacturers’ instructions.  Streptavidin-
allophycocyanin and streptavidin-phycoerythrin conjugates were purchased from BD 
Pharmingen.  Cells were read on a FACSCalibur (BD Biosciences) and analyzed using Flowjo 
8.1 software (Tree Star Inc).  Dead cells were excluded by 1μg/mL propidium iodide staining 
(Sigma). 
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ABSTRACT 
 The adaptive immune system has been described to have paradoxical roles in cancer.  
Just as it serves to eliminate pathogens, T and, perhaps, B cells can function to suppress tumor 
growth.  On the other hand, both cell types have been described to facilitate chronic 
inflammation, which promotes tumor progression.  We have used a spontaneous model of human 
adenocarcinoma in the mouse to assess the role of adaptive immunity in cancer development.  
We observe that adaptive immuntiy promotes tumorigenesis, such that fewer tumors are detected 
in the absence of B and T lymphocytes. 
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INTRODUCTION 
The adaptive immune system consists of B and T lymphocytes, both of which have 
antigen-specific recognition receptors.  In an antigen-specific manner, both cell types are known 
to possess essential roles in the response to and elimination of pathogens.  Additionally, the 
adaptive immune system has been described to have paradoxical roles in cancer development.  In 
the same manner by which pathogen and pathogen-infected cells are eliminated, T cells and, 
perhaps, B cells can target malignant cancer cells by way of mutant, mis-expressed, or over-
expressed antigens.  Consistent with this notion, immune-deficient animals have been reported to 
develop spontaneous and carcinogen-induced tumors at higher frequency than fully immune 
competent mice (Dunn et al., 2004; Swann and Smyth, 2007).  In fact, there is great hope in 
utilizing the immune system therapeutically against cancer (Rosenberg et al., 2008; Stagg et al., 
2007). 
 On the other hand, chronic inflammation has been observed to contribute to cancer 
(Mantovani et al., 2008).  While this phenomenon has been described to be mediated primarily 
by innate immune cells, cells of the adaptive immune system can certainly promote innate 
immunity.  In fact, B cell secretion of immunoglobulins was observed to promote chronic 
inflammation in the skin that supports cancer development (de Visser et al., 2005).  Furthermore, 
there is evidence that a low level of T cell reactivity to tumors actually encourages tumor 
progression (Prehn and Prehn, 2008).  We sought to determine the effect of the adaptive immune 
system in a spontaneous model of lung cancer that does not rely on chronic inflammation for 
oncogene activation. 
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RESULTS and DISCUSSION 
The adaptive immune system promotes lung tumor progression 
The K-ras
LA2
 allele is a duplication of the first coding exon of K-ras, both copies of 
which bear the G12D oncogenic mutation, intervened by a neomycin drug resistance gene 
(Johnson et al., 2001).  In its germline state, K-ras
LA2
 is silent.  Oncogenic K-ras is only 
expressed after spontaneous recombination of the allele, which causes loss of the drug resistance 
gene and restoration of mutant exon 1 to a single copy.  This event occurs in a sporadic manner 
and results in tumor-prone animals that develop lung tumors with full penetrance. 
To determine the role of the adaptive immune system in lung tumor development, we 
crossed tumor-prone K-ras
LA2
 mice onto Rag2 heterozygous and null backgrounds.  We observed 
that tumors from K-ras
LA2/+
;Rag2
+/-
 and Kras
LA2/+
;Rag2
-/-
 mice formed with similar 
morphologies (data not shown).  We then proceeded to compare tumor burdens of littermates 
sacrificed at 4, 8, and 16 weeks of age.  Analysis of animals at 4 and 8 weeks revealed no 
significant difference in the median ratio of tumor to lung areas.  At 16 weeks of age, however, 
we noticed a substantially greater median tumor burden in K-ras
LA2/+
;Rag2
+/-
 mice compared to 
Kras
LA2/+
;Rag2
-/-
 littermates (Figure 1A).  Examining these data kinetically over time, it is 
apparent that lung tumors overall in Rag2
-/-
 mice exhibit stagnant tumor development. 
We then attempted to determine if the cause of increased tumor burden in Rag2
+/-
 mice 
was reflected by an increase in tumor number or average size.  At both 8 and 16 weeks of age, 
we observed more tumors in immune-competent mice compared to immune-compromised mice 
(Figure 1B).  Furthermore, average tumor size was not significantly different at either 8 or 16 
weeks, although tumors tended to be larger at 8 weeks and smaller at 16 weeks in Rag2
-/-
 mice 
versus Rag2
+/- 
(Figure 1C).  Therefore, animals with intact adaptive immune systems have a 
  - 212 - 
greater lung tumor burden than immune-compromised mice and this may be a reflection of 
increased tumor initiation or progression at early stages of tumor devleopment.   
These data indicate that the adaptive immune system is necessary to promote tumor 
development.  As both B and T cells are absent in Rag2
-/-
 mice, either cell type or both together 
could be responsible.  Indeed, there is evidence for both (de Visser et al., 2005; Prehn and Prehn, 
2008).  It is possible that there are opposing effects on tumor development by different 
components of adaptive immunity.  This notion is, perhaps, supported by the observation of 
biphasic tumor growth as judge by average tumor size at 8, then 16 weeks in Rag2
-/-
 mice.  
Alternatively, it is formally possible that expression of Rag2 is required in a cell-autonomous 
manner for cancer growth.  Although expression of Rag2 is restricted to lymphocytes in normal 
somatic tissues, it is possible that expression is activated in the context of malignant growth.  In 
this context, recombinase activity could cause genomic changes that encourage cancer 
advancement.  Thus, some component of adaptive immunity is required to promote lung tumor 
progression, but further studies will be necessary to elucidate the mechanism. 
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METHODS 
Mice.  Rag2- mice were purchased from Taconic. K-ras
LA2
 mice were generated in our laboratory 
(Johnson et al., 2001).  Animals bearing K-ras
LA2
 and Rag2
-
 alleles used for tumor quantification 
were on a mixed 129S4/S6 (SvJae/SvEv) genetic background and comparisons were performed 
among littermates.  For tumor studies, lung histology was prepared and analyzed by Bioquant 
Image Analysis software as previously described (Jackson, 2005).  Animal studies were 
approved by MIT’s Committee for Animal Care and conducted in compliance with Animal 
Welfare Act Regulations and other federal statutes relating to animals and experiments involving 
animals and adheres to the principles set forth in the 1996 National Research Council Guide for 
Care and Use of Laboratory Animals (institutional animal welfare assurance number, A-3125-
01). 
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SUMMARY 
Therapeutic vaccines are being used extensively in pre-clinical and clinical trials against 
various forms of cancer (Lollini et al., 2006; Purcell et al., 2007).  These vaccines vary in form 
and may or may not be designed against specific tumor antigens.  In addition, vaccine therapy 
may be used as a monotherapy or in combination with other therapies, including other immune-
based therapies.  We have demonstrated the ability of a live Influenza vaccine expressing SIY 
antigen (WSN-SIY) to break immune tolerance against a self-antigen SIY that is over-expressed 
by K-ras
G12D
-driven lung tumors(Cheung et al., 2008).  Here, we have pursued these initial 
observations further to determine whether WSN-SIY vaccine has therapeutic efficacy against 
autochthonous lung tumors. 
Previously, we observed high cytotoxic activity against SIY-expressing target cells in 
WSN-SIY-infected recipients of naïve 2C cells, irrespective of genotype (R26
+/+
 or R26
LSL-LSIY/+
) 
and tumor burden(Cheung et al., 2008).  In WSN-SIY-infected, tumor free R26
LSL-LSIY/+ 
animals, 
transferred 2C cells failed to be detectable and could not be boosted to proliferate a month after 
transfer (data not shown).  In tumor-bearing R26
LSL-LSIY/+ 
mice, however, this was not the case.  
When we infected tumor-bearing R26
LSL-LSIY/+ 
mice with WSN-SIY concurrent with naïve 2C 
cells transfer, we could still detect 2C cells 3 weeks after transfer by flow cytometry.  These 2C 
cells represented nearly 40% of all CD8
+
 T cells in bronchoalveolar lavages (BALs) of these 
mice at this time (Figure 1A).  In WSN-infected (control Influenza, not expressing SIY) R26
LSL-
LSIY/+ 
mice, however, 2C cells were only 10% of CD8
+
 T cells.  In addition, lung draining lymph 
nodes of R26
LSL-LSIY/+
 mice had comparable proportions of 2C cells whether WSN- or WSN-SIY-
infected.  These data indicate that 2C cells are better able to persist in the presence of lung 
tumors over-expressing SIY, despite peripheral tolerance.  These conditions do not completely 
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overcome peripheral tolerance to SIY, however, as tumor-bearing R26
+/+
 littermates are able to 
maintain higher proportions of 2C cells (about 70% of CD8
+
 T cells in BAL) when WSN-SIY-
infected (Figure 1A). 
To determine the influence of persisting 2C cells after WSN-SIY vaccination on tumors 
over-expressing SIY, we took tumor-bearing lungs from WSN- and WSN-SIY-infected mice for 
analysis.  We assessed tumor burden by luciferase assay of whole lungs ex vivo.  Remarkably, 
we observe a 90% decrease in luciferase activity in WSN-SIY vaccinated mice compared to 
WSN vaccinated mice (Figure 1B).  Assuming that decreased luciferase represents death of 
tumor cells rather than decreased luciferase expression from live tumor cells, this decrease 
extrapolates to a 90% reduction in tumor burden in WSN-SIY vaccinated animals after just 3 
weeks.  As this assumption cannot be made with the available data, further analysis will be 
needed to determine the actual effect on SIY over-expressing lung tumors.  This study can be 
followed up by longitudinal microCT analysis, histology, and luciferase assays on individual 
tumors remaining after treatment.  Whether tumor cells die or decrease luciferase expression, 
however, it is apparent that WSN-SIY vaccination in addition to naïve 2C cell transfer influences 
tumors that over-express SIY self-antigen. 
  - 220 - 
 
 
  - 221 - 
 
REFERENCES 
Cheung, A. F., Dupage, M. J., Dong, H. K., Chen, J., and Jacks, T. (2008). Regulated expression 
of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of 
lung cancer. Cancer Research 68, 9459-9468. 
Lollini, P. L., Cavallo, F., Nanni, P., and Forni, G. (2006). Vaccines for tumour prevention. Nat 
Rev Cancer 6, 204-216. 
Purcell, A. W., McCluskey, J., and Rossjohn, J. (2007). More than one reason to rethink the use 
of peptides in vaccine design. Nat Rev Drug Discov 6, 404-414. 
 
 
 
 
  - 222 - 
APPENDIX 4: 
 
Exploring combination chemotherapy and immunotherapy against 
autochthonous lung tumors 
 
Ann F. Cheung
1
, Trudy G. Oliver
1
, James Burke
1
, Kamena K. Kostova
1
, Michel J.P. DuPage
1
, 
and Tyler Jacks
1,2
 
 
1
Koch Institute and Department of Biology and 
2
Howard Hughes Medical Institute, MIT, 
Cambridge, MA. 
 
 
 
 
 
 
 
The author performed all of the experiments described with help from Michel DuPage in 
lentiviral infections, from Trudy Oliver and James Burke in cisplatin treatments, and from 
Kamena Kostova in microCT data analysis.  All experiments were performed in the laboratory of 
Tyler Jacks. 
  - 223 - 
INTRODUCTION 
Lung cancer is the leading cause of cancer-related deaths worldwide with a five-year 
survival rate of 15%.  A major obstacle to successful treatment is the resistance of cancer to 
chemotherapy.  Cisplatin is a commonly used chemotherapeutic agent in multiple types of cancer 
including lung cancer.  Chemotherapy with cisplatin has shown therapeutic efficacy in our 
mouse models of non-small cell lung cancer (NSCLC), yet some tumors are either inherently 
resistant or acquire resistance to therapy (Oliver et al, in preparation).  The majority of K-
ras
G12D
-driven lung tumors respond to a single dose of cisplatin by inducing DNA damage 
signaling and undergoing cell cycle arrest or apoptosis.  In fact, tumor regression and stasis were 
observed by micro-computed tomography (micro-CT) analysis of mice treated with just two 
doses of cisplatin.  Despite reducing tumor growth, cisplatin treatment did not prolong survival 
of tumor-bearing K-ras
LSL-G12D/+
 mice when animals received 4 sequential doses.  Interestingly, 
tumors treated with cisplatin in this manner failed to show signs of DNA damage or reduced 
proliferation in response to a final dose of cisplatin in animals that had a month-long interruption 
in chemotherapy.  These data indicate that lung tumors acquire resistance to cisplatin after 
prolonged therapy.  Thus, while cisplatin initially improves tumor burden, it also promotes tumor 
progression and resistance in the long-term. 
The primary goal of conventional anti-cancer therapies, such as chemotherapies and 
radiation therapy, is to directly kill tumor cells that exist in the presence of many sources of 
cellular stress (Luo et al., 2009).  Upon killing tumor cells, however, chemotherapeutic agents 
also support anti-tumor immune responses.  DNA damage induced by various chemotherapeutic 
drugs has been demonstrated to lead to the up-regulation of stress ligands on tumor cells that can 
stimulate the anti-tumor activity of NK cells and CD8
+
 T cells (Diefenbach et al., 2001; Gasser et 
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al., 2005). Chemotherapy may also enhance tumor antigen presentation by improving the 
recruitment and activation of dendritic cells (DCs) that can engulf and cross-present tumor 
antigens to T cells (Zitvogel et al., 2008).  Translocation of calreticulin to the surface of cancer 
cells after anthracyclin or -irradiation treatment has been found to govern DC engulfment and, 
hence, the immunogenicity of cell death in response to chemotherapy (Obeid et al., 2007). 
Furthermore, it has been observed for some time that dying tumor cells and their debris can 
induce DC maturation and the generation of anti-tumor cytotoxic T lymphocytes (Gallucci et al., 
1999; Shi et al., 2000).  Recently, a number of “danger” signals derived from dying and 
distressed cells after chemotherapeutic treatment have been found to be endogenous proteins, 
such as heat shock proteins, alarmin high-mobility-group box 1 protein, and uric acid (Apetoh et 
al., 2007; Binder et al., 2000; Obeid et al., 2007; Shi et al., 2003).  These signals act by binding 
to pattern-recognition receptors on DCs, like Toll-like receptors (TLRs)-2 or -4, originally 
thought to only bind pathogen-associated molecules (Kono and Rock, 2008; Tesniere et al., 
2008).  Finally, chemotherapeutic agents have been shown to improve the trafficking of T cells 
to the tumor, perhaps by changing the inflammatory mediators in the tumor microenvironment or 
inducing the expression of attractive chemokines (Fujimori et al., 2005; Lake and Robinson, 
2005; Matsumura et al., 2008). 
Based on the immune-stimulatory properties of chemotherapy, one might postulate the 
ability to improve treatment of cancer by combining chemotherapy with immune therapy, 
particularly in light of acquired resistance to cisplatin after prolonged treatment.  In fact, 
synergistic action between chemotherapy and immune therapy has been observed in several 
transplanted mouse cancer models.  Combination peptide or DNA vaccines and cisplatin 
chemotherapy has been shown to be more effective than either treatment alone against 
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transplanted tumors expressing HPV antigens in mice (Bae et al., 2007; Tseng et al., 2008).  The 
efficacy of cisplatin treatment was also increased with addition of chemotherapy-resistant 
dendritic cells in mice bearing injected melanoma cells (Perrotta et al., 2007).  In addition, 
apoptosis of mesothelioma cells via gemcitabine treatment increased cross-presentation of tumor 
antigens and synergized with a viral vaccine against transplanted tumors in mice (Nowak et al., 
2003).  Furthermore, combination DC vaccination and paclitaxel treatment of Lewis lung 
carcinoma cells in mice augmented T cell infiltration of tumors and, hence, reduced tumor 
growth (Zhong et al., 2007).  Thus, chemotherapy and immunotherapy are orthogonal treatments 
that will likely yield increased efficacy when used together in cancer treatment. 
 
RESULTS and DISCUSSION 
We explored the use of chemotherapy and immune therapy in combination to treat 
autochthonous lung tumors.  For this investigation, we utilized a new lung cancer model that 
makes use of bi-functional lentiviruses expressing Cre and antigens from ovalbumin (Lv-OVA-
Cre) to generate immunogenic tumors (DuPage et al, in preparation).  Lv-OVA-Cre-induced 
tumors recruit OVA-specific T cells that are initially detectable by histology and flow cytometry.  
As tumors progress, however, immune infiltrates dissipate.  Activated OT-I T cells, which are 
specific to an MHC class I-presented ovalbumin antigen, accumulate in lung tumors when 
adoptively transferred, even when endogenous tumor-infiltrating lymphocytes have dissipated.  It 
is not yet known whether activated OT-I T cells kill tumor cells in this context. 
 For our experiment, we planned to treat animals with chemotherapy and adoptive T cell 
transfer, together or singly, and monitor tumor volume change by microCT scans before and 
after treatment.  A cohort of C57BL/6 K-ras
LSL-G12D/+
 animals infected intratracheally with 
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lentiviruses 7 months prior were scanned by microCT to assess tumor burden and inflammation.  
Of these animals, 22 were infected with Lv-OVA-Cre and 10 were infected with control Lv-Cre, 
which does not bear ovalbumin antigens producing non-immunogenic tumors.  Mice that did not 
have discernible tumors, had too many tumors, and/or had obscuring inflammation by microCT 
analysis were excluded from the study.  The 14 Lv-OVA-Cre-infected and 9 Lv-Cre-infected 
mice remaining were used for the experiment.  These animals were divided into the following 
groups with at least 2 mice per group: 1) Lv-Cre mice left untreated, 2) Lv-OVA-Cre mice left 
untreated, 3) Lv-OVA-Cre mice treated with activated OT-I cells only, 4) Lv-Cre mice treated 
with cisplatin only, 5) Lv-OVA-Cre mice treated with cisplatin only, 6) Lv-Cre mice treated with 
both activated OT-I cells and cisplatin, and 7) Lv-OVA-Cre mice treated with both activated OT-
I cells and cisplatin.  A dose of 7μg/g was used for cisplatin treatments and 1.5x107 activated 
OT-I cells were injected each time for adoptive T cell therapy.  Animals received 3 doses of each 
appropriate treatment separated by 10 days.  For combination therapy, OT-I transfer always 
followed cisplatin treatment by 4 days (see Figure 1A for treatment regimens).  This time was 
chosen based on observing progressively increasing numbers of apoptotic tumor cells 1-3 days 
after cisplatin treatment (Oliver et al, in preparation).  This experiment only serves as a pilot 
study due to the limited number of tumor-bearing animals available in this cohort. 
 MicroCT scans were taken a week before and a week after treatment, yielding 38-41 days 
between scans.  Untreated lung tumors grew 2-2.5-fold on average within this timeframe.  
Tumors in Lv-OVA-Cre mice treated with transferred OT-I cells alone grew 3-fold on average, 
but this was not significantly different from untreated Lv-OVA-Cre tumors.  Fold-change in 
tumor volumes varied greatly for this treatment group, but no individual tumor within this group 
regressed significantly (Figure 1B).  Thus, these data indicate immune therapy alone via adoptive 
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transfer of activated OT-I cells does not substantially kill Lv-OVA-Cre-initated tumors.  We do 
not know, however, if Lv-OVA-Cre tumor cells express/present sufficient levels of SIINFEKL 
(SIN), the ovalbumin antigen to which OT-I cells react, to result in significant cytolysis.  
Nevertheless, we do know that were is sufficient antigen presentation for T cell recognition of 
tumors as we observe lymphocytic infiltration in Lv-OVA-Cre tumors treated with OT-I cells, 
both alone and with cisplatin, when examined histologically (data not shown). 
 Cisplatin treatment alone had a significant effect on Lv-OVA-Cre tumors, yielding about 
80% tumor regression (Figure 1B).  Interestingly, Lv-Cre tumors on average failed to regress and 
instead demonstrated a 2-fold increase in average tumor volume similar to untreated Lv-Cre 
tumors.  These data could indicate the induction of endogenous anti-tumor immunity when 
immunogenic tumors are treated with cisplatin, but not when non-immunogenic tumors are 
treated.  Contradicting this idea, however, is that fact that we do not observe lymphocytic 
infiltration by histology in Lv-OVA-Cre tumors treated with cisplatin alone (data not shown).  
An alternative explanation for these data is that Lv-Cre mice received less cisplatin than Lv-
OVA-Cre mice.  Both Lv-Cre mice treated with cisplatin received only two-thirds of the dose 
Lv-OVA-Cre cisplatin-treated mice received because of their respective body weights (data not 
shown).  In support of this is the effectiveness of cisplatin and OT-I transfer in causing 
regression of Lv-Cre tumors as these mice had body weights similar to Lv-OVA-Cre mice 
treated with cisplatin.  These data indicate that cisplatin chemotherapy alone has a significant 
effect on tumor burden, but the effect may be modified by tumor immunogenicity and/or per 
animals dosage. 
 Combining adoptive OT-I T cell transfer with cisplatin chemotherapy did not appear to 
have an additive effect on killing tumor cells (Figure 1B).  Lv-OVA-Cre mice treated with 
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combined therapy did demonstrate significant tumor regression by microCT analysis when 
compared to untreated mice, but tumor regression was not as great as with cisplatin treatment 
alone.  The failure to see comparable levels of tumor regression could be due to an increase in 
apparent tumor volume when tumors are infiltrated by lymphocytes.  Furthermore, the inability 
to see an additive effect on tumor regression with cisplatin and T cell therapy could be due to the 
unanticipated effectiveness with cisplatin treatment alone.  The dose of cisplatin chosen for this 
experiment was used to treat animals with greater lung tumor burdens, as they are induced with 
higher dose Adenovirus-Cre (Oliver et al, in preparation).  Tumor regression for Adenovirus-
Cre-induced tumors was much more modest than the effect observed here for Lv-OVA-Cre-
induced tumors.  In future experiments, perhaps, a lower dose of cisplatin could be used. 
 Data from this experiment suggest that OT-I T cell transfer is ineffective, either alone or 
in combination with cisplatin, against Lv-OVA-Cre-induced tumors.  In support of this is the 
comparable level of tumor regression observed between Lv-Cre and Lv-OVA-Cre tumors treated 
with combined chemotherapy and immune therapy (Figure 1B).  It would be important to 
determine if the ineffectiveness of activated OT-I cells is due to the analysis of late stage tumors 
since the mice used in this study were aged 7 months after tumor initiation.  Studies should be 
performed on younger mice and tumors should be analyzed at various time points after initiation 
for ovalbumin expression and presentation.  Alternatively, tolerance mechanisms need to be 
investigated further in this model as OT-I T cell activity may be suppressed in such a manner 
that is not overcome by tumor cell death by cisplatin chemotherapy. 
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ABSTRACT 
The Adenomatous Polyposis Coli (APC) gene product is mutated in the vast majority of 
human colorectal cancer.  Apc negatively regulates the Wnt pathway by aiding in the 
degradation of -catenin, the transcriptional factor activated downstream of Wnt signaling.  Apc 
mutation, thus, results in deregulation of -catenin and constitutive Wnt activation leading to 
aberrant cellular proliferation.  Biochemical and molecular studies have, however, revealed 
multiple protein domains within Apc and additional cellular processes in which Apc participates.  
These studies have predominantly been performed in cultured system with the use of ectopically 
expressed Apc protein fragments and, thus, bringing into question the in vivo significance of 
these findings.  We have generated a novel allele of Apc in mice that results in complete loss of 
all Apc protein products.  With this allele, we have identified a role for the N-terminal domains 
of Apc in intestinal tumor suppression.  In addition, we have discovered a novel role for Apc in 
the regulation of -catenin transcripts. 
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INTRODUCTION 
 Colorectal cancer is one of the leading causes of cancer death in the Western world.  
Upwards of 80% of colorectal cancers have mutations in the Adenomatous Polyposis Coli (APC) 
gene.  Both Familial Adenomatous Polyposis (FAP) and sporadic colon cancers tend to have 
APC alterations that result in truncated APC protein (Kinzler and Vogelstein, 1996).  These 
mutations fall in a region of APC termed the mutation cluster region (MCR) and result in 
retained expression of N-terminal domains of the protein (Figure S1).  Genotype-phenotype 
correlations of familial syndromes involving APC mutation suggest that different lengths and 
levels of APC expression can influence the number of polyps in the gut, the distribution of 
polyps, and extra-colonic manifestations of the disease (Soravia et al., 1998).  Specifically, 
patients with Attenuated FAP (AFAP) tend to have fewer polyp counts and later age of colon 
cancer development.  Interestingly, in AFAP, APC mutations tends to fall 5’ and 3’ of the MCR, 
presumably resulting in APC truncations bearing different protein domains than in classical FAP 
and/or hypomorphic APC expression.  More thorough analysis of the phenotypic consequences 
of different heritable APC alleles is hampered by the low frequency of non-classical FAP and the 
existence of numerous genetic and environment modifiers of disease (de la Chapelle, 2004).  
Thus, many have turned to the mouse as a tool to examine the consequences of various Apc 
mutations. 
The Apc
Min
 mouse was the first mutant allele of Apc developed in the mouse, discovered 
in an ethylnitrosourea mutagenesis screen (Su et al., 1992).  Apc
Min
 mice developed multiple 
intestinal neoplasias (Min) that closely resembled human FAP, which had only concurrently 
been identified to be caused by APC mutation (Groden et al., 1991; Kinzler et al., 1991).  In 
addition, the Apc
Min
 mutation is a nonsense mutation in codon 850 that results in a stable, 
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truncated Apc protein similar to that found in classical FAP patients.  Since the development of 
Apc
Min
 mice, additional alleles of Apc have been generated, including those that result in shorter 
Apc products, as well as, longer polypeptides than Apc
Min
 (Colnot et al., 2004; Oshima et al., 
1995; Smits et al., 1999).  These alleles have yielded different phenotypic consequences relating 
to intestinal tumorigenesis (Fodde and Smits, 2001). 
In the canonical Wnt pathway, Apc forms a complex with Axin and Gsk-3 to negatively 
regulate -catenin by sequestering it in the cytoplasm and marking it for degradation.  When Apc 
is lost, -catenin is free to translocate into the nucleus where it binds to Tcf transcription factors 
to regulate target genes, such as c-myc (Clevers, 2006).  Activated -catenin itself is sufficient to 
initiate intestinal tumorigenesis in mice, resembling lesions caused by homozygous mutation of 
Apc (Harada et al., 1999).  Some evidence suggests, however, that the role of Apc mutation in 
tumorigenesis reaches beyond deregulation of -catenin.  First, the vast majority of sporadic 
colon cancers have mutations in APC, whereas other cancers with deregulated WNT signaling 
have an equal or greater proportion of mutations in -Catenin or other Wnt pathway components 
(Giles, 2003).  Second, Apc is a relatively large protein, approximately 312 kDa, with a number 
of protein binding motifs (Figure S1).  Consistent with this, Apc interacts with a variety of 
proteins outside of Wnt signaling and localizes to the nucleus, the plasma membrane, and 
microtubule ends, as well as, to the cytoplasm (Aoki and Taketo, 2007; Fodde et al., 2001; 
Mccartney and Nathke, 2008).  Finally, the majority of APC mutations result in a stable, 
truncated polypeptide, missing most -catenin and Axin binding domains, which lie in the 
middle portion of the protein.  In these mutants, the microtubule-binding domain and EB1-
binding site, at the C-terminus of APC, are also lost, but the N-terminal armadillo domain and 
oligomerization domains are retained (Nathke, 2004). 
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To dissect the pleiotropic roles of Apc in intestinal tumorigenesis, we have generated 
novel alleles of Apc in the mouse.  Comparison of our new alleles to existing mutant Apc alleles 
has allowed us to identify a role for the N-terminal domains of Apc in tumor suppression.  
Furthermore, we have potentially gained insight into a novel function for Apc. 
 
RESULTS 
Generation of conditional Apc
fle1-15
 and constitutive Apc
null 
alleles 
We took a genetic approach to address the role of truncated Apc protein in intestinal 
tumorigenesis by constructing conditional and constitutive null alleles of Apc in mice.  To 
generate a conditional null allele of Apc, Apc
fle1-15
, we targeted the Apc locus in C57BL/6 
embryonic stem cells with two sequential insertions to flank coding exons 1 through 15 with 
loxP sites (described in Figure 1).  Targeting Apc in this manner placed loxP sites around a 
genomic region spanning ~90kb and would ensure the complete loss of the Apc gene product 
when Cre-mediated recombination of the locus was achieved.  Furthermore, to generate a 
heritable constitutive Apc
null
 allele, we crossed Apc
fle1-15
 to Meox-Cre transgenic animals, which 
express Cre in the germline (Figure 1) (Tallquist and Soriano, 2000). 
 To confirm the loss of Apc upon genomic deletion, we performed Real-time PCR to 
detect Apc with Taqman probes spanning exons 9-10 and 14-15.  Analysis of cDNA generated 
from colons of 1 month old animals revealed approximately 50% reduction of Apc in Apc
+/null
 
mice compared to a Apc
+/+
 littermate (Figure 2A).  Apc
+/null
 mice are predisposed to spontaneous 
intestinal tumor formation upon loss of heterozygosity (LOH) of Apc similar to Apc
+/Min
 and 
Apc
+/del14
 mice (Colnot et al., 2004; Su et al., 1992).  We plucked colonic tumors from all aged 
mice from each of the three Apc mutant genotypes for analysis of tumor cDNA.  Consistent with 
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a mechanism of LOH involving mitotic recombination resulting in tumors with Apc
null/null
 
genotype, we observe nearly complete loss of Apc transcript in colonic tumors from Apc
+/null
 
mice (Figure 2A).  Residual Apc is likely derived from stroma within the lesions.  Furthermore, 
in line with Cre-excised genomic regions, we observe retention of exons 9-10, but loss of exons 
14-15 in colonic tumors from Apc
+/del14
 mice, whereas Apc
+/Min
 tumors maintain expression of 
both regions (Figure 2A; Figure S1). 
Mice heterozygous for Apc
 
develop lesions histologically similar to those in Apc
Min
 mice 
 We went on to compare the lesions that developed in the three mutant Apc genotypes.  
Upon histological examination, tumors varied in apparent grades and morphology, but did not 
differ significantly among the genotypes (data not shown).  Heterozygous conditional Apc
+/fle14
 
and Apc
+/fle1-15
 animals were generated that also bore a Villin-Cre transgene (El Marjou et al., 
2004).  Comparison of lesions that develop in mice with conditional Apc alleles revealed a 
similar result to constitutive mutants (Figure 2B-G).  In addition, tumors from all Apc mutant 
mice stained positive for nuclear -catenin by immunohistochemstry, although staining was 
heterogeneous (Figure 2H,I; data not shown). 
Apc
null
 mice have reduced survival compared to other Apc mutant mice 
 We wanted to determine if Apc mutant mice differed in their survival.  We aged cohorts 
of Apc mutants on pure C57BL/6 background since intestinal tumorigenesis is attenuated or 
exacerbated by numerous genetic modifiers.  In addition, to reduce the influence of 
environmental modifiers on morbundity, we only utilized wild-type mothers and aging female 
mutants were kept virgin.  We discovered that median survival was reduced by 23% in Apc
+/null
 
females compared to Apc
+/Min
 females, at 119 and 154 days, respectively (Figure 3A).  In males, 
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there was a similar reduction of 24% between the two genotypes, with median survival of 106.5 
and 140.5, respectively for Apc
+/null
 and Apc
+/Min
 males (Figure 3B).  Moribundity was supported 
by hematocrit measurements indicative of anemia in mice with extensive tumor burdens (Figure 
3C). 
Apc
+/del14
 mice displayed an intermediate survival compared to mice with other mutant 
Apc alleles, but this differed somewhat between females and males (Figure 3).  As the Apc
fle14 
allele, from which Apc
del14
 was derived, was generated on a non-C57BL/6 background, it is 
possible that these mice are influenced by genetic modifiers closely linked to the Apc locus 
(Colnot et al., 2004).  Because of this variable, we will not consider their phenotype in our 
descriptions further, although additional analyses did include these mice. 
Apc
null
 mice are predisposed to increased number of tumors and with larger size 
 We went on to investigate the cause of reduced survival in Apc
+/null
 mice.  Aside from a 
few animals developing mammary lesions, no other extra-intestinal lesion appeared to influence 
animal survival (data not shown).  Therefore, the simplest explanation for altered survival would 
be a difference in tumor development.  We sacrificed additional cohorts of animals at 3 months 
of age to examine tumor multiplicity and size.  Upon counting tumor number, we noticed more 
tumors in both small intestines and colons of Apc
+/null
 mice compared to Apc
+/Min
 mice (Figure 
4).  This result was apparent in both females and males, but only statistically significant in 
females.  Female Apc
+/null
 mice had 50% more small intestinal tumors and greater than twice the 
number of colonic tumors on average than Apc
+/Min
 mice (Figure 4C,D).  The distribution of 
lesions through the intestinal tract, however, did not differ between the Apc mutants (Figure 
4A,B). 
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 From these same animals, we plucked colonic tumors and measured these with calipers.  
In female Apc
+/null
 mice, tumors were more than twice the volume of those in female Apc
+/Min
 
mice (Figure 5A).  There was no distinction, however, among colonic tumor volumes in males 
(Figure 5B).  We reasoned that increased tumor size could be due to either reduced cell death or 
increased proliferation.  We examined cell death by cleaved-caspase 3 staining, but observed no 
apparent difference (data not shown).  In addition, we counted mitotic cells stained positive by 
immunohistochemistry for phospho-histone H3 as a surrogate marker of proliferation, but again 
failed to detect a significant difference between Apc
+/null
 and Apc
+/Min
 lesions (Figure 5C,D,E). 
It is possible that our methods are not sensitive enough to detect changes in these cell fate 
decisions, particularly considering the enormous variability in mitotic cell counts.  Alternatively, 
larger lesions can be the result of earlier tumor initiation.  Bearing in mind the greater number of 
tumors counted in Apc
+/null
 colons compared to Apc
+/Min
, increased volume could simply be a 
reflection of a longer time for tumors to progress, assuming a lower limit of detection (Figure 
4D; Figure 5A).  Thus, truncated Apc acts as a tumor suppressor leading to reduced survival 
when lost.  Additional experiments will need to be conducted to parse out how this function is 
manifested. 
Complete loss of APC in colon tumors results in reduced -catenin levels and activity 
 During analysis of tumor samples stained for -catenin by immunohistochemistry, we 
consistently observed reduced staining in tumors from Apc
+/null
 mice compared to Apc
+/Min
 mice 
(Figure 2H; data not shown).  As both mutations in Apc result in loss of domains that mediate -
catenin destruction, we found this to be rather unexpected (Figure S1).  We investigated this 
further via Real-time PCR for -catenin transcript levels.  Consistent with immunohistochemical 
staining, colonic tumors from Apc
+/null
 mice had lower levels of -catenin than those from 
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Apc
+/Min
 mice (Figure 6A).  We proceeded to measure levels of -catenin activity by using 
mRNA levels of its direct transcriptional target Axin2 as a surrogate marker.  In proportion to -
catenin levels, Axin2 was reduced in tumors from Apc
+/null
 compared Apc
+/Min
 mice (Figure 6B). 
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DISCUSSION 
 We have generated two novel alleles of the Adenomatous polyposis coli (Apc) gene, 
conditional and constitutive null alleles, in mice.  These alleles result in complete loss of all Apc 
protein products allowing us to dissect the role of Apc truncation in intestinal tumorigenesis.  
Our studies indicate that truncated Apc, derived from the Min allele of Apc, has tumor suppressor 
function in the gut, such that mice with heterozygous deletion of Apc have reduced survival and 
are predisposed to an increased tumor burden compared to Apc
Min
 mice.  We have not yet 
determined, however, whether greater tumor burden is a reflection of higher rates of tumor 
initiation or faster tumor progression.  In addition, we observe reduced levels of -catenin 
transcript and protein, which, in turn, results in lower levels of its transcriptional target Axin2.  
To our knowledge, this is the first report of Apc mutation yielding changes in -catenin 
transcript levels.  We do not know how direct this effect on -catenin is or whether this indicates 
a change in -catenin transcription and/or mRNA stability.  Furthermore, it is not clear if -
catenin activity drives the differences we observe in tumor phenotype between truncated and 
deleted alleles of Apc. 
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METHODS 
Mice.  Apc
Min
 and Meox-Cre mice were purchased from Jackson Laboratories.  Apc
fle14
 mice 
were a gift from Dr. M. Giovannini, and Apc
del14
 animals were derived by crossing to Meox-Cre.  
Villin-Cre mice were a gift from Dr. S. Robine.  Apc
fle1-15
 mice were generated from C57BL/6 
embryonic stem cells and maintained on C57BL/6 background, even with the derivation of the 
Apc
null
 germline allele.  All animals used in the survival study and for quantified measurements 
were on C57BL/6 background.  Animals in the survival study were progeny of Apc mutant 
fathers and wild-type Apc mothers.  Females were kept virgin as they aged and animals were 
checked for morbundity on a daily basis.  Animals for tumor multiplicity and colon tumor 
measurements were sacrificed at 3 months of age.  Intestines were flushed with PBS, cut open 
longitudinally, and fixed flat on bibulous paper in 4 segments.  Fixed intestine were stained with 
1:10 dilution in water of 1% methylene blue in 95% ethanol and destained in 70% ethanol before 
counting tumors on a dissection microscope.  Colonic tumor volumes were determined by 
plucking lesions from surface of intestine and measuring tumor masses by calipers.  Volumes 
were calculated based on an ellipsoid shape; volume = (4/3)*pi*x*y*z, with x, y, and z being the 
widths of each perpendicular axis.  Animal studies were approved by MIT’s Committee for 
Animal Care and conducted in compliance with Animal Welfare Act Regulations and other 
federal statutes relating to animals and experiments involving animals and adheres to the 
principles set forth in the 1996 National Research Council Guide for Care and Use of Laboratory 
Animals (institutional animal welfare assurance number, A-3125-01). 
 
Real-time PCR.  Samples were prepared by flushing fresh colons with cold PBS or by plucking 
colonic tumors from intestinal surface.  Tissues were then minced with a razor blade before 
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Trizol extraction for RNA.  RNA was quantified by spectrophotomter, and the quality was 
assessed by agarose gel electrophoresis and visualization of 28S and 18S ribosomal RNA bands.  
Non-degraded samples were subjected to cDNA synthesis using random primers and Superscript 
III reverse transcriptase enzyme.  Samples were treated with RNase H to degrade template RNA 
after cDNA synthesis was complete.  Taqman probes and reagents were purchased from Applied 
Biosystems.  Relative expression of Apc, -catenin and Axin2 were determined by normalization 
to GAPDH. 
 
Immunohistochemistry.  -catenin (cat#9582), -cleaved caspase-3 (cat#9661), and -
phospho-histone H3 (cat#9701) antibodies were purchased from Cell Signaling Technology.  
Immunohistochemistry was performed on paraffin sections as previously described (Haigis et al., 
2008). 
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